{
  "meta": {
    "title": "55_Pharmacology_Ini-Cet_2022",
    "url": "https://brainandscalpel.vercel.app/55-pharmacology-ini-cet-2022-7636ac01.html",
    "scrapedAt": "2025-11-30T12:58:07.462Z"
  },
  "questions": [
    {
      "text": "The extent of drug absorption is represented by:",
      "choices": [
        {
          "id": 1,
          "text": "Tmax"
        },
        {
          "id": 2,
          "text": "Area under the curve"
        },
        {
          "id": 3,
          "text": "Cmax"
        },
        {
          "id": 4,
          "text": "t1/2"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The extent of drug <strong>absorption</strong> is represented by <strong>the area under the curve</strong>.</p>\n<p>The rate and extent of <strong>absorption</strong> of a drug from dosage form administered by any route refer to <strong>the bioavailability</strong> of a drug. Bioavailability is<em> </em>determined by the concentration-time curve in blood or by its excretion in urine. The <strong>area under the blood concentration-time curve (AUC)</strong> is proportional to the dose and the extent of bioavailability of a drug.</p>\n<p>Bioavailability is defined as the fraction of unchanged drug that reaches systemic circulation. It can be represented by the formula:</p>\n<p>Bioavailability(<strong>F</strong>) = Quantity of drug reaching systemic circulation/ Quantity of drug administered.</p>\n<p>Bioavailability depends on two factors:</p>\n<ul>\n<li>Absorption</li>\n<li>1st pass metabolism</li>\n</ul>\n<p>The <strong>area under</strong> the plot of <strong>plasma concentration</strong> of a drug versus <strong>time</strong> after dosage is called the <strong>area under the curve </strong>or <strong>AUC</strong>. It can be used as a measure of the <strong>bioavailability</strong> of a drug and to calculate its <strong>clearance rate</strong> from the body. </p>\n<p>The image given below shows the AUC (bioavailability) in a plasma concentration-time curve:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/faee105612ff4db99088f395111a460ex1280x1008.JPEG\" alt=\"Explanation Image\"><p> </p>\n<p>Bioavailability of drug injected intravenously is 100%, but it is lower after oral ingestion because of incomplete absorption and first-pass metabolism in the intestinal wall/liver.</p>\n<p>The image below shows the difference between the bioavailability of drugs injected intravenously(iv) and orally(PO). Note the area under the respective curves is shaded in red and blue colours which represent the absorption of the drug.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/004ea54ec8dd43dab6444638a0d26247x1184x1162.PNG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF5074",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statement is correct regarding the given graph?",
      "choices": [
        {
          "id": 1,
          "text": "Drug 1 represents agonist and drug 2 represents inverse agonist"
        },
        {
          "id": 2,
          "text": "Drug 3 represents agonist and drug 4 represents inverse agonist"
        },
        {
          "id": 3,
          "text": "Drug  1 represents agonist and drug 4 represents inverse agonist"
        },
        {
          "id": 4,
          "text": "Drug 2 represents partial agonist and drug 3 represents inverse agonist"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The correct statement is <strong>Drug 1 represents agonist and drug 4 represents inverse agonist.</strong></p>\n<p><strong>Graph 1 </strong>represents the <strong>agonist: </strong>An agonist is an agent which initiates the <strong>normal</strong> <strong>physiological response</strong> when combined with a receptor.</p>\n<p>Example: Salbutamol is a beta-2 receptor agonist.</p>\n<p><strong>Graph 2</strong> represents a <strong>partial agonist</strong>: An agent which produces a <strong>submaximal or partial effect</strong> when combined with a receptor.</p>\n<p>Example: B<span class=\"ILfuVd\" lang=\"en\"><span class=\"hgKElc\">uprenorphine and butorphanol are partial agonists at opioid receptors. </span></span></p>\n<p><strong>Graph 3 </strong>represents the <strong>antagonist</strong>: An agent which blocks or reduces the action of an agonist on a receptor, but does not have any effect of its own.</p>\n<p>Example: N<span class=\"ILfuVd\" lang=\"en\"><span class=\"hgKElc\">altrexone and naloxone are antagonists at opioid receptors </span></span></p>\n<p><strong>Graph 4</strong> represents an<strong> inverse agonist</strong>: An agent which activates a receptor to produce an effect in the opposite direction to that of the agonist.</p>\n<p>Example: &beta;-Carboline is an inverse agonist at benzodiazepine site of GABA-A receptor.</p>\n<p>The image given below shows action of various types of selective receptor modulators.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/8d7167c153aa42a5bdc0787fd454473ex1280x1252.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/bef9557aa4ee45d5ac653541181d4996.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF5323",
      "difficulty": "easy"
    },
    {
      "text": "Which among the following drugs is the new FDA approved immune check point inhibitor for carcinoma endometrium?",
      "choices": [
        {
          "id": 1,
          "text": "Nivolumab"
        },
        {
          "id": 2,
          "text": "Pembrolizumab"
        },
        {
          "id": 3,
          "text": "Trastuzumab"
        },
        {
          "id": 4,
          "text": "Ipilimumab"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The new FDA-approved <strong>immune checkpoint inhibitor</strong> for carcinoma endometrium is <strong>pembrolizumab</strong>.</p>\n<p>Pembrolizumab acts by inhibiting programmed death receptor - 1 (<strong>PD-1</strong>) and was used for the treatment of&nbsp;<strong>advanced melanoma</strong>. Now, the FDA has&nbsp;approved the use of pembrolizumab for any cancer with mismatch repair (<strong>MMR</strong>) deficiency or high microsatellite instability (<strong>MSI-H</strong>).</p>\n<p>On March 21, 2022, the food and drug administration approved pembrolizumab, as a single agent, for patients with <strong>advanced endometrial carcinoma</strong> that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test.</p>\n<p>Other options:</p>\n<p>Option A:&nbsp;<strong>Nivolumab</strong> is an&nbsp;immune checkpoint inhibitor that acts by inhibiting programmed death receptor - 1 (<strong>PD-1</strong>) and is used for the treatment of&nbsp;<strong>advanced melanoma </strong>and<strong>&nbsp;</strong>relapsed/refractory<strong>&nbsp;classical Hodgkin lymphoma.</strong></p>\n<p>Option C:<strong>&nbsp; Trastuzumab&nbsp;</strong>is a monoclonal antibody that inhibits the <strong>HER2 receptor</strong>. It is used in the treatment of <strong>HER2-positive breast cancer</strong>.</p>\n<p>Option D:&nbsp;<strong>Ipilimumab</strong> is a monoclonal antibody that binds to cytotoxic T lymphocyte&ndash;associated Protein 4 (<strong>CTLA-4</strong>) and is approved for the treatment of late-stage <strong>melanoma</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4911",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not an immune checkpoint inhibitor?",
      "choices": [
        {
          "id": 1,
          "text": "Nivolumab"
        },
        {
          "id": 2,
          "text": "Pembrolizumab"
        },
        {
          "id": 3,
          "text": "Atezolimumab"
        },
        {
          "id": 4,
          "text": "Cetuximab"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Cetuximab</strong> is not&nbsp;an <strong>immune checkpoint inhibitor</strong>. Cetuximab is a monoclonal antibody against <strong>epidermal growth factor receptor(EGFR)</strong>. It is used for the treatment of <strong>colon cancer</strong> and head and neck squamous cell cancer.</p>\n<p>Other options.</p>\n<p>Option A:<strong> Nivolumab </strong>is an immune checkpoint inhibitor. It acts by inhibiting programmed death receptor - 1 (<strong>PD-1</strong>) and is used for the treatment of <strong>advanced melanoma</strong> and <strong>classical Hodgkin lymphoma.&nbsp;</strong></p>\n<p>Option B: <strong>Pembrolizumab</strong> is an immune checkpoint inhibitor. It acts by inhibiting programmed death receptor - 1 (<strong>PD-1</strong>) and is used for the treatment of <strong>advanced melanoma</strong>.&nbsp;In 2021, approval was granted for the treatment of patients with <strong>endometrial carcinoma</strong> that progressed after systemic treatment, in combination with <strong>lenvatinib</strong>.</p>\n<p>Option C: <strong>Atezolimumab</strong> is an immune checkpoint inhibitor. It acts by&nbsp;inhibiting programmed death-ligand - 1 (<strong>PDL-1</strong>) and is used for the treatment of <strong>non-small cell lung cancer</strong>.&nbsp;</p>\n<p>Important note:</p>\n<p>The FDA on&nbsp;<strong>May 2021</strong>&nbsp;approved the use of&nbsp;<strong>nivolumab</strong>&nbsp;in patients having completely resected <strong>esophageal or gastroesophageal junction cancers</strong>&nbsp;with residual pathologic disease who have received neoadjuvant chemoradiotherapy.</p><hr><h3>Related Pearl: Monoclonal antibodies nomenclature</h3><p>Murine - <strong>0%</strong> human: &ldquo;<strong>omab</strong>&rdquo; (Tositumomab)</p>\n<p>Chimeric - <strong>65%</strong> human: &ldquo;<strong>ximab</strong>&rdquo; (Rituximab)</p>\n<p>Humanized - <strong>95%</strong> human: &ldquo;<strong>zumab</strong>&rdquo; (Trastuzumab)</p>\n<p>Fully human - <strong>100%</strong> human: &ldquo;<strong>umab</strong>&rdquo; (Adalimumab)</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4907",
      "difficulty": "easy"
    },
    {
      "text": "NAPQI is the metabolite of which of the following drug toxicity?",
      "choices": [
        {
          "id": 1,
          "text": "Aspirin"
        },
        {
          "id": 2,
          "text": "Paracetamol"
        },
        {
          "id": 3,
          "text": "Diclofenac"
        },
        {
          "id": 4,
          "text": "Ketorolac"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>N-acetyl-p-benzoquinone imine</strong>&nbsp;(NAPQI) is a metabolite of <strong>paracetamol</strong> drug toxicity.&nbsp;</p>\n<p>Paracetamol is an analgesic and antipyretic with <strong>weak anti-inflammatory action</strong>. It is mainly metabolized&nbsp;in the <strong>liver</strong> by conjugation with <strong>glucuronic acid</strong> and sulfate and is excreted in the urine.</p>\n<p>At toxic doses, the glucuronide and sulfate conjugation pathway becomes <strong>saturated</strong>. The metabolites of paracetamol get converted into NAPQI. NAPQI is&nbsp;<strong>highly reactive</strong> and causes enzymatic dysfunction in the liver. Normally, minor amounts of NAPQI produced in our body are rapidly eliminated by conjugation with <strong>reduced glutathione(GSH)</strong> and then excreted into the urine.</p>\n<p>Therefore, paracetamol toxicity is treated with <strong>N-acetyl cysteine(NAC)</strong>, which <strong>replenishes GSH.&nbsp;</strong>NAC thereby helps in the excretion of NAPQI from the body. N-acetyl cysteine is an <strong>anti-oxidant</strong> and functions by detoxifying NAPQI.</p>\n<p>Paracetamol poisoning is the <strong>most common</strong> cause of liver failure necessitating transplantation.</p>\n<p>The <strong>maximum dose</strong> of acetaminophen that can be given is <strong>4 g/day</strong>.&nbsp;</p><hr><h3>Related Pearl: Specific antidotes for poisoning</h3><table>\n<tbody>\n<tr>\n<td><strong>ANTIDOTE</strong></td>\n<td><strong>POISONING</strong></td>\n</tr>\n<tr>\n<td><strong>4-methyl pyrazole</strong></td>\n<td>Methanol and ethylene glycol</td>\n</tr>\n<tr>\n<td><strong>100% oxygen </strong></td>\n<td>Carbon monoxide, cyanide, methemoglobinemia</td>\n</tr>\n<tr>\n<td><strong>Ammonium chloride </strong></td>\n<td>Phencyclidine, amphetamine</td>\n</tr>\n<tr>\n<td><strong>Amyl nitrate </strong></td>\n<td>Cyanide, hydrogen sulphide</td>\n</tr>\n<tr>\n<td><strong>Atropine</strong></td>\n<td>Carbamate and organophosphorus poisoning</td>\n</tr>\n<tr>\n<td><strong>Bupropion</strong></td>\n<td>Nicotine</td>\n</tr>\n<tr>\n<td><strong>Calcium disodium edetate</strong></td>\n<td>Cadmium, chromium, cobalt, copper, lead, magnesium, nickel, uranium, zinc</td>\n</tr>\n<tr>\n<td><strong>Calcium gluconate </strong></td>\n<td>Precipitates fluorides, magnesium and oxalates</td>\n</tr>\n<tr>\n<td><strong>Chlorpromazine</strong></td>\n<td>Amphetamine</td>\n</tr>\n<tr>\n<td><strong>Deferoxamine</strong></td>\n<td>Iron, aluminium</td>\n</tr>\n<tr>\n<td><strong>Diazepam</strong></td>\n<td>Amphetamine, chloroquine, alcohol withdrawal</td>\n</tr>\n<tr>\n<td><strong>Dicobalt edetate</strong></td>\n<td>Cyanide</td>\n</tr>\n<tr>\n<td><strong>Dimercaprol (BAL)</strong></td>\n<td>Antimony, arsenic, copper, lead, mercury, nickel and gold</td>\n</tr>\n<tr>\n<td><strong>Diphenhydramine</strong></td>\n<td>Phenothiazines and related drugs</td>\n</tr>\n<tr>\n<td><strong>Disodium calcium edetate</strong></td>\n<td><strong>&nbsp;</strong>Lead</td>\n</tr>\n<tr>\n<td><strong>DMPS *, (Unithiol)</strong></td>\n<td><strong>&nbsp;</strong>Mercury</td>\n</tr>\n<tr>\n<td><strong>DMSA ** </strong></td>\n<td><strong>&nbsp;</strong>Lead</td>\n</tr>\n<tr>\n<td><strong>D-Penicillamine (Cuprimine) </strong></td>\n<td>Copper, lead, mercury, chromate, nickel, zinc, arsenic</td>\n</tr>\n<tr>\n<td><strong>Ethanol</strong></td>\n<td>Methanol and ethylene glycol</td>\n</tr>\n<tr>\n<td><strong>Fab fragment</strong></td>\n<td>Digoxin, digitoxin, oleander tea</td>\n</tr>\n<tr>\n<td><strong>Flumazenil</strong></td>\n<td>Benzodiazepine</td>\n</tr>\n<tr>\n<td><strong>Glucagon</strong></td>\n<td>Propranolol and other beta-blockers toxicity</td>\n</tr>\n<tr>\n<td><strong>Hydroxocobalamin</strong></td>\n<td>Cyanide</td>\n</tr>\n<tr>\n<td><strong>Labetalol hydrochloride</strong></td>\n<td>Hypertensive crisis due to cocaine</td>\n</tr>\n<tr>\n<td><strong>Methionine</strong></td>\n<td>Paracetamol</td>\n</tr>\n<tr>\n<td><strong>Methylene blue</strong></td>\n<td>Methemoglobinemia</td>\n</tr>\n<tr>\n<td><strong>N-acetylcysteine </strong></td>\n<td>Paracetamol, acetaminophen toxicity</td>\n</tr>\n<tr>\n<td><strong>Nalorphine</strong></td>\n<td>Morphine</td>\n</tr>\n<tr>\n<td><strong>Naloxone (Naltrexone)</strong></td>\n<td>Narcotic, opiates, CNS depressants</td>\n</tr>\n<tr>\n<td><strong>Nicotinamide</strong></td>\n<td>Vacor poisoning, phenylurea pesticide toxicity</td>\n</tr>\n<tr>\n<td><strong>Pancuronium bromide</strong></td>\n<td>Neuromuscular blocking agents</td>\n</tr>\n<tr>\n<td><strong>Penicillamine</strong></td>\n<td>Copper</td>\n</tr>\n<tr>\n<td><strong>Physostigmine salicylate </strong></td>\n<td>Coma, convulsions from anticholinergics</td>\n</tr>\n<tr>\n<td><strong>Pralidoxime (2-PAM) </strong></td>\n<td>Organophosphorus insecticides, nerve agents</td>\n</tr>\n<tr>\n<td><strong>Propranolol</strong></td>\n<td>Cocaine intoxication, beta adrenergics</td>\n</tr>\n<tr>\n<td><strong>Protamine sulphate </strong></td>\n<td>Heparin overdose</td>\n</tr>\n<tr>\n<td><strong>Prussian blue</strong></td>\n<td>Thallium</td>\n</tr>\n<tr>\n<td><strong>Pyridoxine (Vit. B6) </strong></td>\n<td>Isoniazid, hydrazine toxicity</td>\n</tr>\n<tr>\n<td><strong>Sodium bicarbonate </strong></td>\n<td>Urinary alkalinisation for salicylates, phenobarbital</td>\n</tr>\n<tr>\n<td><strong>Sodium nitrite</strong></td>\n<td>Cyanide</td>\n</tr>\n<tr>\n<td><strong>Sodium thiosulphate</strong></td>\n<td>Cyanide</td>\n</tr>\n<tr>\n<td><strong>Vitamin K</strong></td>\n<td>Warfarin</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4875",
      "difficulty": "easy"
    },
    {
      "text": "Identify the correct match, regarding the drug and its adverse effect.",
      "choices": [
        {
          "id": 1,
          "text": "Hydralazine - heart failure"
        },
        {
          "id": 2,
          "text": "Atenolol - hemolytic anemia"
        },
        {
          "id": 3,
          "text": "Aliskiren - hypokalemia"
        },
        {
          "id": 4,
          "text": "Verapamil - constipation"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The correct match is <strong>verapamil</strong> causes <strong>constipation</strong>.</p>\n<p>Verapamil is a calcium channel blocker used for the treatment of paroxysmal supraventricular tachycardia, atrial fibrillation, and atrial flutter. Bradycardia and <strong>constipation</strong> are the important side effects of verapamil.</p>\n<p>Other options:</p>\n<p>Option A: <strong>Hydralazine</strong> is a <strong>vasodilator</strong> used in the treatment of&nbsp;heart failure, and <strong>hypertensive emergencies</strong>, especially preeclampsia.&nbsp;The drug is used&nbsp;as a combination pill containing isosorbide dinitrate (<strong>BiDil</strong>) in the treatment of heart failure. The important side effect of hydralazine is <strong>drug-induced lupus</strong>.</p>\n<p>Option B: <strong>Atenolol</strong> is a <strong>cardioselective beta-1 blocker</strong> used in the treatment of angina and hypertension. Atenolol doesn't cause <strong>hemolytic anemia</strong>.</p>\n<p>Option C: <strong>Aliskiren</strong> is a <strong>direct renin inhibitor</strong> used as an alternative&nbsp;<strong>antihypertensive</strong> drug for those who do not respond or do not tolerate 1st line drugs. The side effect of aliskiren is <strong>hyperkalemia</strong> and not hypokalemia.</p><hr><h3>Related Pearl: Parenteral drugs used in hypertensive emergencies</h3><table>\n<tbody>\n<tr>\n<td>\n<p>&nbsp;</p>\n</td>\n<td>\n<p><strong>Drugs</strong></p>\n</td>\n<td>\n<p><strong>Contraindications</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Beta-blockers</p>\n</td>\n<td>Labetalol, esmolol, metoprolol</td>\n<td>\n<p>Heart block, systolic heart failure, asthma bradycardia</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Calcium channel blockers</p>\n</td>\n<td>\n<p>Clevidipine, nicardipine</p>\n</td>\n<td>\n<p>Advanced aortic stenosis&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>D1 receptor agonist</p>\n</td>\n<td>Fenoldopam</td>\n<td>\n<p>Caution in glaucoma</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"3\">\n<p>Vasodilators</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>Nitroglycerin</p>\n</td>\n<td>Pericardial tamponade</td>\n</tr>\n<tr>\n<td>\n<p>Nitroprusside</p>\n</td>\n<td>Relatively contraindicated in liver failure and renal failure&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Hydralazine</p>\n</td>\n<td>&nbsp;CAD, RHD</td>\n</tr>\n<tr>\n<td>\n<p>ACE inhibitors</p>\n</td>\n<td>\n<p>Enalaprilat</p>\n</td>\n<td>History of angioedema</td>\n</tr>\n<tr>\n<td>\n<p>Alpha-blocker</p>\n</td>\n<td>\n<p>Phentolamine, Urapidil</p>\n</td>\n<td>&nbsp;Aortic stenosis, AV shunt</td>\n</tr>\n<tr>\n<td>\n<p>Centrally acting sympatholytics</p>\n</td>\n<td>\n<p>Clonidine</p>\n</td>\n<td>Severe AV block, sick-sinus syndrome</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Anti-anginal drugs</h3><p>Anti-anginal drugs can be divided into the following categories:</p>\n<ul>\n<li><strong>Nitrates</strong> - dilates veins &gt; arteries, reduces preload</li>\n<li><strong>Calcium channel blockers</strong> - blocks L-type calcium channels\n<ul>\n<li>Dihydropyridines - amlodipine, nifedipine</li>\n<li>Non-dihydropyridines - verapamil, diltiazem</li>\n</ul>\n</li>\n<li><strong>Beta-blockers</strong> - decreases heart rate, contractility and oxygen demand</li>\n<li>Other drugs:&nbsp;\n<ul>\n<li><strong>Ranolazine</strong> - late Na<sup>+</sup>&nbsp;channel blocker</li>\n<li><strong>Ivabradine</strong> - inhibit funny currents in SA node</li>\n<li><strong>Nicorandil</strong> - K<sup>+</sup>-ATP channel agonist</li>\n<li><strong>Trimetazidine</strong> - pFOX inhibitor</li>\n<li><strong>Fasudil</strong> - rho-kinase inhibitor</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4903",
      "difficulty": "medium"
    },
    {
      "text": "A lady who had undergone mastectomy for breast cancer is being treated with tamoxifen. How long should it be stopped for before she can conceive?",
      "choices": [
        {
          "id": 1,
          "text": "1 month"
        },
        {
          "id": 2,
          "text": "3 months"
        },
        {
          "id": 3,
          "text": "No need to stop"
        },
        {
          "id": 4,
          "text": "Can be stopped and conceived soon after stopping"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>In a post-mastectomy patient undergoing therapy with <strong>tamoxifen</strong>, it should be <strong>stopped</strong> <strong>for</strong> <strong>3 months</strong> before she can <strong>conceive</strong>.</p>\n<p><strong>Tamoxifen</strong>&nbsp;is a selective estrogen receptor modulator&nbsp;<strong>(SERM)</strong>&nbsp;and is used as a chemotherapeutic agent in&nbsp;<strong>receptor positive breast cancer&nbsp;</strong>patients to prevent recurrence after surgery. It is the drug of choice in&nbsp;<strong>pre-menopausal women.</strong>&nbsp;It has an agonistic action on the endometrium, leading to an&nbsp;<strong>increased risk</strong>&nbsp;of&nbsp;<strong>endometrial cancers</strong> (2 fold risk)<strong>.</strong>&nbsp;Hence, it is not used in post-menopausal women.</p>\n<p>It is <strong>contraindicated</strong> in <strong>pregnancy</strong> due to teratogenic effects such as <strong>craniofacial abnormalities&nbsp;</strong>and reproductive tract abnormalities. For the same reason, it has to be stopped for <strong>3 months</strong> (due to long half-life) prior to <strong>conceiving</strong>.&nbsp;It is also stopped during lactation as it is secreted in breast milk. Other complications of tamoxifen include deep vein thrombosis, pulmonary embolism, and hot flashes.</p>\n<p><strong>Other breast cancer risk reduction techniques:</strong></p>\n<ol>\n<li aria-level=\"1\"><strong>Lifestyle modification:</strong>&nbsp;Low-calorie diet, daily exercise, no smoking, no drinking, etc.</li>\n<li aria-level=\"1\">More&nbsp;<strong>frequent screening</strong>&nbsp;with mammogram +/- MRI</li>\n<li aria-level=\"1\">Chemoprevention<strong>:</strong>&nbsp;Preferred in women &gt;35 years of age in patients who are ER/PR positive. Given for 5-10 years.</li>\n<ul>\n<li aria-level=\"2\"><strong>SERMS</strong>&nbsp;(selective estrogen receptor modulators) - Tamoxifen and raloxifene. These have adverse effects.&nbsp;</li>\n<li aria-level=\"2\"><strong>Aromatase Inhibitors</strong>&nbsp;(AIs): They are used only in <strong>post-menopausal women.</strong></li>\n</ul>\n<li aria-level=\"1\"><strong>Risk-reduction surgeries:</strong>&nbsp;preferred in patients with&nbsp;<strong>BRCA1/2</strong>&nbsp;mutations&nbsp;or patients with first-degree relatives with breast cancers. Provides &gt;90% risk-reduction. preferred in patients who have completed their family.</li>\n<ul>\n<li aria-level=\"2\"><strong>Bilateral mastectomy</strong></li>\n<li aria-level=\"2\"><strong>Salpingo-oophorectomy:</strong>&nbsp;Best results when done &lt; 40 years of age.</li>\n</ul>\n</ol><hr><h3>Related Pearl: Hormonal therapy in breast carcinoma given for ER/PR-positive cases</h3><p><strong>Role:</strong></p>\n<ul>\n<li>Reduce risk of recurrence</li>\n<li>Reduce risk of contralateral breast cancer</li>\n<li>Reduce risk of progression of in situ to invasive carcinoma</li>\n</ul><table>\n<tbody>\n<tr>\n<td>Selective estrogen- receptor modulator</td>\n<td>Aromatase inhibitors</td>\n<td>Ovarian suppression/ ablation</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Tamoxifen</li>\n<li>Raloxifen</li>\n<li>Arzoxifen</li>\n<li>Fenoxifen</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Anastrazole</li>\n<li>Letrozole</li>\n<li>Exemestane</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Oophorectomy</li>\n<li>GnRH analogues</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF5027",
      "difficulty": "easy"
    },
    {
      "text": "A young boy with a history of multiple blood transfusions presents with bone pain for the past 6 months.  A peripheral smear showed sickle-shaped RBCs. Which of the following drugs are not used in the treatment of his condition?",
      "choices": [
        {
          "id": 1,
          "text": "Bebtelovimab"
        },
        {
          "id": 2,
          "text": "Voxelotor"
        },
        {
          "id": 3,
          "text": "Hydroxyurea"
        },
        {
          "id": 4,
          "text": "L-glutamine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Bebtelovimab</strong> is not used in the treatment of <strong>sickle cell disease</strong>. The clinical features of <strong>multiple blood transfusions</strong>, <strong>bone pain,</strong> and <strong>sickle cells</strong> on peripheral smear are suggestive of <strong>sickle cell disease</strong>.</p>\n<p>Bebtelovimab is the new monoclonal antibody used for the treatment of COVID-19. It&nbsp;works by binding to the <strong>spike protein</strong> of the COVID-19 virus. It has been found useful in reducing the risk of hospitalization or death.&nbsp;Bebtelovimab retains the activity against the <strong>omicron</strong> variant.</p>\n<p>Other options:</p>\n<p>Option B: <strong>Voxelotor</strong> is an inhibitor of&nbsp;<strong>hemoglobin S</strong> <strong>polymerase </strong>and<strong>&nbsp;stabilizer </strong>of sickle cell hemoglobin<strong> (HbS)</strong> that is used in the therapy of sickle cell disease.</p>\n<p>Option C:&nbsp;<strong>Hydroxyurea</strong> improves fetal haemoglobin <strong>(HbF)</strong> and is the primary drug for <strong>controlling HbS</strong> in sickle cell disease. Thus improving the oxygen-carrying capacity of the blood.&nbsp;Hydroxyurea also inhibits the enzyme <strong>ribonucleotide reductase (RNR)</strong>, which is a rate-limiting step in the biosynthesis of DNA. This property of hydroxyurea is used in the treatment of various cancers, and myeloproliferative disorders like chronic myelogenous leukemia, and polycythemia.</p>\n<p>Option D: <strong>L-glutamine</strong>&nbsp;is a naturally occurring amino acid with <strong>antioxidant properties</strong>. It&nbsp;increases the availability of reduced glutathione which may lessen oxidative damage in sickle red blood cells.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4918",
      "difficulty": "medium"
    },
    {
      "text": "The half-life of letrozole is:",
      "choices": [
        {
          "id": 1,
          "text": "45 hours"
        },
        {
          "id": 2,
          "text": "70 hours"
        },
        {
          "id": 3,
          "text": "90 hours"
        },
        {
          "id": 4,
          "text": "120 hours"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The half-life of <strong>letrozole</strong> is <strong>45 hours</strong>.</p>\n<p>Letrozole is a <strong>reversible aromatase inhibitor</strong>. It is a non-steroidal compound that inhibits the aromatization of estrogen thereby causing <strong>estrogen depletion</strong>. Letrozole is rapidly absorbed with 99.9% oral bioavailability and has a&nbsp;<strong>t&frac12;</strong> of around <strong>41 hours</strong>.</p>\n<p>Letrozole is used as the first-line drug for <strong>estrogen-positive</strong> breast cancer following mastectomy in post-menopausal women.</p>\n<p>Adverse effects of letrozole are due to the depletion of estrogen. The commonly seen adverse effects are <strong>hot flashes</strong>, <strong>vaginal dryness</strong>, nausea, diarrhea, dyspepsia, accelerated bone loss, and thinning of hair.</p><hr><h3>Related Pearl: Hormonal therapy in breast carcinoma given for ER/PR-positive cases</h3><p><strong>Role:</strong></p>\n<ul>\n<li>Reduce risk of recurrence</li>\n<li>Reduce risk of contralateral breast cancer</li>\n<li>Reduce risk of progression of in situ to invasive carcinoma</li>\n</ul><table>\n<tbody>\n<tr>\n<td>Selective estrogen- receptor modulator</td>\n<td>Aromatase inhibitors</td>\n<td>Ovarian suppression/ ablation</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Tamoxifen</li>\n<li>Raloxifen</li>\n<li>Arzoxifen</li>\n<li>Fenoxifen</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Anastrazole</li>\n<li>Letrozole</li>\n<li>Exemestane</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Oophorectomy</li>\n<li>GnRH analogues</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4871",
      "difficulty": "medium"
    },
    {
      "text": "Identify the false statement about eicosanoids.",
      "choices": [
        {
          "id": 1,
          "text": "Synthesized from arginine"
        },
        {
          "id": 2,
          "text": "Synthesized from arachidonic acid"
        },
        {
          "id": 3,
          "text": "Prostaglandins have 5 carbon ring"
        },
        {
          "id": 4,
          "text": "Synthesized in platelets"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div class=\"ng-star-inserted\">\n<div class=\"table-responsive font-weight-light answer-scroll ng-star-inserted\">\n<p>A false statement about eicosanoids is they are synthesized from arginine. <strong>Eicosanoids</strong> are synthesized from <strong>arachidonic acid </strong>(Option B)</p>\n<p><strong>Eicosanoids</strong> are the most universally distributed autocoids in the body. <strong>Prostaglandins, thromboxanes,&nbsp;</strong>and <strong>leukotrienes</strong> comprise eicosanoids. Every cell is capable of synthesizing one or more eicosanoids. <strong>Platelets</strong> primarily synthesize <strong>thromboxanes</strong> (Option D).</p>\n<p>Eicosanoids are synthesized from <strong>arachidonic acid</strong>. Arachidonic acid is derived from membrane phospholipids. The release of <strong>arachidonic acid</strong>&nbsp;(AA) from the membrane phospholipids is mainly mediated by <strong>phospholipase</strong> <strong>A.</strong></p>\n<p>AA is metabolized by <strong>cyclooxygenases</strong> to produce <strong>prostaglandins </strong>and <strong>lipoxygenases</strong> to produce <strong>leukotrienes</strong> and lipoxins.</p>\n<div class=\"ng-star-inserted\">\n<div class=\"table-responsive font-weight-light answer-scroll ng-star-inserted\">\n<p>Inhibitors of metabolism of arachidonic acid:</p>\n<ul>\n<li><strong>Corticosteroids</strong> cause inhibition of prostaglandin synthesis by inhibiting<strong> phospholipase A2. <br /></strong></li>\n<li>Non-steroidal anti-inflammatory (<strong>NSAIDs</strong>) drugs inhibit the synthesis of <strong>prostaglandins</strong> by inhibiting the enzyme cyclooxygenase.</li>\n<li><strong>Zileuton</strong> inhibits the enzyme lipoxygenase thereby decreasing the synthesis of <strong>leukotrienes</strong>.</li>\n</ul>\n<p>Chemically, all prostaglandins are considered to be derivatives of prostanoic acid, having&nbsp;a<strong> five-carbon ring&nbsp;</strong>(Option C).</p>\n<p>The image given below shows the synthesis of various eicosanoids from arachidonic acid:</p>\n</div>\n</div>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/796e4a43627f4b17b0530b4e3b118f9ex1280x2080.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF5258",
      "difficulty": "medium"
    },
    {
      "text": "The given diagram shows the steps in bacterial cell wall formation. Identify the site of action of beta-lactam antibiotics.",
      "choices": [
        {
          "id": 1,
          "text": "1"
        },
        {
          "id": 2,
          "text": "2"
        },
        {
          "id": 3,
          "text": "3"
        },
        {
          "id": 4,
          "text": "4"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Beta lactams</strong> act on <strong>step 4</strong> in the given image.</p>\n<p>Mechanism of action of beta-lactams: They are the <strong>cell wall synthesis inhibitor</strong>. The β-lactam antibiotics inhibit this last step in peptidoglycan synthesis. They inhibit the enzyme <strong>transpeptidase</strong> which is required for cross-linking of the peptidoglycan chain. Transpeptidases cleave the terminal <strong>D-alanine</strong> of the peptide chains and form cross-linkages between them. This cross-linking provides <strong>rigidity</strong> and stability to the cell wall.   </p>\n<p>Transpeptidases and other related proteins constitute <strong>penicillin-binding proteins(PBP)</strong> and, are located in the bacterial cell membrane. β-lactam antibiotics are <strong>bactericidal</strong>. This is because bacterias swell and burst due to deficient cell walls when they divide in the presence of β-lactam antibiotics. <strong>Penicillins, cephalosporins, monobactams</strong>, and <strong>carbapenems</strong> are examples of β-lactam antibiotics.</p>\n<p><strong>Gram-positive bacteria</strong> are more susceptible to β-lactam antibiotics than gram-negative because their cell wall is almost entirely made of peptidoglycan.</p>\n<p>Resistance to β-lactam antibiotics develops due to the production of the<strong> beta-lactamase</strong> enzyme and the development of altered penicillin-binding proteins like in methicillin-resistant <em>Staphylococcus aureus</em> (<strong>MRSA</strong>). β-lactamases inactivate β-lactam antibiotics by opening the β-lactam ring. This could be overcome by using drugs that inhibit this enzyme. Examples of <strong>β-lactamase inhibitors</strong> are <strong>clavulanic acid</strong>, <strong>sulbactam</strong>, and <strong>tazobactam.</strong></p>\n<p>Other options:</p>\n<p>Option A: <strong>Fosfomycin</strong> inhibits <strong>step 1</strong> in the image. It inhibits the cytoplasmic enzyme<strong> enol pyruvate transferase </strong>that catalyses the initial step in the bacterial cell wall and hence cell wall synthesis. It is used for the treatment of urinary tract infections.</p>\n<p>Option B: <strong>Bacitracin</strong> inhibits <strong>step 2</strong> in the image. It is a cell wall synthesis inhibitor that interferes with <strong>dephosphorylation</strong> in the cycling of the <strong>lipid carrier</strong> which transfers peptidoglycan subunits to the growing cell wall. It is only given for topical application because of its severe nephrotoxicity when given systemically.</p>\n<p>Option C: <strong>Vancomycin</strong> inhibits <strong>step 3</strong> in the image. It binds to the <strong>D-Ala-D-Ala terminus</strong> of the newly formed peptidoglycan pentapeptide. This <strong>prevents further elongation</strong> of <strong>the peptidoglycan</strong> and its cross-linking. It is used against MRSA and <em><strong>Clostridium difficile </strong></em>infection. <strong>Redman syndrome</strong> due to histamine release following infusion is an important side effect.</p>\n<p>Note: The FDA has approved the use of <strong>cefepime-enmetazobactam</strong>, a combination of a fourth-generation cephalosporin and beta-lactamase inhibitor for use in<strong> complicated UTI</strong>s (including pyelonephritis).</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/abc89b147ae645269bf56a6a300e37ea.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4935",
      "difficulty": "medium"
    },
    {
      "text": "Phospholipase C acts via which of the following G protein-coupled receptors?",
      "choices": [
        {
          "id": 1,
          "text": "Gs"
        },
        {
          "id": 2,
          "text": "Gi"
        },
        {
          "id": 3,
          "text": "Gq"
        },
        {
          "id": 4,
          "text": "Go"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Phospholipase C</strong> acts via the&nbsp;<strong>Gq</strong> type of G protein-coupled receptors.</p>\n<p><strong>G protein-coupled receptors</strong> (GPCRs) are<strong>&nbsp;cell membrane receptors</strong>&nbsp;that span across the membrane 7 times. They also serve as receptors for various <strong>peptide hormones</strong>, neurotransmitters, amino acids, etc.</p>\n<p>Subtypes of GPCRs are distinguished by their alpha subunits. The important subtypes of GPCRs are Gs, Gp, <strong>Gq</strong>, and Go.</p>\n<p>GPCRs act via various second messengers.&nbsp;The important ones with their action on the effector are:</p>\n<ul>\n<li>Gs causes activation of adenylyl cyclase and results in Ca2+ channel opening.</li>\n<li>Gi causes inhibition of adenylyl cyclase and results in K+ channel opening.</li>\n<li>Go causes Ca2+ channel inhibition.</li>\n<li><strong>Gq</strong> causes activation of <strong>p</strong><strong>hospholipase C</strong>&nbsp;which generates the second messengers inositol 1,4,5-trisphosphate (<strong>IP3</strong>) and diacylglycerol (<strong>DAG</strong>). The&nbsp;water-soluble IP3 diffuses to the cytosol and mobilizes <strong>Ca2+</strong> from endoplasmic reticular depots.</li>\n</ul>\n<p>The given below image shows the effects of phospholipase C after activation by <strong>Gq</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e96493e16a4840bbac92bc927f00f27dx1159x976.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Membrane receptors and their mechanisms</h3><p><strong>1. G protein coupled receptor(GPCR)</strong></p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td>&nbsp;<strong>Effect</strong></td>\n<td><strong>2nd messenger</strong></td>\n<td>&nbsp;<strong>Action</strong></td>\n</tr>\n<tr>\n<td>Gs</td>\n<td>Activates adenylate cyclase</td>\n<td>Stimulation of cAMP production</td>\n<td>Activates protein kinase A</td>\n</tr>\n<tr>\n<td>Gi</td>\n<td>Inhibits adenylate cyclase</td>\n<td>Inhibition of cAMP production</td>\n<td>-</td>\n</tr>\n<tr>\n<td>Gq</td>\n<td>Activates phospholipase C</td>\n<td>Liberate DAG and IP3 which mobilize Ca2+ from endoplasmic reticulum</td>\n<td>Activates protein kinase C</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><br /><strong>2. Guanylyl cyclase receptor</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Effector</strong></td>\n<td><strong>2nd messenger</strong></td>\n</tr>\n<tr>\n<td>Guanylyl cyclase</td>\n<td>Stimulation of cGMP production</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><br /><strong>3. Receptor tyrosine kinase</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Effector</strong></td>\n<td><strong>2nd messenger</strong></td>\n</tr>\n<tr>\n<td>Tyrosine kinase</td>\n<td>MAP kinase</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><br /><strong>4. Cytokine receptor tyrosine kinase</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Effector</strong></td>\n<td><strong>2nd messenger</strong></td>\n</tr>\n<tr>\n<td>JAK, tyrosine kinase</td>\n<td>STAT, MAP kinase</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><br /><strong>5. Serine kinase</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Effector</strong></td>\n<td><strong>2nd messenger</strong></td>\n</tr>\n<tr>\n<td>Serine kinase</td>\n<td>Smads</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4895",
      "difficulty": "medium"
    },
    {
      "text": "A patient was diagnosed with pulmonary tuberculosis and was started on first-line antitubercular drugs. Which of the following drug acts by inhibiting the synthesis of the marked layer shown in the image?",
      "choices": [
        {
          "id": 1,
          "text": "Isoniazid"
        },
        {
          "id": 2,
          "text": "Rifampicin"
        },
        {
          "id": 3,
          "text": "Pyrazinamide"
        },
        {
          "id": 4,
          "text": "Ethambutol"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Isoniazid</strong> is the first-line antitubercular drug that acts by inhibiting the synthesis of&nbsp;<strong>mycolic acid</strong>.</p>\n<p><strong>Isoniazid</strong> is a first-line bactericidal drug that is used for the treatment of tuberculosis. This drug enters bacilli by <strong>passive diffusion</strong>. It then gets activated to its toxic form by the enzyme <strong>catalase-peroxidase</strong>(the enzyme encoded by the <strong>Kat gene</strong>).</p>\n<p>Normally, InhA and KasA are involved in the synthesis of mycolic acid. Upon activation, the reactive metabolite of isoniazid forms complexes with <strong>NAD</strong> that inhibit <strong>InhA</strong> and <strong>KasA</strong>. Hence, isoniazid inhibits the production of <strong>mycolic acid</strong>.</p>\n<p>The reactive isoniazid metabolite also forms complexes with <strong>NADP</strong>. This complex inhibits mycobacterial dihydrofolate reductase which results in the interruption of <strong>DNA synthesis</strong>.</p>\n<p>Side effects of isoniazid include:</p>\n<ul>\n<li><strong>Peripheral neuritis</strong> due to interference with the production of active coenzyme pyridoxal phosphate from pyridoxine. Therefore, <strong>pyridoxine 10mg/day (vitamin B6)</strong> is given prophylactically along with isoniazid to prevent neurotoxicity.</li>\n<li><strong>Hepatitis</strong> - isoniazid must be stopped at the first sign of hepatotoxicity.</li>\n<li>Rashes</li>\n<li>Anaemia</li>\n<li>Arthralgia</li>\n</ul>\n<p>Toxicity of isoniazid results in <strong>metabolic acidosis</strong>,&nbsp;<strong>seizures, and coma.</strong></p>\n<p>Other options:</p>\n<p>Option B:&nbsp;Rifampin acts by binding to <strong>DNA-dependent RNA polymerase</strong> to form a stable drug-enzyme complex. This complex suppresses RNA synthesis. Side effects of rifampin are hepatitis,<strong>&nbsp;flu-like illness, orange-red colored urine</strong>, and body secretions.</p>\n<p>&nbsp;Option C: Pyrazinamide is a prodrug, it is converted into an active metabolite<strong> pyrazinoic acid </strong>which makes the intracellular environment <strong>acidic</strong> and collapses the transmembrane proton motive force, thereby killing the bacteria. Side effects include&nbsp;<strong>hyperuricemia</strong> and hepatotoxicity.&nbsp;</p>\n<p>Option D: Ethambutol<strong> inhibits arabinose transferase III, </strong>thereby decreasing arabinogalactan biosynthesis<strong>. </strong>This results in&nbsp;disruption in&nbsp;mycobacterial cell wall synthesis.&nbsp;<strong>Optic neuritis</strong> is an important side effect of<strong> ethambutol</strong>. It results in decreased visual acuity and&nbsp;<strong>loss of red-green discrimination.</strong></p><hr><h3>Related Pearl: General properties of the first line drugs in TB</h3><table>\n<tbody>\n<tr>\n<td>\n<div><span><strong>First-line drugs</strong></span></div>\n</td>\n<td>\n<div><span><strong>Isoniazid</strong></span></div>\n</td>\n<td>\n<div><span><strong>Rifampicin</strong></span></div>\n</td>\n<td>\n<div><span><strong>Pyrazinamide</strong></span></div>\n</td>\n<td>\n<div><span><strong>Ethambutol</strong></span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Mechanism</strong></span></div>\n</td>\n<td>\n<div><span>Bactericidal</span></div>\n</td>\n<td>\n<div><span>Bactericidal</span></div>\n<div><span>(Maximum)</span></div>\n</td>\n<td>\n<div><span>Bactericidal</span></div>\n</td>\n<td>\n<div><span>Bacteriostatic</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Location of Mycobacteria</strong></span></div>\n</td>\n<td>\n<div><span>Intracellular +&nbsp; Extracellular</span></div>\n</td>\n<td>\n<div><span>Intracellular +&nbsp; Extracellular</span></div>\n</td>\n<td>\n<div><span>Intracellular</span></div>\n</td>\n<td>\n<div><span>Extracellular</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span><strong>Metabolism</strong></span></div>\n</td>\n<td>\n<div><span>Liver</span></div>\n</td>\n<td>\n<div><span>Liver</span></div>\n<div><span>(Maximum)</span></div>\n</td>\n<td>\n<div><span>Liver</span></div>\n</td>\n<td>\n<div><span>Kidney</span></div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p><hr><h3>Related Pearl: ATT Regimen for TB Patients</h3><p>As per the latest recommendations from <strong>National Tuberculosis Elimination Programme (NTEP)</strong>, treatment of TB is now based primarily on <strong>drug susceptibility testing</strong>. This is irrespective of new cases, previously treated cases or recurrent TB cases. <br />All cases of TB are treated with Drug Sensitive TB Regimen, as long as the patient is sensitive to isoniazid and rifampicin. (<strong>No classification into category I or II</strong>)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type of TB Case</strong></td>\n<td><strong>Intensive Phase</strong></td>\n<td><strong>Continuation Phase</strong></td>\n</tr>\n<tr>\n<td>New and previously treated cases (H and R sensitive)</td>\n<td>2 months H R Z E</td>\n<td>4 months H R E</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2><strong><span>Classification based on drug resistance. </span></strong></h2>\n<p><span>The<strong> </strong>cases are classified as:</span></p>\n<ul>\n<li><strong>Mono-resistant (MR):</strong> A TB patient, who is resistant to one 1st line anti-TB drug only.</li>\n<li><strong>Poly-Drug Resistant (PDR):</strong> A TB patient, who is resistant to more than one 1st line anti-TB drug, other than Rifampicin and isoniazid. </li>\n<li><strong>Rifampicin Resistant (RR):</strong> A TB patient, who is resistant to <strong>rifampicin</strong> with or without resistance to other drugs. Patients, who have rifampicin resistance, should be managed as if they are an MDR TB case.</li>\n<li><strong>Multi-Drug Resistant (MDR):</strong> A TB patient, who is resistant to <strong>both isoniazid and rifampicin.</strong></li>\n<li><strong>Extensively Drug-Resistant (XDR):</strong> A MDR TB patient who is additionally resistant to a <strong>fluoroquinolone</strong> (ofloxacin, levofloxacin, or moxifloxacin) and at least one additional group A drug (as of 2021, these are bedaquiline and linezolid)</li>\n</ul>\n<h2><strong><span>Standard DR TB regimen</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Regimen class</strong></td>\n<td><strong>Drugs</strong></td>\n<td><strong>Comments</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/ poly-drug resistant TB regimen</strong></td>\n<td>Lfx R E Z for 6 months</td>\n<td>\n<p>6 months long</p>\n<p>Oral drugs only</p>\n</td>\n</tr>\n<tr>\n<td><strong>BPaLM regime (New MDR regime by WHO)</strong></td>\n<td>Bdq Pa Lzd Mfx for 6 months</td>\n<td>\n<p>6 months long</p>\n</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter oral bedaquiline regime (Shorter MDR)</strong></td>\n<td>\n<p><strong>Intensive Phase:</strong></p>\n<p>Lfx Bdq(6 months) Cfz Z Hh E Eto for 4-6 months</p>\n<p><strong>Continuation phase:</strong></p>\n<p>Lfx Cfz Z E for 5 months</p>\n</td>\n<td>\n<p>9-11 months long totally</p>\n<p>Injectables used in Intensive phase.</p>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Bdq(6 months or longer) Lfx Lzd Cfz Cs </td>\n<td>\n<p>18-20 months long</p>\n<p>Oral drugs only</p>\n<p>This regimen is used for XDR TB patients for 20 months.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2> </h2>\n<h2><strong><span>Criteria for patients to receive standard Drug Resistant TB regimen:</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Standard Drug Resistant TB regimen</strong></td>\n<td><strong>Inclusion criteria</strong></td>\n<td><strong>Exclusion criteria</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/poly-drug resistant TB regimen</strong></td>\n<td><strong>Isoniazid resistant</strong> TB with <strong>rifampicin sensitive</strong></td>\n<td>No specific criteria</td>\n</tr>\n<tr>\n<td><strong>BPaLM regimen (New MDR TB regimen by WHO)</strong></td>\n<td>\n<ol>\n<li><strong>MDR/RR-TB</strong> or <strong>pre-XDR-TB</strong> ( MDR/RR-TB and resistance to fluoroquinolones). </li>\n<li>Those with <strong>confirmed</strong> pulmonary TB and all forms of extrapulmonary TB (except for TB involving CNS, osteoarticular, and miliary TB).</li>\n<li>Patients <strong>&gt;14 years of age.<br /></strong></li>\n</ol>\n</td>\n<td>Pregnant and lactating women</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter MDR TB regimen</strong></td>\n<td>Patient with <strong>rifampicin resistant</strong> pulmonary or extra pulmonary TB</td>\n<td>Non drug sensitivity test based criteria:\n<ul>\n<li>Pregnancy</li>\n<li>Any extra pulmonary disease in PLHIV</li>\n<li>Disseminated meningeal or central nervous system TB</li>\n<li>Intolerance to any drug in the shorter MDR TB regimen</li>\n</ul>\nDrug sensitivity test based criteria:\n<ul>\n<li>If DST/DRT result for FQ or SLI is resistant (XDR TB)</li>\n<li>Presence of InhA mutation</li>\n<li>Resistant to Z </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Patients in whom <strong>shorter MDR TB regimen cannot be considered</strong> due to any reason</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Legend</p>\n<p>FQ: Fluoroquinolone</p>\n<p>SLI: Second Line Injectable</p>\n<p>PLHIV: People Living with HIV</p>\n<p>Lfx: Levofloxacin</p>\n<p>Pa: Pretomanid</p>\n<p>H: Isoniazid</p>\n<p>Hh: High Dose Isoniazid</p>\n<p>R: Rifampicin</p>\n<p>E: Ethambutol</p>\n<p>Z: Pyrazinamide</p>\n<p>Mfx: Moxifloxacin</p>\n<p>Km: Kanamycin</p>\n<p>Am: Amikacin</p>\n<p>Eto: Ethionamide</p>\n<p>Cfz: Clofazimine</p>\n<p>Bdq: Bedaquiline</p>\n<p>Lzd: Linezolid</p>\n<p>Cs: Cycloserine</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/ebe55c0cc99a42b383d1f16c8023a2ff.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF5139",
      "difficulty": "easy"
    },
    {
      "text": "A man was brought to the emergency room after poisoning with an unknown substance. Muscarinic poisoning was suspected and he was treated for the same. What is the possible presenting feature which led to the diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Mydriasis"
        },
        {
          "id": 2,
          "text": "Diuresis"
        },
        {
          "id": 3,
          "text": "Muscle fasciculations"
        },
        {
          "id": 4,
          "text": "Bradycardia"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Bradycardia</strong> is the possible presenting feature which led to the diagnosis of <strong>muscarinic</strong> <strong>poisoning</strong>.</p>\n<p>Muscarinic poisoning occurs due to the consumption of <strong>poisonous mushroom</strong>-like <em>Inocybe</em>. <strong>Muscarinic symptoms</strong> appear within an hour of eating the mushroom. These symptoms (along with nicotinic symptoms) can also be seen in <strong>organophosphate poisoning</strong>.</p>\n<p>There are <strong>5 subtypes</strong> of muscarinic receptors they are M<sub>1</sub>, M<sub>2</sub>, M<sub>3</sub>, M<sub>4</sub>, and M<sub>5</sub>. The effects exerted by the <strong>M receptors</strong> are given below:</p>\n<ul>\n<li>M<sub>1</sub>: Increased seizure activity.</li>\n<li>M<sub>2</sub>: <strong>Tremors</strong>, <span class=\"ILfuVd\" lang=\"en\"><span class=\"hgKElc\">bronchoconstriction,<strong> bradycardia</strong>, abdominal cramping</span></span><sub><br /></sub></li>\n<li>M<sub>3</sub>: Increased bladder contraction, <strong>miosis</strong>, increased salivary secretion</li>\n<li>M<sub>4</sub>: Cataplexy(sudden muscle weakness)</li>\n</ul>\n<p><strong>Atropine </strong>is used for the management of muscarinic poisoning. It <strong>competitively </strong>blocks the acetylcholine at the muscarinic receptors.</p><hr><h3>Related Pearl: Acetyl Choline Receptors</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Type</strong></p>\n</td>\n<td>\n<p><strong>Location</strong></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p><strong>Nicotinic (ionotropic) receptors</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>N<sub>M</sub></p>\n</td>\n<td>\n<p>Neuromuscular junction</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>N<sub>N</sub></p>\n</td>\n<td>\n<p>Autonomic ganglia</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p><strong>Muscarinic (metabotropic) receptors</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>M<sub>1</sub>, M<sub>4</sub>, M<sub>5</sub></p>\n</td>\n<td>\n<p>CNS</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>M<sub>2</sub></p>\n</td>\n<td>\n<p>Heart</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>M<sub>3</sub></p>\n</td>\n<td>\n<p>Glands and smooth muscle</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Muscarinic and Nicotinic Signs and symptoms of Organophosphorus Poisoning</h3><table>\n<tbody>\n<tr>\n<td><strong>Mechanism</strong></td>\n<td><strong>Site affected</strong></td>\n<td><strong>Symptoms</strong></td>\n</tr>\n<tr>\n<td rowspan=\"6\"><strong>Muscarinic</strong></td>\n<td>\n<p>Exocrine glands</p>\n</td>\n<td>\n<p>Salivation, lacrimation, perspiration</p>\n</td>\n</tr>\n<tr>\n<td>Eyes</td>\n<td>\n<p>Miosis, blurred vision</p>\n</td>\n</tr>\n<tr>\n<td>GIT</td>\n<td>Abdominal cramps, vomiting, diarrhea</td>\n</tr>\n<tr>\n<td>\n<p>Respiratory tract</p>\n</td>\n<td>Increased secretions, bronchoconstriction</td>\n</tr>\n<tr>\n<td>Bladder</td>\n<td>\n<p>Urinary frequency, incontinence</p>\n</td>\n</tr>\n<tr>\n<td>CVS</td>\n<td>\n<p>Bradycardia, hypotension</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\"><strong>Nicotinic</strong></td>\n<td>\n<p>Skeletal muscles</p>\n</td>\n<td>Muscle fasciculations, Flaccid paralysis</td>\n</tr>\n<tr>\n<td>\n<p>CVS</p>\n<p>(through cholinergic stimulation of sympathetic ganglia)</p>\n</td>\n<td>Tachycardia, Transient hypertension</td>\n</tr>\n<tr>\n<td><strong><span>Muscarinic and nicotinic</span></strong></td>\n<td>CNS</td>\n<td>Dizziness, lethargy, fatigue, headache, mental confusion, depression of respiratory centres, convulsions, coma</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF5101",
      "difficulty": "medium"
    },
    {
      "text": "A 29-year-old lady came to psychiatry OPD with symptoms of hypomania. There is a past history of maniac episode. Now, she is planning to conceive.  Which drug should be avoided for being highly teratogenic to the fetus?",
      "choices": [
        {
          "id": 1,
          "text": "Valproate"
        },
        {
          "id": 2,
          "text": "Lithium"
        },
        {
          "id": 3,
          "text": "Oxcarbazepine"
        },
        {
          "id": 4,
          "text": "Olanzapine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Valproate&nbsp;</strong>should be avoided for being highly teratogenic to the fetus.</p>\n<p>Valproate is an <strong>anti-epileptic medication</strong>. It is also used as a mood stabilizer in manic episodes as well as in bipolar disorder. The repetitive firing caused by depolarization of cortical or spinal cord neurons is <strong>inhibited</strong> by valproate. It also <strong>prolongs</strong> the sodium channel inactivation.&nbsp;</p>\n<p>The&nbsp;<strong>side effects</strong>&nbsp;of valproate (mnemonic:&nbsp;<strong>VALPROATE</strong>)</p>\n<ul>\n<li><strong>V</strong>omiting</li>\n<li><strong>A</strong>lopecia</li>\n<li><strong>L</strong>iver toxicity</li>\n<li><strong>P</strong>ancreatitis</li>\n<li><strong>R</strong>ash</li>\n<li><strong>O</strong>besity</li>\n<li><strong>A</strong>norexia</li>\n<li><strong>T</strong>eratogenicity</li>\n<li><strong>O</strong>edema</li>\n</ul>\n<p>It causes congenital anomalies like <strong>neural tube defects (spina bififda), clefts,</strong> and<strong> cardiac anomalies.</strong>&nbsp;The intelligence quotient score of school-going children who were exposed in utero to valproate is found reduced. It also contributes to poor cognitive development in children. <strong>Folate supplementation</strong> reduces the chances of neural tube defects.&nbsp;</p>\n<p>The images below show a baby and a USG with spinal bifida:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/52b96313ea0e49d49c0cf2421b8a135cx720x527.PNG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/c7d2d20a09874772b14772066b893f24x720x542.JPEG\" alt=\"Explanation Image\"><p>&nbsp;</p>\n<p>Other options:</p>\n<p>Option B: <strong>Lithium&nbsp;</strong>is used for the treatment of <strong>bipolar disorder</strong> as well as<strong> mania</strong>. It was earlier implicated in causing&nbsp;<strong>Ebstein anomaly</strong>, however, recent studies suggest that lithium has a weak teratogenic effect.</p><p>Option C:&nbsp;<strong>Oxcarbazepine </strong>was earlier associated with teratogenicity and fetal malformations, however, recent studies suggest that oxcarbazepine monotherapy during pregnancy does not carry a significant risk of fetal malformations.</p>\n<p>Option D:&nbsp;<strong>Olanzapine</strong>&nbsp;is an antipsychotic and an antimanic and it is not associated with&nbsp;teratogenicity.&nbsp;</p><hr><h3>Related Pearl: Teratogenic drugs and the birth defects</h3><table>\n<tbody>\n<tr>\n<td><strong>Drugs</strong></td>\n<td><strong>Adverse effects</strong></td>\n</tr>\n<tr>\n<td>Penicillamine</td>\n<td>Cutis laxa syndrome</td>\n</tr>\n<tr>\n<td><strong>Lithium</strong></td>\n<td><strong>Ebstein anomaly</strong></td>\n</tr>\n<tr>\n<td>Isotretinoin</td>\n<td>Facial-ear anomalies, heart disease, CNS anomalies</td>\n</tr>\n<tr>\n<td>Progesterone</td>\n<td>Masculinization of the female fetus</td>\n</tr>\n<tr>\n<td>Quinine</td>\n<td>Abortion, thrombocytopenia, deafness</td>\n</tr>\n<tr>\n<td>Topiramate</td>\n<td>Cleft lip</td>\n</tr>\n<tr>\n<td><strong>Valproate</strong></td>\n<td>Spina bifida, limb defects, <strong>autism spectrum disorder</strong>, facial and cardiac anomalies, <strong>Coarctation of the aorta</strong>, Aortic stenosis, Pulmonary atresia, Ventricular Septal Defect. </td>\n</tr>\n<tr>\n<td><strong>Vitamin D</strong></td>\n<td><strong>Supravalvular aortic stenosis</strong></td>\n</tr>\n<tr>\n<td><strong>Warfarin</strong></td>\n<td>Fetal bleeding, <strong>hypoplastic nasal structures</strong></td>\n</tr>\n<tr>\n<td><strong>Statins</strong></td>\n<td>Vertebral, anal, cardiac, tracheoesophageal fistula, renal, arterial, limb (<strong>VACTERAL</strong>) defects</td>\n</tr>\n<tr>\n<td><strong>Phenytoin</strong></td>\n<td>Ventricular septal defect, Atrial Septal Defect, Coarctation of the aorta, Patent Ductus Arteriosus</td>\n</tr>\n<tr>\n<td>ACE inhibitors and ARBs</td>\n<td>\n<p>Hypoplasia of organs, anuria, irreversible renal failure</p>\n</td>\n</tr>\n<tr>\n<td>Carbimazole and Methimazole</td>\n<td> \n<p>Choanal atresia, aplasia cutis, tracheoesophageal fistula and fetal goiter</p>\n</td>\n</tr>\n<tr>\n<td>Alcohol</td>\n<td>Atrial Septal Defect, Ventricular Septal Defect</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF5062",
      "difficulty": "medium"
    },
    {
      "text": "True statement regarding the administration of 5 alpha-reductase inhibitors is/are:<div class='question-desc-html'><p>1. Reduces dihydrotestosterone levels</p>\n<p>2. Reduces testosterone levels</p>\n<p>3. Elevates PSA levels</p>\n<p>4. Decreases PSA levels</p>\n<p>PSA - Prostate-specific antigen </p></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 3"
        },
        {
          "id": 2,
          "text": "1, 3, 4"
        },
        {
          "id": 3,
          "text": "1, 4"
        },
        {
          "id": 4,
          "text": "2, 3"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>True statements regarding the administration of <strong>5 alpha-reductase inhibitors</strong> are <strong>1,4</strong>. They reduce dihydrotestosterone levels and decrease prostate-specific antigen (PSA) levels.</p>\n<p>5 alpha-reductase inhibitors are the <strong>competitive</strong> inhibitors of the enzyme 5 α-reductase which converts testosterone into the more active dihydroxy testosterone (<strong>DHT</strong>). This enzyme inhibition results in:</p>\n<ul>\n<li><strong>Decreased DHT </strong>levels</li>\n<li><strong>Decreased PSA </strong>levels</li>\n<li>Reduces prostate volume</li>\n</ul>\n<p>However, plasma <strong>testosterone</strong> levels and <strong>LH</strong> (luteinizing hormone) levels remain <strong>unchanged </strong></p>\n<p><strong>Finasteride</strong> and <strong>dutasteride</strong> are the 5 α-reductase drugs currently in use. They are used in benign prostatic hyperplasia (<strong>BPH</strong>) along with surgery and adrenergic α1 blockers for symptomatic relief. They can also be used in <strong>male pattern of baldness</strong> and hirsutism.</p>\n<p>Side effects of 5 α-reductase drugs are:</p>\n<ul>\n<li><strong>Impotence</strong></li>\n<li>Decreased libido</li>\n<li>Gynecomastia</li>\n<li>Skin rashes</li>\n</ul><hr><h3>Related Pearl: Benign prostatic hyperplasia treatment</h3><ul>\n<li>Static component: 5 alpha-reductase inhibitor [eg: Finasteride]</li>\n<li>Dynamic component: Alpha 1 blockers [eg: Tamsulosin, terazosin etc]</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF5100",
      "difficulty": "easy"
    },
    {
      "text": "The manufacturer of a drug company labels a drug as having 500 mg paracetamol. On quantitative analysis of the drug, it actually contained only 200 mg of paracetamol. What is this type of drug called?",
      "choices": [
        {
          "id": 1,
          "text": "Spurious drug"
        },
        {
          "id": 2,
          "text": "Adulterated drug"
        },
        {
          "id": 3,
          "text": "Unethical drug"
        },
        {
          "id": 4,
          "text": "Misbranded drug"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>This type of drug is called a <strong>misbranded drug</strong>. A drug stating that 500mg of paracetamol is present in each tablet, but contains only 200mg is a&nbsp;<strong>misbranded</strong>&nbsp;<strong>drug</strong>, according to the <strong>Drugs and Cosmetics Act, 1940</strong> definition of misbranded drugs.</p>\n<p>According to the Drugs and Cosmetics act, 1940,&nbsp;a misbranded drug is a drug if its <strong>label</strong> or container or anything accompanying the drug bears any statement, design, or device which makes any <strong>false claim</strong> for the drug or which is false or misleading in any particular.</p>\n<p>Other options:</p>\n<p>Option A:&nbsp;<strong>Spurious drugs</strong>&nbsp;include drugs manufactured under&nbsp;<strong>another drug&nbsp;</strong>or<strong>&nbsp;manufacturer's name</strong>,&nbsp;<strong>imitations</strong>&nbsp;of other drugs, and drugs with labels from a&nbsp;<strong>fictitious company</strong>&nbsp;or individual. It also includes drugs substituted partly or wholly by another drug or substance.</p>\n<p>Option B:&nbsp;<strong>Adulterated drugs</strong>&nbsp;include those drugs that contain&nbsp;<strong>filthy</strong>, or decomposed&nbsp;<strong>substances</strong>, substances that are&nbsp;<strong>injurious to health</strong>, or if the drug harmful substances to&nbsp;<strong>reduce&nbsp;</strong>the<strong>&nbsp;quality&nbsp;</strong>or<strong>&nbsp;strength&nbsp;</strong>of the drug. It also includes drugs that were prepared in unsanitary conditions.</p>\n<p>Option C: The term&nbsp;unethical drug is not standard terminology in pharmacology. However, the term<strong> ethical drug </strong>is sometimes used to describe those <strong>drugs</strong> that are available <strong>only by prescription</strong> of a medical practitioner.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4922",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following anti-diabetic drugs is associated with the increased risk of fractures?",
      "choices": [
        {
          "id": 1,
          "text": "Rosiglitazone"
        },
        {
          "id": 2,
          "text": "Liraglutide"
        },
        {
          "id": 3,
          "text": "Voglibose"
        },
        {
          "id": 4,
          "text": "Canagliflozin"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Canagliflozin</strong> is associated with an increased risk of <strong>fractures</strong>.&nbsp;</p>\n<p>Canagliflozin is a <strong>sodium-glucose transporter-2 </strong>(SGLT2) inhibitor. SGLT2 is a Na+-glucose <strong>cotransporter</strong> that is located in the <strong>proximal convoluted tubule</strong>. They reabsorb glucose and sodium from the tubular lumen back into the blood through the epithelial cells. SGLT2 inhibitors block the transport of glucose&nbsp;in the proximal tubule and promote <strong>glycosuria</strong> and hence,&nbsp;lowering blood glucose.</p>\n<p>The currently available SGLT2 inhibitors are canagliflozin, dapagliflozin, and empagliflozin. Other than decreasing blood glucose they also decrease&nbsp;blood pressure and,&nbsp;cause <strong>weight loss</strong> of 2&ndash;4 kg. Empagliflozin and canagliflozin reduce the risk for major cardiovascular events.</p>\n<p>The main side effect of SGLT2 inhibitors is an increase in <strong>lower urinary tract infections</strong> and&nbsp;genital mycotic infections. This is because of their glycosuric properties. A recent warning from the FDA says that SGLT2 inhibitors may increase the risk of <strong>fractures</strong>. They also<strong>&nbsp;</strong>affect&nbsp;circulating levels of parathyroid hormone, and 1,25-hydroxy vitamin D thereby affecting&nbsp;the mineral balance in bone.</p>\n<p>Other options:</p>\n<p>Option A: <strong>Rosiglitazone</strong> is a thiazolidinedione that acts as a peroxisome proliferator-activated receptor &gamma; agonist in the adipose tissue which increases insulin sensitivity and adipose differentiation. Side effects are <strong>weight gain, edema,&nbsp;</strong>and<strong> increased risk of fractures.</strong>&nbsp;Compared to rosiglitazone, canagliflozin is commonly used in clinical practice. American diabetes association recommends canagliflozin as the first-line drug along with metformin, in patients with a high risk of cardiovascular disease, renal failure, and heart failure. Even when thiazolidinediones are required, clinicians prefer pioglitazone over rosiglitazone due to the higher risk of cardiovascular-related mortality in rosiglitazone. Therefore, <strong>canagliflozin</strong> would be a <strong>better</strong> option compared to rosiglitazone.&nbsp;</p>\n<div class=\"ng-star-inserted\">\n<div class=\"table-responsive font-weight-light answer-scroll ng-star-inserted\">\n<p>Option B: <strong>Liraglutide</strong> is a long-acting glucagon-like peptide-1 agonist. Nausea, diarrhea, and <strong>acute pancreatitis</strong> are some frequent side effects.</p>\n</div>\n</div>\n<p>Option C: <strong>Voglibose</strong> reduces the intestinal absorption of starch, dextrin, and disaccharides by inhibiting the action of<strong> &alpha;-glucosidase </strong>in the intestinal brush border. The most prominent adverse effects are malabsorption, flatulence, diarrhea, and abdominal bloating.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4942",
      "difficulty": "medium"
    },
    {
      "text": "The active metabolite of cyclophosphamide is:",
      "choices": [
        {
          "id": 1,
          "text": "N - hydroxy cyclophosphamide"
        },
        {
          "id": 2,
          "text": "4 - hydroxy cyclophosphamide"
        },
        {
          "id": 3,
          "text": "4 - acetyl cyclophosphamide"
        },
        {
          "id": 4,
          "text": "N - acetyl cyclophosphamide"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The active metabolite of cyclophosphamide is&nbsp;<strong>4 - hydroxy cyclophosphamide.&nbsp;</strong></p>\n<p><strong>Cyclophosphamide&nbsp;</strong>is an <strong>alkylating agent</strong> with antitumor and <strong>immunosuppressant</strong> properties. It is used for many solid tumors. The important side effects are<strong> cystitis</strong> due to metabolite <strong>acrolein</strong> and <strong>bladder carcinoma</strong>.&nbsp;</p>\n<p><strong>Cystitis</strong> caused by cyclophosphamide is treated by&nbsp;systemic administration of <strong>mesna</strong> and by irrigating the bladder with <strong>acetylcysteine</strong>. Both these drugs contain &ndash;SH which detoxifies the toxic metabolites. Plenty of fluids and frequent bladder voiding are also helpful.</p><hr><h3>Related Pearl: Classification of antineoplastic drugs</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/fd047e306bdc4310be749978ffaf0c5dx1280x1780.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><strong>&nbsp; &nbsp;Non-cell-cycle specific drugs</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Alkylating agents</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Nitrogen mustards</p>\n<ul>\n<li>Cyclophosphamide</li>\n<li>Ifosfamide</li>\n<li>Mechlorethamine</li>\n<li>Melphalan</li>\n<li>Chlorambucil</li>\n<li>Bendamustine</li>\n</ul>\n<p>Nitrosoureas</p>\n<ul>\n<li>Carmustine</li>\n<li>Lomustine</li>\n<li>Semustine</li>\n<li>Streptozocin</li>\n</ul>\n<p>Triazines (methylating agents)</p>\n<ul>\n<li>Procarbazine</li>\n<li>Dacarbazine</li>\n<li>Temozolomide</li>\n</ul>\n<p>Ethyleneimines</p>\n<ul>\n<li>Altretamine</li>\n<li>Thio-TEPA</li>\n</ul>\n<p>Alkyl sulfonates</p>\n<ul>\n<li>Busulfan</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Platinum compounds</strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Cisplatin</li>\n<li>Carboplatin</li>\n<li>Oxaliplatin&nbsp;</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Anti-tumor antibiotics</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Anthracyclines</p>\n<ul>\n<li>Doxorubicin (adriamycin)</li>\n<li>Daunorubicin (rubidomycin)</li>\n<li>Epirubicin</li>\n<li>Valrubicin</li>\n<li>Mitoxantrone</li>\n</ul>\n<p>Others</p>\n<ul>\n<li>Actinomycin-D (Dactinomycin)</li>\n<li>Mitomycin-C</li>\n<li>Bleomycin (also a G2-M phase inhibitor)</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong> Cell-cycle specific drugs</strong></td>\n</tr>\n<tr>\n<td><strong>S-phase inhibitors</strong></td>\n</tr>\n<tr>\n<td><strong>Antimetabolites</strong></td>\n</tr>\n<tr>\n<td>Antifolate\n<ul>\n<li>Methotrexate</li>\n<li>Pemetrexed</li>\n<li>Pralatrexate</li>\n<li>Raltitrexed</li>\n</ul>\nPurine analogues\n<ul>\n<li>6-Mercaptopurine</li>\n<li>6-Thioguanine</li>\n<li>Fludarabine</li>\n<li>Cladribine</li>\n<li>Pentostatin</li>\n</ul>\nPyrimidine analogues\n<ul>\n<li>5-Fluorouracil</li>\n<li>Capecitabine</li>\n<li>Gemcitabine</li>\n<li>Cytarabine</li>\n</ul>\n&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Topoisomerase inhibitors</strong></td>\n</tr>\n<tr>\n<td>Topoisomerase-1 inhibitors (ca)\n<ul>\n<li>Irinotecan</li>\n<li>Topotecan</li>\n</ul>\nTopoisomerase-2 inhibitors\n<ul>\n<li>Etoposide</li>\n<li>Teniposide</li>\n</ul>\n&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Histone deacetylase inhibitors</strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Vorinostat</li>\n<li>Belinostat</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Others </strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>&nbsp;Hydroxyurea</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td><strong>M-phase inhibitors (antimitotics or microtubule damaging agents)</strong></td>\n</tr>\n<tr>\n<td><strong>Vinca alkaloids</strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Vincristine(Oncovin)</li>\n<li>Vinblastine</li>\n<li>Vinorelbine</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Taxanes</strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Paclitaxel</li>\n<li>Docetaxel</li>\n<li>Cabazitaxel</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Others</strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Epothilones</li>\n<li>Eribulin</li>\n<li>Estramustine</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>G1-S phase inhibitor</strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Epipodophyllotoxin</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF4883",
      "difficulty": "medium"
    },
    {
      "text": "Urinary alkalinization will be most useful in toxicity of which of the following drugs?",
      "choices": [
        {
          "id": 1,
          "text": "Beta blockers"
        },
        {
          "id": 2,
          "text": "Calcium channel blockers"
        },
        {
          "id": 3,
          "text": "Acetaminophen"
        },
        {
          "id": 4,
          "text": "Aspirin"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Alkalinization of urine will be helpful in the removal of aspirin, which is a&nbsp;<strong>weakly acidic drug</strong>&nbsp;and is susceptible to<strong>&nbsp;ion trapping</strong> in the&nbsp;urine.</p>\n<p>Aspirin is a weak acid, with a <strong>pKa of 3.0</strong>.&nbsp;Drugs that are subjected to renal clearance are excreted into the urine by glomerular filtration and active tubular secretion. Nonionized compounds are reabsorbed more rapidly than ionized polar molecules. When the&nbsp;<strong>pH</strong>&nbsp;of the&nbsp;<strong>urine&nbsp;increases</strong>, more salicylate is in its ionized form at equilibrium. Hence, salicylic acid&nbsp;<strong>diffuses</strong>&nbsp;into the&nbsp;<strong>tubular lumen</strong>&nbsp;of the kidney. Urine alkalinization is recommended as a first-line treatment only for moderately severe salicylate poisoning that&nbsp;does not meet the criteria for hemodialysis.</p>\n<p>Alkalinization of the urine is achieved by administration of&nbsp;<strong>100&ndash;150 mEq</strong>&nbsp;of&nbsp;<strong>sodium bicarbonate</strong>&nbsp;in 1 L of 5% dextrose in water (D5W). It is infused intravenously&nbsp;at twice the maintenance fluid requirements.</p>\n<p>Alkalinization of urine is&nbsp;<strong>contraindicated</strong>&nbsp;in&nbsp;<strong>renal failure</strong>&nbsp;or if fluid administration may worsen&nbsp;<strong>pulmonary edema</strong>&nbsp;or congestive heart failure.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7244",
      "difficulty": "easy"
    },
    {
      "text": "A hospital is conducting a study to check the efficacy of statins in multiple centers. There are 4-5 patients per center and half of the patients receive the drug and the other half receive the placebo. Neither the patients nor clinicians know which drug is being administered. What phase of the clinical trial describes the above scenario?",
      "choices": [
        {
          "id": 1,
          "text": "Phase 1"
        },
        {
          "id": 2,
          "text": "Phase 3"
        },
        {
          "id": 3,
          "text": "Phase 2"
        },
        {
          "id": 4,
          "text": "Phase 4"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div class=\"page\" title=\"Page 108\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>A hospital conducting a <strong>double-blinded</strong> study in <strong>multiple centers</strong> to check the <strong>efficacy of statins</strong>&nbsp;describes <strong>phase 3</strong> of the clinical trial. A <strong>phase 2</strong> clinical trial is generally conducted at a <strong>few centers (2-4)</strong> by physicians.</p>\n<p><strong>Phase 3</strong> of a clinical trial is also known as a <strong>multisite trial</strong>. It is conducted on a <strong>large patient population</strong> (500&ndash;3000) by several physicians at <strong>multiple centers</strong>. This phase involves patients who have been diagnosed with the disease that the drug claims to treat. Its purpose is to <strong>confirm the efficacy </strong>of the newly developed drug in a larger population. Phase 3 is <strong>randomized</strong>, <strong>controlled</strong>, and may be <strong>blinded</strong>.</p>\n</div>\n</div>\n</div>\n</div><hr><h3>Related Pearl: Phases of Clinical Trials</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Phase I</strong></p>\n<p>(First in human)</p>\n</td>\n<td>\n<p><strong>Phase II</strong></p>\n<p>(First in patient)</p>\n</td>\n<td>\n<p><strong>Phase III</strong></p>\n<p>(Multisite trial)</p>\n</td>\n<td>\n<p><strong>Phase IV</strong></p>\n<p>(Postmarketing)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>10&ndash;100&nbsp;</p>\n</td>\n<td>\n<p>50 - 500&nbsp;</p>\n</td>\n<td>\n<p>500 - 3000</p>\n</td>\n<td>\n<p>Large or according to study</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Usually healthy volunteers</p>\n</td>\n<td>\n<p>Patients with the target disease</p>\n</td>\n<td>\n<p>Patients&nbsp; with the target disease</p>\n</td>\n<td>\n<p>Real-world patients</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Open-label study</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Usually the observational or open-label</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Human pharmacology and safety</strong>: The study aims at safety and tolerability; PK parameters</p>\n</td>\n<td>\n<p><strong>Therapeutic exploration and dose-ranging</strong>: Efficacy and dose-ranging</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Therapeutic confirmation/comparison</strong>: Indications&nbsp;are finalized and guidelines for therapeutic use are formulated. Monitoring of adverse reactions</p>\n</td>\n<td>\n<p><strong>Postmarketing surveillance/studies</strong>: Drug interactions; long-term or rare side effects</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Extends from Months to 1year</p>\n</td>\n<td>\n<p>1&ndash;2 years</p>\n</td>\n<td>\n<p>3&ndash;5 years</p>\n</td>\n<td>\n<p>Unending, after drug approval</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Randomized Controlled Trials</h3><p><strong>Randomized controlled trials</strong> are a type of <strong>experimental studies</strong>.</p>\n<p><strong>Types</strong></p>\n<ul>\n<li>Clinical trials</li>\n<li>Preventive trials</li>\n<li>Risk factor trials</li>\n<li>Cessation experiments</li>\n<li>Trial of etiological agents</li>\n<li>Evaluation of health services</li>\n</ul>\n<p><strong>General Design of an RCT</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b18b067a5846405b95d6bb11b2e1546fx1280x1482.JPEG\" alt=\"Pearl Image\"><p><strong>Steps of an RCT</strong></p>\n<ul>\n<li>Drawing up a <strong>protocol</strong></li>\n<li>Selecting <strong>reference and experimental</strong> population</li>\n<li><strong>Randomization</strong></li>\n<li>Manipulation or <strong>intervention</strong></li>\n<li><strong>Follow-up</strong></li>\n<li><strong>Assessment</strong> of outcome.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7266",
      "difficulty": "medium"
    },
    {
      "text": "A patient who is a known addict is brought to the hospital with the intoxication of an agent. An ocular examination shows the following finding. Which of the following is true regarding this condition?",
      "choices": [
        {
          "id": 1,
          "text": "This action can be reversed by phenylephrine."
        },
        {
          "id": 2,
          "text": "It cannot be reversed by levallorphan."
        },
        {
          "id": 3,
          "text": "It is caused by activation of the Edinger-Westphal nucleus."
        },
        {
          "id": 4,
          "text": "Tolerance develops due to long-term use."
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical scenario and the image showing a pin-point pupil (miosis) suggest&nbsp;<strong>opioid overdose</strong>. The true statement among those given is that it is caused by activation of the<strong> Edinger-Westphal nucleus.</strong></p>\n<p><strong>Edinger-Westphal nucleus</strong> is a part of the <strong>light reflex pathway </strong>and is&nbsp;located in the midbrain. This nucleus is responsible for causing <strong>pupillary constriction</strong> when the retina is exposed to light.&nbsp;</p>\n<p>Opioid overdose symptoms are a triad of coma, respiratory depression, and pinpoint pupils (miosis). Other features are hypotension, bradycardia, shallow breathing, and hypothermia.</p>\n<p><strong>Tolerance</strong>&nbsp;to miosis does not develop even in addicts who develop a high tolerance to opioids. Miosis is induced by all opioid agonists.</p>\n<p><strong>Naloxone&nbsp;</strong>is the drug of choice for opioid overdose.&nbsp;It<strong>&nbsp;</strong>is administered<strong>&nbsp;</strong>after adequate ventilation is established. <strong>Airway protection&nbsp;</strong>and&nbsp;<strong>ventilatory maintenance</strong>&nbsp;are the most important steps in the treatment of opioid overdose; this is because&nbsp;<strong>respiratory depression</strong>&nbsp;is the major cause of mortality in such cases.&nbsp;<strong>Single-dose</strong>&nbsp;<strong>activated charcoal</strong>&nbsp;can be administered if the opioid ingestion occurred within&nbsp;<strong>one hour</strong>.</p>\n<p><strong>Levallorphan</strong> is an <strong>opioid antagonist</strong>, with properties similar to those of <strong>naloxone</strong>. It can be used for <strong>opioid overdose</strong>. It reverses severe opioid-induced respiratory depression.</p>\n<p><strong>Phenylephrine</strong> is an <strong>&alpha;1-selective agonist</strong> that causes mydriasis,<strong>&nbsp;</strong>but it is not useful in the reversal of opioid-induced miosis.</p>",
      "question_images": [
        "https://dhmbxeygs57ff.cloudfront.net/uploads/644ef3e20c3a40cd848cbccfa38d4188x1280x1006.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7277",
      "difficulty": "medium"
    },
    {
      "text": "Match the following drugs in Column A with their contraindications in Column B.<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td>Column A</td>\n<td>Column B</td>\n</tr>\n<tr>\n<td>A. Morphine</td>\n<td>1. QT prolongation</td>\n</tr>\n<tr>\n<td>B. Amiodarone</td>\n<td>2. Thromboembolism</td>\n</tr>\n<tr>\n<td>C. Vigabatrin</td>\n<td>3. Pregnancy</td>\n</tr>\n<tr>\n<td>D. Estrogen preparations</td>\n<td>4. Head injury</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div>",
      "choices": [
        {
          "id": 1,
          "text": "A-1, B-3, C-2, D-4"
        },
        {
          "id": 2,
          "text": "A-4, B-1, C-3, D-2"
        },
        {
          "id": 3,
          "text": "A-2, B-4, C-1, D-3"
        },
        {
          "id": 4,
          "text": "A-3, B-2, C-4, D-1"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The correct answer is option B: A-4, B-1, C-3, D-2</p>\n<table>\n<tbody>\n<tr>\n<td>A. Morphine</td>\n<td>4. Head Injury</td>\n</tr>\n<tr>\n<td>B. Amiodarone</td>\n<td>1. QT prolongation</td>\n</tr>\n<tr>\n<td>C. Vigabatrin</td>\n<td>3. Pregnancy</td>\n</tr>\n<tr>\n<td>D. Estrogen preparations</td>\n<td>2. Thromboembolism</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>In a patient with head injury, <strong>morphine</strong> is contraindicated because it <strong>increases intracranial tension</strong> due to CO₂ retention, precipitates <strong>respiratory depression,</strong> and may cause vomiting, miosis, and altered mental state which <strong>interferes with assessment</strong> of mental state.</p>\n<p><strong>Amiodarone</strong> should not be used in patients with <strong>prolonged QT interval</strong> because it may cause <strong>marked prolongation</strong> of the QT interval, bradycardia, and<strong> torsades de pointes</strong>.</p>\n<p><strong>Vigabatrin</strong>, an inhibitor of GABA-transaminase, an anti-convulsant, is contraindicated in pregnancy due to its potential <strong>teratogenic effect</strong>.</p>\n<p><strong>Estrogen preparations&nbsp;</strong>can contribute to the incidence and severity of <strong>t</strong><strong>hromboembolism,&nbsp;</strong>particularly if other risk factors are present. The risk of serious cardiovascular side effects is particularly marked in women more than 35 years of age who smoke heavily.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7275",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements is true regarding memantine?<div class='question-desc-html'><p>1. Its therapeutic effect is due to its action on NMDA.<br />2. It is reserved for moderate-to-severe diseases.<br />3. It is used as monotherapy and should not be used with other cholinesterase inhibitors.<br />4. It is given at a daily dose of 15&ndash;30 mg/day.</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 3, 4"
        },
        {
          "id": 2,
          "text": "1, 2"
        },
        {
          "id": 3,
          "text": "3, 4"
        },
        {
          "id": 4,
          "text": "1, 2, 3"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>1 and 2</strong> are true statements regarding memantine.</p>\n<p>Memantine is a non-competitive&nbsp;<strong>NMDA receptor antagonist</strong>. It inhibits glutamate excitotoxicity. It delays the progression of dementia in<strong> Alzheimer's disease</strong>. Commonly, it is started in patients with <strong>moderate-to-severe</strong> disease.</p>\n<p>It can be given both as <strong>monotherapy</strong> or can be given <strong>along</strong> with <strong>cholinesterase inhibitors</strong>. It can be started at a dose of <strong>5 mg once daily</strong> and then progressively increased <strong>up to 10 mg twice daily</strong> for a minimum of 6 months.&nbsp;</p>\n<p>It can cause dizziness and headache. Since it is excreted in the kidney, careful dose adjustments should be made in patients with renal failure.</p><hr><h3>Related Pearl: Alzheimer’s disease</h3><p><strong>Alzheimer’s disease:</strong></p>\n<ul>\n<li>Age of onset &gt; 60 years</li>\n<li>Mini-mental state examination (MMSE) &lt; 24</li>\n<li>Diagnosis: Clinical\n<ul>\n<li>2 or more areas of cognitive deficits</li>\n<li>Progressive worsening of memory and other cognitive function</li>\n<li>No disturbance in consciousness</li>\n<li>Other systemic causes must be ruled out </li>\n</ul>\n</li>\n</ul>\n<p><strong>Risk Factors:</strong></p>\n<ul>\n<li>Most important risk factor: Old age</li>\n<li>Other risk factors – Family history, presenilin-1, presenilin-2, Apolipoprotein E4 <strong><strong>(ApoE ε4 allele)</strong></strong>, Ubiquitin, Down syndrome and smoking.</li>\n</ul>\n<p><strong>Protective factors:</strong> NSAIDs and Apolipoprotein <strong>E2</strong></p>\n<p><strong>Causes: </strong>Decrease in <strong>acetylcholine</strong> causing depletion of the cholinergic neurons in the <strong>nucleus basalis of Meynert</strong> resulting in short-term memory defects. </p>\n<p><strong>Early findings:</strong></p>\n<ul>\n<li><strong>Anterograde</strong> memory loss (immediate recall affected, distant memories preserved)</li>\n<li><strong>Visuospatial deficits</strong> (lost in own neighborhood)</li>\n<li><strong>Language difficulties</strong> (difficulty finding words)</li>\n<li><strong>Cognitive impairment</strong> with a progressive decline</li>\n<li>Anosognosia </li>\n<li>Visual processing dysfunction (posterior cortical atrophy syndrome)</li>\n<li>Difficulties with naming and repetition (logopenic aphasia)</li>\n</ul>\n<p><strong>Late findings:</strong></p>\n<ul>\n<li>Psychotic symptoms: <strong>delusions</strong></li>\n<li><strong>Apraxia</strong>: Difficulty to perform learned motor tasks</li>\n<li><strong>Lack of insight</strong> regarding deficits</li>\n<li>Non-cognitive neurologic deficits: Pyramidal and extrapyramidal, myoclonus and seizures</li>\n<li>disrupted sleep - wake pattern.</li>\n<li><strong>Urinary incontinence.</strong></li>\n<li>Loss of procedural memory</li>\n</ul>\n<p><strong>Histopathology:</strong></p>\n<ul>\n<li><strong>Senile plaques</strong> (amyloid deposits), <strong>neurofibrillary tangles</strong> (composed of <strong>tau</strong> proteins), neuronal loss, synaptic loss, and granulovacuolar degeneration of neurons.</li>\n</ul>\n<p>The image below shows neurofibrillary tangles in Alzheimer's disease.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e5db3b220b5c4a6fb0a82d0c724c68c5x640x784.JPEG\" alt=\"Pearl Image\"><p><strong>CT/MRI:</strong></p>\n<ul>\n<li>Later stages: Cortical and subcortical atrophy prominent in parietal and temporal lobes, particularly <strong>hippocampus</strong>. </li>\n</ul>\n<p><strong>Treatment:</strong></p>\n<ul>\n<li>NMDA antagonist: <strong>memantine</strong></li>\n<li>Cholinesterase inhibitors: <strong>donepezil</strong>, <strong>galantamine</strong>, <strong>rivastigmine</strong>.</li>\n<li>Monoclonal antibodies against the N-terminus of the Aβ peptide - <strong>l</strong><strong>ecanemab, donanemab</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7283",
      "difficulty": "medium"
    },
    {
      "text": "The image below shows the life cycle of a virus. Which of the following drugs acts at step 5?",
      "choices": [
        {
          "id": 1,
          "text": "Raltegravir"
        },
        {
          "id": 2,
          "text": "Enfuvirtide"
        },
        {
          "id": 3,
          "text": "Tenofovir"
        },
        {
          "id": 4,
          "text": "Zidovudine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Step 5 in the given life cycle shows the <strong>integration</strong> of the <strong>viral DNA</strong> into the <strong>host genome</strong>. <strong>Raltegravir</strong> is an integrase inhibitor and is active against both <strong>HIV-1</strong> and <strong>HIV-2</strong>. It can be used in <strong>adults</strong> and <strong>children</strong>&nbsp;<strong>&gt;1 month old.&nbsp;</strong></p>\n<p>It is advised for patients to consume <strong>antacids</strong> and <strong>sucralfate,</strong> 6 hours before or 2 hours after raltegravir intake.</p>\n<p>It may cause <strong>headaches, nausea, weakness</strong> and <strong>fatigue.</strong> Rarely, it can lead to drug reactions with eosinophilia and systemic symptoms (DRESS) syndrome.</p>\n<p>The steps involved in the lifecycle of HIV as given in the image are described as follows:</p>\n<ul>\n<li>Step 1: Binding of HIV-1 to the cell membrane of a CD4+ cell</li>\n<li>Step 2: HIV-1 enters the cell via interaction with the membrane glycoproteins</li>\n<li>Step 3: Reverse transcription of the viral genetic material using the virus' reverse transcriptase enzyme</li>\n<li>Step 4: The HIV-1 genome travels into the nucleus</li>\n<li>Step 5: The viral genome integrates into the host's DNA through the integrase enzyme</li>\n<li>Step 6: The HIV-1 proviral genome undergoes transcription with the host DNA</li>\n<li>Step 7: The viral messenger RNA (mRNA) undergoes translation to produce new viral proteins</li>\n<li>Steps 8 and 9: Assembly and maturation of the virion</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/61c1774501b74506af250308d493739ax850x704.PNG\" alt=\"Explanation Image\"><p>Other options:</p>\n<p>Option B: Enfuvirtide acts at <strong>step 2</strong> in the given image. It blocks gp41 of the cell membrane and <strong>blocks the entry</strong> of the virus into the cell. It prevents the free viral particles from invading new CD4+ cells. It is effective against <strong>HIV-1.</strong></p>\n<p>Option C: Tenofovir acts at <strong>step 3</strong> in the given image. It is a nucleotide reverse transcriptase inhibitor (NRTI) that is effective against <strong>HIV-1,2</strong> and <strong>hepatitis B</strong> infections. It is used in adults and <strong>children &gt;2 years old. </strong>It can also be used for<strong> pre-exposure prophylaxis.&nbsp;</strong></p>\n<p>Option D: Zidovudine also acts at <strong>step 3</strong> in the given image. It is an NRTI and is effective against <strong>HIV-1,2</strong> and <strong>Human T-cell Lymphoma Virus (HTLV).</strong> It can be used in adults and children. It can also be used to prevent <strong>mother-to-child transmission.</strong></p><hr><h3>Related Pearl: Classification of antiretroviral drugs</h3><table>\n<tbody>\n<tr>\n<td><strong>CLASS</strong></td>\n<td><strong>DRUGS</strong></td>\n</tr>\n<tr>\n<td>Nucleoside Reverse Transcriptase Inhibitors</td>\n<td>Zidovudine, Stavudine, Lamivudine, Abacavir, Emtricitabine, Didanosine</td>\n</tr>\n<tr>\n<td>Nucleotide Reverse Transcriptase Inhibitors</td>\n<td>Tenofovir</td>\n</tr>\n<tr>\n<td>Non-nucleoside Reverse Transcriptase Inhibitors</td>\n<td>Nevirapine, Efavirenz, Delavirdine,&nbsp;Etravirine</td>\n</tr>\n<tr>\n<td>Protease Inhibitors</td>\n<td>Saquinavir, Indinavir, Ritonavir, Nelfinavir, Lopinavir, Atazanavir, Tiprinavir, Darunavir</td>\n</tr>\n<tr>\n<td>Entry Inhibitors</td>\n<td>Enfuvirtide, Maraviroc</td>\n</tr>\n<tr>\n<td>Integrase Inhibitors</td>\n<td>Raltegravir, Elvitegravir, Dolutegravir</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p class=\"p1\">&nbsp;</p>\n<p>&nbsp;</p><hr><h3>Related Pearl: NACO ART Guidelines- 2021</h3><table class=\"t1\">\n<tbody>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">ART regimen</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">First-line for:</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tenofovir + Lamivudine + Dolutegravir</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li>All PLHIV who are<strong> age &gt;10 years and body weight &gt;30 kg&nbsp;</strong>with <strong>HIV-1, HIV-2, HIV 1&amp;2 co-infection</strong>&nbsp;who have not received any ART&nbsp;</li>\n<li aria-level=\"1\">Those with <strong>HIV-TB and HIV hepatitis co-infections</strong></li>\n<li aria-level=\"1\"><strong>Pregnant women</strong>, pregnant women presenting in <strong>active labour</strong> and <strong>breastfeeding women</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Abacavir + Lamivudine + Efavirenz</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li aria-level=\"1\">All PLHIV with <strong>abnormal serum creatinine</strong> values&nbsp;</li>\n<li aria-level=\"1\">All PLHIV with <strong>bodyweight less &lt;30 kg</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tenofovir + Lamivudine + Efavirenz /Lopinavir /Ritonavir</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li>Women of childbearing age group who do not wish to take Dolutegravir</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<ul>\n<li class=\"p1\">All PLHIV who were on the previous recommended regime&nbsp;(Tenofovir+Lamivudine+Efavirenz) to be counselled to switch to new regime. Continue older regime if response is good</li>\n<li class=\"p1\">Women in child-bearing age group to be counselled about Dolutegravir with opt-out option before switching to new regime</li>\n</ul>\n<p>*PLHIV: People living with HIV</p><hr><h3>Related Pearl: Opportunistic Infections/HIV related conditions and ART initiation</h3><table>\n<tbody>\n<tr>\n<td>Clinical scenario</td>\n<td>Action&nbsp;</td>\n</tr>\n<tr>\n<td>Any undiagnosed active infection with fever</td>\n<td>Diagnose and treat first; start Anti-Retroviral Therapy (ART) when stable</td>\n</tr>\n<tr>\n<td>Tuberculosis (TB)</td>\n<td>Start TB treatment first; start ART as soon as possible after 2 weeks and before 2 months. For those with CD4 less than 50/cmm, start ART within 2 weeks Caution is needed for PLHIV with TB meningitis, since immediate ART is associated with more severe adverse events than initiating ART 2 months after the start of TB treatment</td>\n</tr>\n<tr>\n<td>\n<p>Pneumocystis pneumonia (PCP)</p>\n</td>\n<td>Treat PCP first; start ART when PCP treatment is completed</td>\n</tr>\n<tr>\n<td>Invasive fungal diseases: Oesophageal candidiasis, penicilliosis, histoplasmosis</td>\n<td>Start treatment for oesophageal candidiasis first; start ART as soon as the patient can swallow comfortably. Treat penicilliosis, and histoplasmosis first; start ART when the patient is stabilized or opportunistic infection treatment is completed.</td>\n</tr>\n<tr>\n<td>Cryptococcal meningitis</td>\n<td>Treat cryptococcal meningitis. ART initiation should be deferred until there is evidence of sustained clinical response to anti-fungal therapy and after 4 weeks of induction and consolidation treatment with amphotericin B containing regimen.</td>\n</tr>\n<tr>\n<td>Bacterial pneumonia</td>\n<td>Treat pneumonia first; start ART when treatment is completed</td>\n</tr>\n<tr>\n<td>Malaria</td>\n<td>Treat malaria first; start ART when treatment is completed</td>\n</tr>\n<tr>\n<td>Acute diarrhoea which may reduce absorption of ART</td>\n<td>Diagnose the cause and treat diarrhoea first; start ART when diarrhoea is stabilized or controlled</td>\n</tr>\n<tr>\n<td>Non-severe anaemia (Hb&lt; 9 g/dl)</td>\n<td>Start ART if no other causes for anaemia are found (HIV is often the cause of anaemia)&nbsp;</td>\n</tr>\n<tr>\n<td>Skin conditions such as PPE and seborrhoeic dermatitis, psoriasis, HIV-related exfoliative dermatitis</td>\n<td>Start ART (ART may resolve these problems)&nbsp;</td>\n</tr>\n<tr>\n<td>Suspected Mycobacterium Avium Complex (MAC), Cryptosporidiosis and Microsporidiosis</td>\n<td>Start ART (ART may resolve these problems)</td>\n</tr>\n<tr>\n<td>Cytomegalovirus retinitis</td>\n<td>Start treatment for CMV urgently and start ART after 2 weeks of CMV treatment&nbsp;</td>\n</tr>\n<tr>\n<td>Toxoplasmosis</td>\n<td>Treat toxoplasmosis; start ART after 6 weeks of treatment and when the patient is stabilized</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p>&nbsp;</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/b656eec2969545cab6981b79ab874ed5.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7222",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statements is correct regarding clinical trials?",
      "choices": [
        {
          "id": 1,
          "text": "New drug application is done after phase 4"
        },
        {
          "id": 2,
          "text": "Phase 4 is also called post-marketing surveillance"
        },
        {
          "id": 3,
          "text": "Phase 3 is always double-blinded"
        },
        {
          "id": 4,
          "text": "Phase 2 is done on healthy individuals"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Phase 4</strong> clinical trials are also called <strong>post-marketing surveillance&nbsp;</strong>is the correct statement.</p>\n<p>Other options:</p>\n<p>Option A: New drug application is done after <strong>phase 3</strong> of clinical trials.</p>\n<p>Option C:&nbsp;<strong>Phase 3</strong> trials <strong>may or may not be blinded</strong>.</p>\n<p>Option D:&nbsp;<strong>Phase 2</strong> trials are the first round of trials in <strong>patients</strong>. <strong>Phase 1</strong> trials are done in <strong>healthy</strong> volunteers.</p><hr><h3>Related Pearl: Phases of Clinical Trials</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Phase I</strong></p>\n<p>(First in human)</p>\n</td>\n<td>\n<p><strong>Phase II</strong></p>\n<p>(First in patient)</p>\n</td>\n<td>\n<p><strong>Phase III</strong></p>\n<p>(Multisite trial)</p>\n</td>\n<td>\n<p><strong>Phase IV</strong></p>\n<p>(Postmarketing)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>10&ndash;100&nbsp;</p>\n</td>\n<td>\n<p>50 - 500&nbsp;</p>\n</td>\n<td>\n<p>500 - 3000</p>\n</td>\n<td>\n<p>Large or according to study</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Usually healthy volunteers</p>\n</td>\n<td>\n<p>Patients with the target disease</p>\n</td>\n<td>\n<p>Patients&nbsp; with the target disease</p>\n</td>\n<td>\n<p>Real-world patients</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Open-label study</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Usually the observational or open-label</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Human pharmacology and safety</strong>: The study aims at safety and tolerability; PK parameters</p>\n</td>\n<td>\n<p><strong>Therapeutic exploration and dose-ranging</strong>: Efficacy and dose-ranging</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Therapeutic confirmation/comparison</strong>: Indications&nbsp;are finalized and guidelines for therapeutic use are formulated. Monitoring of adverse reactions</p>\n</td>\n<td>\n<p><strong>Postmarketing surveillance/studies</strong>: Drug interactions; long-term or rare side effects</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Extends from Months to 1year</p>\n</td>\n<td>\n<p>1&ndash;2 years</p>\n</td>\n<td>\n<p>3&ndash;5 years</p>\n</td>\n<td>\n<p>Unending, after drug approval</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7284",
      "difficulty": "easy"
    },
    {
      "text": "Match the following teratogenic drugs with their teratogenic effects.<div class='question-desc-html'><p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Match the following teratogenic drugs with their teratogenic effects\\nColumn A\\n1. Lithium\\n2. Chloramphenicol\\n3. Warfarin\\n4. Thalidomide\\n\\nColumn B\\nA. Phecomelia\\nB. Depressed nasal bridge\\nC. Gray baby syndrome\\nD. Ebstein anomaly&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:963,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16776960},&quot;9&quot;:0,&quot;10&quot;:1,&quot;11&quot;:4,&quot;12&quot;:0}\">&nbsp;</span></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Match the following teratogenic drugs with their teratogenic effects\\nColumn A\\n1. Lithium\\n2. Chloramphenicol\\n3. Warfarin\\n4. Thalidomide\\n\\nColumn B\\nA. Phecomelia\\nB. Depressed nasal bridge\\nC. Gray baby syndrome\\nD. Ebstein anomaly&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:963,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16776960},&quot;9&quot;:0,&quot;10&quot;:1,&quot;11&quot;:4,&quot;12&quot;:0}\">Column A<br /></span></p>\n</td>\n<td><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Match the following teratogenic drugs with their teratogenic effects\\nColumn A\\n1. Lithium\\n2. Chloramphenicol\\n3. Warfarin\\n4. Thalidomide\\n\\nColumn B\\nA. Phecomelia\\nB. Depressed nasal bridge\\nC. Gray baby syndrome\\nD. Ebstein anomaly&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:963,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16776960},&quot;9&quot;:0,&quot;10&quot;:1,&quot;11&quot;:4,&quot;12&quot;:0}\">Column B<br /><br /></span></td>\n</tr>\n<tr>\n<td>\n<p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Match the following teratogenic drugs with their teratogenic effects\\nColumn A\\n1. Lithium\\n2. Chloramphenicol\\n3. Warfarin\\n4. Thalidomide\\n\\nColumn B\\nA. Phecomelia\\nB. Depressed nasal bridge\\nC. Gray baby syndrome\\nD. Ebstein anomaly&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:963,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16776960},&quot;9&quot;:0,&quot;10&quot;:1,&quot;11&quot;:4,&quot;12&quot;:0}\">1. Lithium<br /></span></p>\n</td>\n<td><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Match the following teratogenic drugs with their teratogenic effects\\nColumn A\\n1. Lithium\\n2. Chloramphenicol\\n3. Warfarin\\n4. Thalidomide\\n\\nColumn B\\nA. Phecomelia\\nB. Depressed nasal bridge\\nC. Gray baby syndrome\\nD. Ebstein anomaly&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:963,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16776960},&quot;9&quot;:0,&quot;10&quot;:1,&quot;11&quot;:4,&quot;12&quot;:0}\">A. Phocomelia<br /><br /></span></td>\n</tr>\n<tr>\n<td>\n<p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Match the following teratogenic drugs with their teratogenic effects\\nColumn A\\n1. Lithium\\n2. Chloramphenicol\\n3. Warfarin\\n4. Thalidomide\\n\\nColumn B\\nA. Phecomelia\\nB. Depressed nasal bridge\\nC. Gray baby syndrome\\nD. Ebstein anomaly&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:963,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16776960},&quot;9&quot;:0,&quot;10&quot;:1,&quot;11&quot;:4,&quot;12&quot;:0}\">2. Chloramphenicol<br /></span></p>\n</td>\n<td><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Match the following teratogenic drugs with their teratogenic effects\\nColumn A\\n1. Lithium\\n2. Chloramphenicol\\n3. Warfarin\\n4. Thalidomide\\n\\nColumn B\\nA. Phecomelia\\nB. Depressed nasal bridge\\nC. Gray baby syndrome\\nD. Ebstein anomaly&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:963,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16776960},&quot;9&quot;:0,&quot;10&quot;:1,&quot;11&quot;:4,&quot;12&quot;:0}\">B. Depressed nasal bridge<br /><br /></span></td>\n</tr>\n<tr>\n<td>\n<p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Match the following teratogenic drugs with their teratogenic effects\\nColumn A\\n1. Lithium\\n2. Chloramphenicol\\n3. Warfarin\\n4. Thalidomide\\n\\nColumn B\\nA. Phecomelia\\nB. Depressed nasal bridge\\nC. Gray baby syndrome\\nD. Ebstein anomaly&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:963,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16776960},&quot;9&quot;:0,&quot;10&quot;:1,&quot;11&quot;:4,&quot;12&quot;:0}\">3. Warfarin</span></p>\n</td>\n<td><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Match the following teratogenic drugs with their teratogenic effects\\nColumn A\\n1. Lithium\\n2. Chloramphenicol\\n3. Warfarin\\n4. Thalidomide\\n\\nColumn B\\nA. Phecomelia\\nB. Depressed nasal bridge\\nC. Gray baby syndrome\\nD. Ebstein anomaly&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:963,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16776960},&quot;9&quot;:0,&quot;10&quot;:1,&quot;11&quot;:4,&quot;12&quot;:0}\">C. Gray baby syndrome<br /><br /></span></td>\n</tr>\n<tr>\n<td><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Match the following teratogenic drugs with their teratogenic effects\\nColumn A\\n1. Lithium\\n2. Chloramphenicol\\n3. Warfarin\\n4. Thalidomide\\n\\nColumn B\\nA. Phecomelia\\nB. Depressed nasal bridge\\nC. Gray baby syndrome\\nD. Ebstein anomaly&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:963,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16776960},&quot;9&quot;:0,&quot;10&quot;:1,&quot;11&quot;:4,&quot;12&quot;:0}\">4. Thalidomide</span></td>\n<td><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Match the following teratogenic drugs with their teratogenic effects\\nColumn A\\n1. Lithium\\n2. Chloramphenicol\\n3. Warfarin\\n4. Thalidomide\\n\\nColumn B\\nA. Phecomelia\\nB. Depressed nasal bridge\\nC. Gray baby syndrome\\nD. Ebstein anomaly&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:963,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16776960},&quot;9&quot;:0,&quot;10&quot;:1,&quot;11&quot;:4,&quot;12&quot;:0}\">D. Ebstein anomaly</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Match the following teratogenic drugs with their teratogenic effects\\nColumn A\\n1. Lithium\\n2. Chloramphenicol\\n3. Warfarin\\n4. Thalidomide\\n\\nColumn B\\nA. Phecomelia\\nB. Depressed nasal bridge\\nC. Gray baby syndrome\\nD. Ebstein anomaly&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:963,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16776960},&quot;9&quot;:0,&quot;10&quot;:1,&quot;11&quot;:4,&quot;12&quot;:0}\"><br /><br /><br /></span></p></div>",
      "choices": [
        {
          "id": 1,
          "text": "1-a, 2-b, 3-c, 4-d"
        },
        {
          "id": 2,
          "text": "1-c, 2-d, 3-a, 4-b"
        },
        {
          "id": 3,
          "text": "1-d, 2-a, 3-d, 4-c"
        },
        {
          "id": 4,
          "text": "1-d, 2-c, 3-b, 4-a"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The correctly matched pairs of teratogenic drugs and their effects is <strong>1-d, 2-c, 3-b, 4-a</strong>.</p>\n<p><span data-preserver-spaces=\"true\">Lithium use in early pregnancy causes <strong>Ebstein anomaly</strong> in the fetus. Fetal lithium exposure is associated with <strong>neonatal goiter</strong>, CNS depression, hypotonia (floppy baby syndrome), and cardiac murmur.</span></p>\n<p><strong>Gray baby syndrome </strong>occurs in neonates, especially premature ones, exposed to&nbsp;<strong>high doses of chloramphenicol&nbsp;</strong>(100 mg/kg), which are administered prophylactically.</p>\n<p><span data-preserver-spaces=\"true\"><strong>Fetal warfarin syndrome </strong>or<strong> warfarin embryopathy&nbsp;</strong>presents with&nbsp;</span><span data-preserver-spaces=\"true\">CNS abnormalities, <strong>d</strong></span><span data-preserver-spaces=\"true\"><strong>epressed nasal bridge</strong>/ saddle nose at birth, b</span><span data-preserver-spaces=\"true\">leeding diathesis, and g</span><span data-preserver-spaces=\"true\">rowth retardation. Hypoplasia of the nose, eye sockets, and long bones with stippling of epiphyses are also seen.</span></p>\n<p>Fetal thalidomide exposure causes phocomelia. This disorder is associated with <strong>underdeveloped limbs</strong> and <strong>absent pelvic bones.</strong> Both <strong>upper</strong> and <strong>lower</strong> limbs are <strong>affected</strong>, and a part of the limbs may be missing. Fused fingers and missing thumbs are also seen. Thalidomide was originally used for the treatment of <strong>pregnancy-associated morning sickness</strong> but was <strong>withdrawn</strong> due to this adverse effect.&nbsp;It re-entered the market for the treatment of erythema nodosum leprosum. It also has&nbsp;<strong>antiangiogenic</strong> and <strong>immunomodulatory</strong> effects.</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7246",
      "difficulty": "easy"
    },
    {
      "text": "A young man sustained a scorpion sting 2 hours ago. On examination, his blood pressure is 108/ 60 mm Hg; HR, 72 beats/minute, and respiratory rate, 32 breaths/minute. He also complains of breathlessness. How do you manage this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Metoprolol"
        },
        {
          "id": 2,
          "text": "Ivabradine"
        },
        {
          "id": 3,
          "text": "Prazosin"
        },
        {
          "id": 4,
          "text": "Frusemide"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The drug used to manage this condition is <strong>prazosin</strong> as it can counteract the effects of breathlessness most probably caused by pulmonary edema.</p>\n<p>The venom is a potent <strong>autonomic stimulator</strong> that causes the release of massive amounts of <strong>catecholamines</strong> from the adrenals. It also has a direct effect on the myocardium.</p>\n<p>It can present as <strong>neurotoxicity</strong> with restlessness or seizure-like activity, abnormal oculomotor function, and loss of pharyngeal muscle control that leads to respiratory compromise. Tongue fasciculations and hypersalivation are also common. <strong>Cardiovascular toxicity</strong> from systemic envenomation includes tachycardia, hypertension, pulmonary edema, and cardiogenic shock.</p>\n<p>If the scorpion has<strong> hemolytic</strong> venom, the reaction is mainly <strong>local</strong>, with edema, pain, and reddening. This usually lasts for one to two hours.&nbsp;</p>\n<p>Treatment:</p>\n<ul>\n<li>Pain - Paracetamol, NSAIDs, or opioids&nbsp;</li>\n<li>Sedation for agitation, oculomotor abnormalities, uncoordinated neuromuscular activity, and muscle spasms - <strong>Benzodiazepines</strong>&nbsp;</li>\n<li>Hypertension and<strong> pulmonary edema&nbsp;</strong>-&nbsp;<strong>Prazosin</strong> counteracts the adrenergic surge that can lead to these effects</li>\n<li>Cardiogenic shock - Antivenom, prazosin, nitroglycerin, dobutamine</li>\n<li>Cholinergic effects - Atropine</li>\n<li>Supportive care, wound care</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7245",
      "difficulty": "easy"
    },
    {
      "text": "An experiment is being conducted on a cat spine to study the effect of acetylcholine. The blood pressure is recorded at each intervention and is shown below. What does phase 4 in the graph indicate?",
      "choices": [
        {
          "id": 1,
          "text": "Muscarinic action of acetylcholine"
        },
        {
          "id": 2,
          "text": "Potentiation of acetylcholine"
        },
        {
          "id": 3,
          "text": "Antagonism of acetylcholine"
        },
        {
          "id": 4,
          "text": "Nicotinic action of acetylcholine"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Phase 4 in the graph indicates the <strong>nicotinic action</strong>&nbsp;of acetylcholine at<strong> higher doses</strong>.</p>\n<p>In phases 1 and 2, acetylcholine (Ach) acts on muscarinic receptors (at 2 micrograms and 50 micrograms) bringing down blood pressure. <strong>Atropine</strong> <strong>blocks</strong> the <strong>muscarinic receptor</strong>, so this action of acetylcholine is not seen in phase 3. However, in phase 4, <strong>higher doses</strong> of Ach (like 5 mg) act via the <strong>nicotinic receptor</strong>, shooting up the blood pressure. This phenomenon is called the reversal of Ach in blood pressure and was studied by Dale.&nbsp;</p>\n<p><strong>Nicotinic receptors</strong> are <strong>ligand-gated</strong> ion channels. It can be divided into two groups: muscle receptors (N<sub>M</sub>), which are found at the skeletal neuromuscular junction, and <strong>neuronal receptors</strong> (N<sub>N</sub>), which are found in the ganglia and CNS. When stimulated at higher doses, Ach acts on N<sub>N</sub>&nbsp;receptors, leading to the stimulation of <strong>sympathetic ganglia</strong> and <strong>adrenal medulla</strong>. This&nbsp;<strong>increases</strong> the heart rate, <strong>blood pressure</strong>, and myocardial contractility.</p>\n<p><strong>Muscarinic</strong> receptors are <strong>G-coupled protein</strong> receptors involved in the parasympathetic nervous system.&nbsp;M1, M2, M3, M4, and M5 are the receptor subtypes. They act via Gi or Gq subunits. When <strong>Ach</strong> is administered, it acts on&nbsp;muscarinic receptors, primarily the<strong> M3 receptors</strong>, which are located on <strong>vascular endothelial cells</strong>. It stimulates <strong>guanylyl cyclase</strong> and promotes relaxation via a cyclic GMP&ndash;dependent mechanism. At higher doses, it acts on&nbsp;<strong>M2 receptors,</strong> which have direct effects on the <strong>heart</strong>. It also inhibits the release of norepinephrine from sympathetic nerve terminals and decreases cyclic AMP levels.</p><hr><h3>Related Pearl: Acetyl Choline Receptors</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Type</strong></p>\n</td>\n<td>\n<p><strong>Location</strong></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p><strong>Nicotinic (ionotropic) receptors</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>N<sub>M</sub></p>\n</td>\n<td>\n<p>Neuromuscular junction</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>N<sub>N</sub></p>\n</td>\n<td>\n<p>Autonomic ganglia</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p><strong>Muscarinic (metabotropic) receptors</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>M<sub>1</sub>, M<sub>4</sub>, M<sub>5</sub></p>\n</td>\n<td>\n<p>CNS</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>M<sub>2</sub></p>\n</td>\n<td>\n<p>Heart</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>M<sub>3</sub></p>\n</td>\n<td>\n<p>Glands and smooth muscle</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/2b3ddec429404fce9e5a9874a7a2d2f7.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7271",
      "difficulty": "medium"
    },
    {
      "text": "A patient who is a known case of HIV is started on combined active antiretroviral therapy (cART). After 5 months of treatment, he develops hyperpigmentation in the palms and soles. What is the most likely drug causing this?",
      "choices": [
        {
          "id": 1,
          "text": "Nelfinavir"
        },
        {
          "id": 2,
          "text": "Emtricitabine"
        },
        {
          "id": 3,
          "text": "Abacavir"
        },
        {
          "id": 4,
          "text": "Zidovudine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The most likely drug causing hyperpigmentation of the hands and soles would be <strong>emtricitabine.&nbsp;</strong></p>\n<p>Emtricitabine is an anti-retroviral drug that acts by <strong>inhibiting nucleoside reverse transcriptase</strong> (<strong>NRTI</strong>). It is well-tolerated and has minimal toxic effects. Adverse effects include <strong>hyperpigmentation</strong> of<strong>&nbsp;</strong>the <strong>skin</strong> (especially sun-exposed areas, palms, and soles), headache, vomiting, and nausea.</p>\n<p>Other options:</p>\n<p>Option A: Nelfinavir is a protease inhibitor that causes <strong>diarrhea</strong> or loose stools. It usually <strong>resolves within a month</strong> of starting the drug.&nbsp;</p>\n<p>Option C: Abacavir is an NRTI that can cause a life-threatening hypersensitivity syndrome. The syndrome presents with <strong>fever, abdominal pain,</strong> and&nbsp;<strong>maculopapular rash</strong>&nbsp;<strong>within 6 weeks</strong> of initiating abacavir. The drug must be immediately discontinued and must not be administered to the patient thereafter. Rarely, there might be respiratory and musculoskeletal side effects.&nbsp;</p>\n<p>Option D: Zidovudine is an NRTI that causes malaise, fatigue, myalgia, anorexia, and insomnia. Chronic use leads to <strong>nail hyperpigmentation</strong>. It can also cause bone marrow suppression.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7218",
      "difficulty": "medium"
    },
    {
      "text": "Dorzolamide is a ______.",
      "choices": [
        {
          "id": 1,
          "text": "Topically applied sulfonamide antibacterial"
        },
        {
          "id": 2,
          "text": "Topical ocular carbonic anhydrase inhibitor"
        },
        {
          "id": 3,
          "text": "Second-generation sulfonylurea"
        },
        {
          "id": 4,
          "text": "Opioid receptor agonist"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Dorzolamide</strong> is a <strong>topical ocular carbonic anhydrase inhibitor</strong>.</p>\n<div class=\"page\" title=\"Page 462\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>It acts on carbonic anhydrase in the ciliary processes of the eye and mediates the formation of HCO<sub>3</sub><sup>-</sup><sub>&nbsp;</sub>in aqueous humor. Inhibition of carbonic anhydrase decreases the rate of formation of aqueous humor and consequently reduces intraocular pressure.</p>\n<div class=\"page\" title=\"Page 462\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>The major indication for carbonic anhydrase inhibitors is <strong>open-angle glaucoma</strong>. Dorzolamide and <strong>brinzolamide</strong>, which are available only as ophthalmic <strong>drops</strong>, are used for this purpose.</p>\n<p>Dorzolamide may be used for secondary glaucoma and in acute angle-closure glaucoma to lower intraocular pressure before surgery.</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div><hr><h3>Related Pearl: Antiglaucoma drugs: Mechanism of lowering intraocular pressure (IOP) at a glance</h3><p><strong>Drugs that increase trabecular outflow</strong></p>\n<ul>\n<li>Miotics (e.g., pilocarpine)</li>\n<li>Epinephrine, dipivefrine</li>\n<li>Bimatoprost</li>\n<li>Rho-kinase inhibitor (Netarsudil)</li>\n</ul>\n<p><strong>Drugs that increase uveoscleral outflow</strong></p>\n<ul>\n<li>Prostaglandins (latanoprost)</li>\n<li>Epinephrine, dipivefrine</li>\n<li>Brimonidine</li>\n<li>Apraclonidine</li>\n</ul>\n<p><strong>Drugs that decrease aqueous production</strong></p>\n<ul>\n<li>Carbonic anhydrase inhibitors (e.g., acetazolamide, dorzolamide)</li>\n<li>Alpha receptor stimulators in ciliary process (e.g., epinephrine, dipivefrine, clonidine, brimonidine, apraclonidine)</li>\n<li>Beta-blockers</li>\n</ul>\n<p><strong>Hyperosmotic agents</strong> - (e.g., glycerol, mannitol, urea)</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/52d74961d2524b3bb5c22c2677259778x1280x1532.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5408",
      "difficulty": "easy"
    },
    {
      "text": "A patient with erectile dysfunction is given sildenafil. The penile erectile function is found to be improved after the therapy. Which of the following mediates the action of sildenafil?",
      "choices": [
        {
          "id": 1,
          "text": "cAMP"
        },
        {
          "id": 2,
          "text": "cGMP"
        },
        {
          "id": 3,
          "text": "Calcium"
        },
        {
          "id": 4,
          "text": "Phosphatidyl glycerol and inositol phosphate"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Sildenafil </strong>is a<strong> phosphodiesterase 5 inhibitor </strong>and<strong>&nbsp;</strong>the<strong>&nbsp;</strong>action of the drug is mediated through<strong> cGMP</strong>. Erectile dysfunction&nbsp;is treated by phosphodiesterase-5&nbsp;(PDE-5) inhibitors like sildenafil, vardenafil, and tadalafil<strong>.&nbsp;</strong></p>\n<p>The corpus cavernosum produces nitric oxide during arousal that stimulates the formation of cGMP. cGMP causes relaxation of the smooth muscle of the corpus cavernosum and penile arteries, engorgement of the corpus cavernosum, and erection.&nbsp;</p>\n<p>The above-mentioned drugs<strong> compete</strong> for <strong>cyclic GMP</strong>, binding at the site of cyclic GMP hydrolysis on PDE5, enhancing the <strong>accumulation </strong>of<strong> cGMP&nbsp;</strong>and hence used in the management of erectile dysfunction. They are useful in treating pulmonary arterial hypertension.</p>\n<p><strong>Adverse effects</strong> of the drug are&nbsp;headache, flushing, nasal congestion, nasopharyngitis, and dyspepsia.&nbsp;Sildenafil and Vardenafil&nbsp;also cause <strong>retinal</strong> <strong>PDE-6 inhibition</strong> and can result in blurring of vision and <strong>blue-green tinting of the vision</strong>.</p>\n<p>&nbsp;</p><hr><h3>Related Pearl: PDE inhibitors</h3><table>\n<tbody>\n<tr>\n<td><span><strong>PDE inhibitors</strong></span></td>\n<td><span><strong>Drugs</strong></span></td>\n<td><span><strong>Clinical application</strong></span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Non-selective PDE inhibitors</strong></span></p>\n<p><span><strong>&nbsp;</strong></span></p>\n</td>\n<td>\n<p><span>Methylated xanthines, Caffeine, Theophylline</span></p>\n</td>\n<td>\n<p><span>Asthma, COPD</span></p>\n</td>\n</tr>\n<tr>\n<td><span><strong>&nbsp;</strong></span></td>\n<td>\n<p><span>Pentoxifylline</span></p>\n</td>\n<td>\n<p><span>Peripheral artery disease &nbsp;</span></p>\n</td>\n</tr>\n<tr>\n<td><span><strong>PDE 2 inhibitor</strong></span></td>\n<td>\n<p><span>Anagrelide</span></p>\n</td>\n<td><span>Essential thrombocytosis</span></td>\n</tr>\n<tr>\n<td><span><strong>PDE 3 inhibitor</strong></span></td>\n<td>\n<p><span>Cilostazol</span></p>\n</td>\n<td><span>Peripheral artery disease</span></td>\n</tr>\n<tr>\n<td><span><strong>&nbsp;</strong></span></td>\n<td>\n<p><span>Milrinone, Amrinone</span></p>\n</td>\n<td><span>Cardiac failure&nbsp;&nbsp;</span></td>\n</tr>\n<tr>\n<td><span><strong>PDE 4 inhibitor</strong></span></td>\n<td>\n<p><span>Roflumilast</span></p>\n</td>\n<td><span>COPD</span></td>\n</tr>\n<tr>\n<td><span><strong>&nbsp;</strong></span></td>\n<td>\n<p><span>Drotaverine</span></p>\n</td>\n<td><span>Antispasmodic drug</span></td>\n</tr>\n<tr>\n<td><span><strong>PDE 5 inhibitor</strong></span></td>\n<td>\n<p><span>Sildenafil, Vardenafil, Tadalafil (Also inhibit PDE6)</span></p>\n</td>\n<td><span>Erectile dysfunction Pulmonary hypertension</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span>&nbsp;</span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7260",
      "difficulty": "medium"
    },
    {
      "text": "Match the following diuretics in column A to their site of action in column B.<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td>Column A</td>\n<td>Column B</td>\n</tr>\n<tr>\n<td>A. Acetazolamide</td>\n<td>1. Thick ascending loop of Henle</td>\n</tr>\n<tr>\n<td>B. Torsemide</td>\n<td>2. Collecting duct</td>\n</tr>\n<tr>\n<td>C. Chlorthalidone</td>\n<td>3. Distal convoluted tubule</td>\n</tr>\n<tr>\n<td>D. Vasopressin</td>\n<td>4. Proximal convoluted tubule</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Match the following diuretics in column A to their site of action in column B\\nColumn A\\nA. Proximal convoluted tubule\\nB. Thick ascending loop of henle\\nC. Distal tubule\\nD. Collecting duct\\n\\nColumn B\\n1. Torasemide\\n2. Vasopressin\\n3. Chlorthalidone\\n4. Acetazolamide&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:963,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:3,&quot;3&quot;:2},&quot;9&quot;:0,&quot;10&quot;:1,&quot;11&quot;:4,&quot;12&quot;:0}\"><br /><br /></span></p></div>",
      "choices": [
        {
          "id": 1,
          "text": "A-2, B-3, C-1, D-4"
        },
        {
          "id": 2,
          "text": "A-3, B-4, C-2, D-1"
        },
        {
          "id": 3,
          "text": "A-1, B-2, C-4, D-3"
        },
        {
          "id": 4,
          "text": "A-4, B-1, C-3, D-2"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The correct match is as follows:</p>\n<table>\n<tbody>\n<tr>\n<td>Column A</td>\n<td>Column B</td>\n</tr>\n<tr>\n<td>A. Acetazolamide</td>\n<td>4. Proximal convoluted tubule</td>\n</tr>\n<tr>\n<td>B. Torsemide</td>\n<td>1. Thick ascending loop of Henle</td>\n</tr>\n<tr>\n<td>C. Chlorthalidone</td>\n<td>3. Distal convoluted tubule</td>\n</tr>\n<tr>\n<td>D. Vasopressin</td>\n<td>2. Collecting duct</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p><strong>Acetazolamide,</strong> a <strong>carbonic anhydrase inhibitor,</strong> acts on the enzyme in epithelial cells of the <strong>proximal convoluted tubule.</strong> Acetazolamide is mainly used in patients with secondary glaucoma to reduce intra-ocular pressure, provide symptomatic relief in acute mountain sickness, and as treatment for absence seizures.</p>\n<p><strong>Torsemide,</strong> a loop diuretic, inhibits the Na<sup>+</sup>-K<sup>+</sup>-ATPase symporter in the <strong>thick ascending loop of Henle.</strong>&nbsp;It is used in <strong>acute pulmonary edema,</strong> edema associated with <strong>congestive cardiac failure, hypertension</strong> with renal insufficiency, and hyponatremia.</p>\n<p><strong>Chlorthalidone</strong>, a thiazide-like diuretic, inhibits the<strong> Na<sup>+</sup>-Cl<sup>-</sup> symporter</strong> in the <strong>distal convoluted tubule</strong>. It is used in&nbsp;<strong>hypertension and</strong>&nbsp;in&nbsp;<strong>edema</strong> associated with <strong>congestive cardiac failure, hepatic cirrhosis,</strong> nephrotic syndrome, and <strong>chronic renal failure</strong><strong>.</strong></p>\n<p><strong>Vasopressin</strong>, also known as <strong>anti-diuretic hormone</strong>, is secreted by the <strong>posterior pituitary</strong> and mainly acts on the <strong>collecting duct,</strong> and increases the <strong>reabsorption of water</strong> (anti-diuresis). Vasopressin or its agonists (such as desmopressin) are used in cases of <strong>diabetes insipidus</strong>, <strong>type I and type II von Willebrand's disease</strong>, primary nocturnal enuresis, and postoperative ileus.</p><hr><h3>Related Pearl: Site and mechanism of action of diuretics</h3><table>\n<tbody>\n<tr>\n<td><span><strong>Diuretics&nbsp;</strong></span></td>\n<td><span><strong>Site of action&nbsp;&nbsp;</strong></span></td>\n<td>\n<p><span><strong>Enzyme/receptor</strong><strong>/transporter inhibited&nbsp;</strong></span></p>\n</td>\n</tr>\n<tr>\n<td><span><strong>Carbonic anhydrase inhibitors&nbsp;&nbsp;</strong></span></td>\n<td><span>Proximal tubule&nbsp;&nbsp;</span></td>\n<td><span>Carbonic anhydrase&nbsp;&nbsp;</span></td>\n</tr>\n<tr>\n<td><span><strong>Loop diuretics&nbsp;</strong></span></td>\n<td><span>Thick ascending loop of Henle&nbsp;</span></td>\n<td><span>Na<sup>+</sup>- K<sup>+</sup>- 2Cl<sup>-</sup>&nbsp;symporter</span></td>\n</tr>\n<tr>\n<td><span><strong>Thiazides</strong></span></td>\n<td><span>Distal convoluted tubule&nbsp;</span></td>\n<td><span>Na<sup>+</sup>- Cl<sup>-</sup> symporter</span></td>\n</tr>\n<tr>\n<td><span><strong>Epithelial sodium channel inhibitors&nbsp;</strong></span></td>\n<td><span>Late distal tubule and collecting ducts&nbsp;&nbsp;</span></td>\n<td><span>ENaC&nbsp;</span></td>\n</tr>\n<tr>\n<td><span><strong>Aldosterone antagonists&nbsp;</strong></span></td>\n<td><span>Late distal tubule and collecting ducts&nbsp;</span></td>\n<td><span>Mineralocorticoid receptors (indirectly ENaC)&nbsp;</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1eebed7de1f34fd99539e6c7613f42f0x1280x1306.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5449",
      "difficulty": "easy"
    },
    {
      "text": "Alkalinization of urine will be helpful in the removal of _____.",
      "choices": [
        {
          "id": 1,
          "text": "Weakly basic drugs"
        },
        {
          "id": 2,
          "text": "Strong electrolytes"
        },
        {
          "id": 3,
          "text": "Polar drugs"
        },
        {
          "id": 4,
          "text": "Weakly acidic drugs"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Alkalinization of urine will be helpful in the removal of <strong>weakly acidic drugs</strong> as they are susceptible to<strong>&nbsp;ion trapping</strong> in the&nbsp;urine.</p>\n<p>Drugs that are subjected to renal clearance are excreted into the urine by glomerular filtration and active tubular secretion. Nonionized compounds are reabsorbed more rapidly than ionized polar molecules. When the <strong>pH</strong> of the <strong>urine&nbsp;increases</strong>, more salicylate is in its ionized form at equilibrium. Hence, salicylic acid <strong>diffuses</strong> into the <strong>tubular lumen</strong> of the kidney. Urine alkalinization is recommended as a first-line treatment only for moderately severe salicylate poisoning that&nbsp;does not meet the criteria for hemodialysis.</p>\n<p>Alkalinization of the urine is achieved by administration of <strong>100&ndash;150 mEq</strong> of <strong>sodium bicarbonate</strong> in 1 L of 5% dextrose in water (D5W). It is infused intravenously&nbsp;at twice the maintenance fluid requirements.</p>\n<p>Alkalinization of urine is <strong>contraindicated</strong> in <strong>renal failure</strong> or if fluid administration may worsen&nbsp;<strong>pulmonary edema</strong> or congestive heart failure.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7241",
      "difficulty": "easy"
    },
    {
      "text": "All of the following side effects are more commonly seen with carbamazepine than oxcarbazepine, except_____.",
      "choices": [
        {
          "id": 1,
          "text": "Hypotension"
        },
        {
          "id": 2,
          "text": "Hyponatremia"
        },
        {
          "id": 3,
          "text": "Rash"
        },
        {
          "id": 4,
          "text": "Elevated levels of gamma glutamyl transpeptidases"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Hyponatremia </strong>occurs more frequently&nbsp;in the case of oxcarbazepine than carbamazepine.</p>\n<p>Both carbamazepine and oxcarbazepine are<strong>&nbsp;sodium-channel blockers.&nbsp;</strong></p>\n<p>Carbamazepine is most effective in <strong>complex partial seizures</strong>. It is also used in<strong>&nbsp;</strong>GTCS and simple partial seizures, trigeminal and related neuralgias, and <strong>manic</strong> depressive psychosis.</p>\n<p>Carbamazepine potentiates the action of antidiuretic hormone (ADH). It can result in&nbsp;water retention with decreased osmolarity and hyponatremia, especially in elderly patients with cardiac disease. Carbamazepine and oxcarbazepine can cause leukopenia, aplastic anemia, hepato-toxicity and hyponatremia in the elderly.&nbsp;</p>\n<p>Oxcarbazepine shows <strong>lesser hypersensitivity</strong> reaction. Hence, rashes are more commonly seen with carbamazepine than with oxcarbazepine.</p>\n<p>Studies have shown that carbamazepine elevates enzyme <strong>gamma-glutamyl transpeptidases</strong> (GGT) more frequently than oxcarbazepine because of enzyme P450 induction.&nbsp;</p><p>Mechanism of action of some common antiepileptics:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Mechanism of action</strong></td>\n<td><strong>Antiepileptics</strong></td>\n</tr>\n<tr>\n<td>Sodium-channel blockers</td>\n<td>\n<p>Phenytoin</p>\n<p>Carbamazepine, Oxcarbazepine</p>\n<p>Eslicarbazepine</p>\n<p>Lamotrigine</p>\n<p>Topiramate</p>\n<p>Felbamate</p>\n<p>Valproate</p>\n<p>Rufinamide</p>\n<p>Levetiracetam</p>\n</td>\n</tr>\n<tr>\n<td>Calcium-channel blockers</td>\n<td>\n<p>Valproate</p>\n<p>Lamotrigine</p>\n<p>Ethosuximide</p>\n</td>\n</tr>\n<tr>\n<td>GABA<sub>A</sub>&nbsp;receptor modulators</td>\n<td>\n<p>Benzodiazepines</p>\n<p>Phenobarbital</p>\n<p>Felbamate</p>\n<p>Primidone</p>\n<p>Topiramate</p>\n<p>Carbamazepine, Oxcarbazepine</p>\n<p>Stiripentol</p>\n<p>Clobazam</p>\n</td>\n</tr>\n<tr>\n<td>\n<p class=\"p1\">GABA uptake inhibitors</p>\n</td>\n<td>\n<p class=\"p1\">Tiagabine</p>\n<p class=\"p1\">Vigabatrin</p>\n</td>\n</tr>\n<tr>\n<td>NMDA receptor antagonist</td>\n<td>Felbamate</td>\n</tr>\n<tr>\n<td>AMPA/Kainate receptor antagonist</td>\n<td>\n<p>Phenobarbital</p>\n<p>Topiramate</p>\n<p>Perampanel</p>\n</td>\n</tr>\n<tr>\n<td>HCN channel activity enhancers</td>\n<td>Lamotrigine</td>\n</tr>\n<tr>\n<td>Inhibitors of brain carbonic anhydrase</td>\n<td>\n<p>Acetazolamide</p>\n<p>Zonisamide</p>\n<p>Topiramate</p>\n</td>\n</tr>\n<tr>\n<td>Potassium-channel openers</td>\n<td>\n<p>Retigabine</p>\n<p>Topiramate</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: First-line Agents in Different Types of Seizures</h3><table>\n<tbody>\n<tr>\n<td><strong>Type of seizure&nbsp;</strong></td>\n<td><strong>1st-line antiepileptic drugs</strong></td>\n</tr>\n<tr>\n<td>\n<p>Focal seizures&nbsp;</p>\n</td>\n<td>\n<ul>\n<li>Carbamazepine</li>\n<li>Oxcarbazepine&nbsp;</li>\n<li>Lamotrigine</li>\n<li>Levetiracetam</li>\n<li>Phenytoin</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>GTCS&nbsp;</td>\n<td>\n<ul>\n<li aria-level=\"1\">Sodium valproate</li>\n<li aria-level=\"1\">Levetiracetam&nbsp;</li>\n<li aria-level=\"1\">Lamotrigine&nbsp;</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>Typical absence seizures&nbsp;</td>\n<td>\n<ul>\n<li><strong>Ethosuximide&nbsp;</strong>(drug of choice)</li>\n<li>Sodium valproate</li>\n<li>Lamotrigine</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>Atypical absence seizures</td>\n<td>\n<ul>\n<li aria-level=\"1\">Sodium valproate&nbsp;</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>Myoclonic seizures</td>\n<td>\n<ul>\n<li aria-level=\"1\"><strong>Sodium valproate</strong> (drug of choice)</li>\n<li aria-level=\"1\">Lamotrigine</li>\n<li aria-level=\"1\">Topiramate</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7280",
      "difficulty": "medium"
    },
    {
      "text": "Match the following drugs with the targets of their actions.<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td>A. Trastuzumab&nbsp;</td>\n<td>1. BCR-ABL tyrosine kinase&nbsp;</td>\n</tr>\n<tr>\n<td>B. Infliximab</td>\n<td>2. mTOR&nbsp;</td>\n</tr>\n<tr>\n<td>C. Sirolimus&nbsp;</td>\n<td>3. TNF &alpha;&nbsp;</td>\n</tr>\n<tr>\n<td>D. Imatinib</td>\n<td>4. HER2/neu</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div>",
      "choices": [
        {
          "id": 1,
          "text": "A-2, B-3 , C-1 , D-4"
        },
        {
          "id": 2,
          "text": "A-4, B-3 , C-1 , D-2"
        },
        {
          "id": 3,
          "text": "A-3, B-4 , C-2 , D-1"
        },
        {
          "id": 4,
          "text": "A-4, B-3 , C-2 , D-1"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The correct pairs are as follows:</p>\n<table>\n<tbody>\n<tr>\n<td>A. Trastuzumab&nbsp;</td>\n<td>4. HER2/neu</td>\n</tr>\n<tr>\n<td>B. Infliximab</td>\n<td>3.&nbsp; TNF &alpha;&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td>C. Sirolimus&nbsp;</td>\n<td>2.&nbsp;mTOR</td>\n</tr>\n<tr>\n<td>D. Imatinib</td>\n<td>1.&nbsp;BCR-ABL tyrosine kinase&nbsp;&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p><strong>Trastuzumab</strong> is a <strong>humanized monoclonal antibody against</strong>&nbsp;the external domain of <strong>HER2/neu</strong>. It&nbsp;is indicated as an adjuvant in the management of&nbsp;<strong>metastatic HER-2-positive breast cancer</strong>.</p>\n<div class=\"page\" title=\"Page 657\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Infliximab</strong> binds with high affinity to <strong>TNF-&alpha;</strong> and prevents the cytokine from binding to its receptors. Infliximab is used for the treatment of <strong>rheumatoid arthritis</strong>;&nbsp;it is used&nbsp;<strong>in combination with methotrexate</strong>&nbsp;in patients who do not respond to methotrexate alone. Infliximab is also used for the treatment of the symptoms of <strong>moderate-to-severe Crohn's disease</strong>.</p>\n</div>\n</div>\n</div>\n</div>\n<p><strong>Sirolimus</strong> is an antimetabolic and antiproliferative drug. It acts by forming a complex with an immunophilin called&nbsp;<strong>FKBP-12</strong>, which in turn inhibits the&nbsp;mammalian target of rapamycin (<strong>mTOR</strong>). mTOR is a protein kinase that blocks cell cycle progression at the G1 phase to S phase transition. It is used in the prophylaxis of organ transplant rejection.</p>\n<div class=\"page\" title=\"Page 1218\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Imatinib&nbsp;</strong>is a first-generation&nbsp;<strong>tyrosine kinase inhibitor. </strong>Imatinib attacks <strong>BCR-ABL translocation</strong>&nbsp;and is used in&nbsp;<strong>chronic myelocytic leukemia.</strong> It also inhibits c-kit and produces extended control of <strong>GI stromal tumors</strong>.</p>\n</div>\n</div>\n</div>\n</div><hr><h3>Related Pearl: Indications for Imatinib</h3><p><strong>BCR-ABL kinase mutations</strong></p>\n<ul>\n<li>Chronic myelogenous leukaemia (CML)</li>\n<li>Acute lymphoblastic leukaemia (ALL)</li>\n</ul>\n<p><strong>C-KIT mutations</strong></p>\n<ul>\n<li>Gastrointestinal stromal tumors (GIST)</li>\n</ul>\n<p><strong>PDGFR mutations</strong></p>\n<ul>\n<li>Dermatofibrosarcoma protuberans</li>\n<li>Hypereosinophilia syndrome</li>\n<li>Chronic myelomonocytic leukaemia (CML)</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7252",
      "difficulty": "easy"
    },
    {
      "text": "A patient is brought with altered sensorium and seizures. Attender shows the laboratory report which reveals elevated transaminases. Which of the following can be used in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Midazolam"
        },
        {
          "id": 2,
          "text": "Diazepam"
        },
        {
          "id": 3,
          "text": "Alprazolam"
        },
        {
          "id": 4,
          "text": "Oxazepam"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Oxazepam&nbsp;</strong>can be used in patients with elevated transaminases. It is <strong>short-acting</strong>&nbsp;and so, can be used in patients with<strong> liver impairment</strong> or <strong>brain damage.</strong></p>\n<p>Oxazepam is an orally available benzodiazepine used to treat anxiety and alcohol withdrawal states. Hepatic oxidation is decreased in persons with liver disease and the elderly. Oxazepam and lorazepam&nbsp;undergo <strong>only</strong> <strong>hepatic glucuronidation</strong>.</p>\n<p>Other options:</p>\n<p>Option A:<strong> Midazolam</strong> is the <strong>benzodiazepine of choice</strong> for<strong> induction</strong> of anesthesia. The onset of anesthesia is within <strong>30 to 60</strong> seconds. It can also be used to control seizures, but there is <strong>no difference</strong> in the efficacy of intravenous midazolam and intravenous diazepam.</p>\n<p>Option B:<strong> Diazepam</strong> is a long-acting benzodiazepine. It is <strong>metabolized</strong> in the <strong>liver</strong> to active metabolites like nordazepam which are long-acting.&nbsp;Diazepam and its long-acting metabolites can <strong>accumulate</strong> significantly in <strong>elderly</strong> patients with <strong>liver disease</strong> and therefore should<strong> not</strong> be used in such cases.</p>\n<p>Option C:<strong> Alprazolam</strong>&nbsp;is metabolized by hepatic oxidation which is significantly decreased in liver impairment and elderly patients.</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7264",
      "difficulty": "medium"
    },
    {
      "text": "The lipid profile of a patient who suffered from acute coronary syndrome is given below. What drug can be used to treat this condition?<div class='question-desc-html'><p>Serum low-density lipoprotein: 127 g/dL<br />Serum high-density lipoprotein: 32 mg/dL<br />Serum triglycerides: 278 mg/dL</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Fenofibrate 160 mg"
        },
        {
          "id": 2,
          "text": "Rosuvastatin + Fenofibrate"
        },
        {
          "id": 3,
          "text": "Rosuvastatin 10 mg"
        },
        {
          "id": 4,
          "text": "Atorvastatin 80 mg"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Atorvastatin 80 mg</strong> can be used to treat this condition.&nbsp;The first line of therapy in controlling cholesterol in patients with atherosclerotic cardiovascular disease (ASCVD) is starting a high-intensity statin. <strong>High-intensity statins</strong> include <strong>atorvastatin</strong> (40-80 mg) and <strong>rosuvastatin </strong>(20-40 mg)<strong>.</strong></p>\n<p>Statins are <strong>competitive inhibitors</strong> of <strong>HMG-CoA reductase</strong>. This leads to a decrease in cholesterol biosynthesis. Statins are also effective in reducing LDL and triglyceride levels.&nbsp;</p>\n<p>Other options:&nbsp;</p>\n<p>Option A. <strong>Fenofibrate</strong> reduces lipoprotein levels by interacting with Peroxisome proliferator-activated receptor (PPAR-&alpha;) and stimulating <strong>lipoprotein lipase</strong>. They are used as drugs of choice for treating hyperlipoproteinemia and severe hypertriglyceridemia (&gt;1000 mg/dL).</p>\n<p>Option B. <strong>Rosuvastatin and fenofibrate</strong> combination was previously used to reduce atherosclerotic cardiovascular disease risk. But recent studies have indicated no change in reduction and hence is <strong>not recommended anymore</strong>.&nbsp;</p>\n<p>Option C: <strong>Rosuvastatin 10 mg</strong> is a<strong> low-intensity statin</strong> and is mainly used for <strong>primary prevention</strong> against atherosclerotic cardiovascular disease.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7237",
      "difficulty": "medium"
    },
    {
      "text": "An anti-arrhythmic drug is shown to have the following effect. It is effective in both atrial and ventricular arrhythmias. Identify the drug.",
      "choices": [
        {
          "id": 1,
          "text": "Tocainide"
        },
        {
          "id": 2,
          "text": "Propranolol"
        },
        {
          "id": 3,
          "text": "Quinidine"
        },
        {
          "id": 4,
          "text": "Lignocaine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Quinidine </strong>is a<strong>&nbsp;class IA</strong> anti-arrhythmic agent. Class 1a agents are sodium channel blockers with significant potassium channel blocking properties. This slows conduction and <strong>prolongs the QRS duration </strong>and <strong>action potential duration</strong>.&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/290d9cdbaa444b8590f4728bb58ece8fx1280x647.PNG\" alt=\"Explanation Image\"><p>&nbsp;</p>\n<p>&nbsp;</p>\n<p><strong>Lignocaine</strong> and <strong>tocainide </strong>(Options D and A) are <strong>class 1b anti-arrhythmic</strong> drugs. These are sodium channel blockers that inhibit both inactivated and open sodium channels and can <strong>open potassium channels</strong>. It <strong>reduces phase 4 slope</strong> and reduces automaticity. It also alters the excitation threshold.</p>\n<p>The below image shows the changes in the action potential of a cardiac muscle when a class 1b anti-arrhythmic drug is used.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e807614673e74d1abc58bf1072520068x1280x719.PNG\" alt=\"Explanation Image\"><p>&nbsp;</p>\n<p>&nbsp;</p>\n<p><strong>Class 1c</strong> agents like <strong>flecainide</strong> and <strong>propafenone</strong> block sodium channels with insignificant potassium channel-blocking properties.</p>\n<p>The image below illustrates the action potential changes when a class 1c anti-arrhythmic is used.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/222629548464450caaf40ff6f14c9debx1280x681.PNG\" alt=\"Explanation Image\"><p>&nbsp;</p>\n<p>&nbsp;</p>\n<p>Option B:&nbsp;<strong>Propranolol</strong>&nbsp;is a&nbsp;<strong>&beta;-receptor-blocker </strong>and&nbsp;a<strong>&nbsp;class II antiarrhythmic.</strong></p><hr><h3>Related Pearl: Anti-arrhythmic drugs</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/7d6c4d5ed4a54f70b2030d71f3d06969x1280x1697.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><span><strong>Class of antiarrhythmic drugs&nbsp;</strong></span></p>\n</td>\n<td>\n<p><span>&nbsp;</span></p>\n<p><span><strong>Mechanism of action</strong></span></p>\n</td>\n<td>\n<p><span><strong>Effect on action potential duration</strong></span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class I</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IA</strong></span></p>\n<p><span>Procainamide</span></p>\n<p><span>Quinidine</span></p>\n<p><span>Disopyramide</span></p>\n</td>\n<td>\n<p><span>&nbsp;</span></p>\n<p><span>Na+ channel blockers with significant K<sup>+</sup> channel blocking property</span></p>\n<p><span>&nbsp;</span></p>\n</td>\n<td>\n<p><span>Prolonged</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IB</strong></span></p>\n<p><span>Lidocaine</span></p>\n<p><span>Mexiletine</span></p>\n</td>\n<td><span>Na+ channel blockers with K<sup>+</sup> channel opening property&nbsp;</span></td>\n<td>\n<p><span>Shortened or no effect</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IC</strong></span></p>\n<p><span>Flecainide</span></p>\n<p><span>Propafenone</span></p>\n<p><span>Moricizine</span></p>\n</td>\n<td><span>Na+ channel blockers with negligible K<sup>+</sup> channel blocking property&nbsp;</span></td>\n<td>\n<p><span>Variable or no effect</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class II</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Propranolol</span></p>\n<p><span>Esmolol</span></p>\n</td>\n<td><span>&beta;- blockers</span></td>\n<td><span>-&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class III</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Amiodarone, dronedarone</span></p>\n<p><span>Dofetilide</span></p>\n<p><span>Sotalol</span></p>\n<p><span>Ibutilide</span></p>\n<p><span>Vernakalant</span></p>\n</td>\n<td><span>K<sup>+</sup> channel blockers&nbsp;</span></td>\n<td><span>Prolonged&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IV</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Verapamil</span></p>\n<p><span>Diltiazem</span></p>\n</td>\n<td><span>Ca<sup>2+</sup> channel blockers</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Miscellaneous</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Adenosine</span></p>\n</td>\n<td><span>Activates adenosine receptors</span></td>\n<td><span>Shortened</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Digoxin</span></p>\n</td>\n<td><span>Na<sup>+</sup>-K<sup>+</sup> ATPase inhibitor</span></td>\n<td><span>Increases AV node refractoriness</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Magnesium</span></p>\n</td>\n<td><span>Unknown</span></td>\n<td><span>-</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/9a743f063aa049a4abcbf92fcafe7d5e.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7228",
      "difficulty": "medium"
    },
    {
      "text": "Which among the following is the false statement regarding statins?",
      "choices": [
        {
          "id": 1,
          "text": "Although HMG-CoA reductase inhibitors substantially reduce the risk of cardiovascular events, there is mild increase in lipoprotein a (Lpa) levels."
        },
        {
          "id": 2,
          "text": "These drugs should not be stopped even in severe conditions like injury, surgery, etc."
        },
        {
          "id": 3,
          "text": "They can be given with verapamil and other enzyme inhibitors."
        },
        {
          "id": 4,
          "text": "With the long term use, there is slight increase in the incidence of type 2 diabetes mellitus."
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The <strong>false</strong> statement regarding statins is that they&nbsp;<strong>can be given with verapamil and other enzyme inhibitors</strong>.</p>\n<p>Statins like atorvastatin and rosuvastatin are metabolized by the cytochrome 3A4 enzymes of the liver. <strong>Verapamil</strong> is a <strong>cytochrome 3A4 inhibitor</strong> and may interfere with statin degradation. This leads to an increase in serum statin levels. The most important feature of statin toxicity is myopathy. It can present as myalgia but can sometimes also lead to fatal <strong>rhabdomyolysis</strong>.&nbsp;</p>\n<p><strong>Statins</strong>&nbsp;are the most commonly used hypolipidemic drugs. Statins act by&nbsp;<strong>inhibiting</strong>&nbsp;the rate-limiting<strong>&nbsp;HMG-CoA reductase</strong>&nbsp;enzyme, which in turn&nbsp;<strong>inhibits cholesterol synthesis</strong>. They decrease levels of low-density lipoproteins (LDL) and triglycerides and increase the levels of high-density lipoproteins (HDL) in plasma.</p>\n<p>Other options:</p>\n<p>Option A:<strong> Lipoprotein (lp) a</strong> is an LDL molecule that has apolipoprotein b and an additional apolipoprotein a. Studies indicate that these molecules are atherogenic and may independently cause cardiovascular disease. Although <strong>HMG-CoA reductase inhibitors</strong> substantially reduce the risk of cardiovascular events, there is a mild <strong>increase</strong> in lipoprotein a levels.</p>\n<p>Option B: Statins can be continued during <strong>surgery</strong>. These drugs have proved to decrease overall mortality due to cardiovascular events. Statins also influence inflammatory responses and can be safely used in <strong>trauma.</strong></p>\n<p>Option D: Chronic administration of high statin doses also leads to an <strong>increased incidence</strong> of <strong>type 2 diabetes mellitus.</strong></p><hr><h3>Related Pearl: Drugs that can be continued on the day of surgery</h3><ol>\n<li>Antihypertensive medications (Exceptions are&nbsp;ACE Inhibitors and ARB)<strong>&nbsp;</strong></li>\n<li>Cardiac medications (e.g., &beta;-blockers, digoxin)</li>\n<li>Antidepressants, anxiolytics, and other psychiatric medications</li>\n<li>Thyroid medications</li>\n<li>Eye drops</li>\n<li>Heartburn or reflux medications</li>\n<li>Narcotic medications</li>\n<li>Anticonvulsants</li>\n<li>Asthma medications</li>\n<li>Steroids (oral and inhaled)</li>\n<li>Statins</li>\n<li>Levodopa</li>\n<li>Mono Amine Oxidase inhibitors are continued when:(1) Anesthesiologist is comfortable with use of MAO-safe procedures (2) Possibility of exacerbation or precipitation of depressive syndrome.&nbsp;</li>\n</ol>\n<div class=\"page\" title=\"Page 1127\">&nbsp;</div><hr><h3>Related Pearl: Metabolism of drugs</h3><p><strong>Drugs metabolized by cyp3A4 enzymes:</strong></p>\n<ul>\n<li>Protease inhibitors</li>\n<li>Statins</li>\n<li>Benzodiazepines</li>\n<li>Amiodarone</li>\n<li>Estrogen</li>\n<li>Erythromycin</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7231",
      "difficulty": "medium"
    },
    {
      "text": "Identify the drugs marked as A, B, and C.",
      "choices": [
        {
          "id": 1,
          "text": "A - Aspirin, B -Vorapaxar, C - Prasugrel"
        },
        {
          "id": 2,
          "text": "A - Aspirin, B - Eptifibatide, C - Vorapaxar"
        },
        {
          "id": 3,
          "text": "A - Aspirin, B - Eptifibatide, C - Prasugrel"
        },
        {
          "id": 4,
          "text": "A - Aspirin, B - Prasugrel, C - Eptifibatide"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The drugs marked A, B and C are <strong>aspirin</strong>, <strong>eptifibatide</strong>, and <strong>vorapaxar</strong>,<strong>&nbsp;</strong>respectively.</p>\n<p><strong>Aspirin</strong> causes inhibition of <strong>cyclooxygenase-1 (COX-1)</strong>,<strong>&nbsp;</strong>which would inhibit the formation of <strong>thromboxane A2</strong>. Thromboxane A2 is an inducer of platelet aggregation and is a potent vasoconstrictor. Hence, inhibition of its formation is responsible for antiplatelet action.</p>\n<p>Aspirin is a <strong>non-competitive, irreversible inhibitor</strong> of the cyclooxygenase (COX) enzyme. It is a <strong>nonselective COX inhibitor</strong> and inhibits both COX-1 and COX-2.&nbsp;</p>\n<p>Abciximab, tirofiban, and <strong>eptifibatide</strong> act by&nbsp;<strong>blocking Gp IIb/IIIa receptors</strong>. They are mainly used during&nbsp;<strong>percutaneous coronary intervention</strong>&nbsp;for acute coronary syndrome. They carry a&nbsp;<strong>high risk of bleeding</strong>&nbsp;and can cause&nbsp;<strong>thrombocytopenia</strong>.</p>\n<p><strong>Vorapaxar&nbsp;</strong>primarily inhibits platelet aggregation caused by&nbsp;<strong>thrombin.&nbsp;</strong>PAR-1 activation by thrombin contributes to platelet aggregation. Vorapaxar is a competitive antagonist of protease-activated receptor-1 (PAR-1). Vorapaxar is&nbsp;<strong>indicated in combination</strong>&nbsp;with aspirin and/or clopidogrel to reduce thromboembolic events in patients with MI or peripheral vascular disease.</p>\n<p><strong>Prasugrel&nbsp;</strong>is an<strong>&nbsp;irreversible P2Y12&nbsp;inhibitor </strong>and lasts for the entire lifetime of a platelet.</p>\n<div class=\"page\" title=\"Page 606\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Prasugrel is a&nbsp;<strong>prodrug</strong>&nbsp;that is used in patients with acute coronary syndrome who have undergone&nbsp;<strong>percutaneous coronary intervention.</strong>&nbsp;It<strong>&nbsp;reduces</strong>&nbsp;the rate of&nbsp;<strong>thrombotic cardiovascular events</strong>&nbsp;in such patients.&nbsp;</p>\n</div>\n</div>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/672ca9540c3b4fe7b9d71a5ec95b1f1dx1280x1585.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Classification of anti-platelet drugs</h3><table>\n<tbody>\n<tr>\n<td><span><strong>Class</strong></span></td>\n<td><span><strong>Drugs</strong></span></td>\n</tr>\n<tr>\n<td><span>Cyclooxygenase- I inhibitors</span></td>\n<td><span>Aspirin</span></td>\n</tr>\n<tr>\n<td><span>Irreversible P2Y<sub>12&nbsp;</sub>inhibitors</span></td>\n<td>\n<p><span>Ticlopidine, Clopidogrel, Prasugrel</span></p>\n</td>\n</tr>\n<tr>\n<td><span>Reversible P2Y<sub>12&nbsp;</sub>inhibitors</span></td>\n<td><span>Ticagrelor, Cangrelor</span></td>\n</tr>\n<tr>\n<td><span>GpIIb/IIIa inhibitors</span></td>\n<td><span>Abciximab, Eptifibatide, Tirofiban</span></td>\n</tr>\n<tr>\n<td><span>Thrombin (PAR-1) receptor antagonist</span></td>\n<td><span>Vorapaxar&nbsp;</span></td>\n</tr>\n<tr>\n<td><span>Phosphodiesterase inhibitors</span></td>\n<td>\n<p class=\"p1\"><span>Dipyridamole</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/1cdc3b043f0b47cbac9a11aee230237c.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7436",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is false regarding disulfiram?<div class='question-desc-html'><ol>\n<li>Does not stop cravings</li>\n<li>Accumulates acetaldehyde</li>\n<li>Inhibits alcohol dehydrogenase</li>\n<li>Starting dose is 250 mg</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "Only 3"
        },
        {
          "id": 2,
          "text": "1, and 3"
        },
        {
          "id": 3,
          "text": "1, 3, and 4"
        },
        {
          "id": 4,
          "text": "2, 3, and 4"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The wrong statement/s regarding disulfiram is only 3.</p>\n<p>Disulfiram is an <strong>irreversible inhibitor</strong> of both cytosolic and mitochondrial forms of <strong>aldehyde dehydrogenase.</strong>&nbsp;It is used in behavioral modification for alcohol de-addiction.&nbsp;The principle of action is <strong>aversive conditioning</strong> (not anti-craving).</p>\n<p>Disulfiram can be given only to <strong>highly motivated</strong> individuals. It should not be administered until the person has <strong>abstained</strong> from alcohol for <strong>at least 12 hours</strong>.&nbsp;The disulfiram-alcohol reaction may persist as long as 14 days after the last dose of disulfiram.</p>\n<p>Alcohol consumption during disulfiram therapy can lead to <strong>increased</strong> concentrations of <strong>acetaldehyde</strong>. This can cause aversive reactions, resulting in flushing, pulsating headache, throbbing pain in the head and neck, nausea, vomiting, rashes, <strong>respiratory difficulties</strong>, chest pain, and autonomic manifestations.</p>\n<p>Disulfiram is usually given in the dose of <strong>250 mg/day</strong> (range of 125&ndash;500 mg/day).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7435",
      "difficulty": "medium"
    },
    {
      "text": "G6PD can manifest with which of the following drugs?<div class='question-desc-html'><p>G6PD - Glucose-6-phosphate dehydrogenase</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Primaquine"
        },
        {
          "id": 2,
          "text": "Chloroquine"
        },
        {
          "id": 3,
          "text": "Penicillin"
        },
        {
          "id": 4,
          "text": "Tetracycline"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>G6PD deficiency will manifest with <strong>primaquine</strong>.</p>\n<p>G6PD deficiency is an X-linked recessive <strong>(XLR)</strong> disorder that causes <strong>congenital hemolytic anemia</strong>&nbsp;<strong>due to enzyme deficiency. </strong>Hemolysis occurs&nbsp;in conditions of high oxidative stress that are triggered by infections,&nbsp;fava beans, and&nbsp;certain drugs.</p>\n<p>G6PD is an enzyme in the&nbsp;hexose monophosphate pathway <strong>(HMP)</strong>&nbsp;that maintains the cellular levels of NADPH.&nbsp;<strong>NADPH</strong>&nbsp;then provides reducing equivalents needed for the conversion of oxidized glutathione to&nbsp;<strong>reduced glutathione</strong>. Reduced glutathione helps neutralize free radicles, protecting against oxidant injury.&nbsp;<strong>&nbsp;</strong></p>\n<p>Clinically, most patients are asymptomatic. Some patient develops <strong>episodic hemolysis</strong>,<strong>&nbsp;</strong>causing&nbsp;<strong>hemolytic anemia</strong>, <strong>hemoglobinemia,</strong> and<strong> hemoglobinuria.</strong></p>\n<p>Both primaquine and chloroquine cause hemolysis in G6PD-deficient individuals, but hemolysis is <strong>rare with chloroquine</strong> and it can be used in patients with G6PD deficiency, whereas <strong>primaquine is contraindicated</strong> in these individuals.</p>\n<p>Hematological findings in G6PD deficiency are shown below:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/4dc646e0a7344b62b2f3ad958aed8038x1279x914.JPEG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1fed3123012943dd8852893c0cf05c83x1279x914.JPEG\" alt=\"Explanation Image\"><p>Drugs that carry a risk of clinical hemolysis in persons with G6PD deficiency:</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>CLASS</strong></p>\n</td>\n<td>\n<p><strong>DRUGS</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Antimalarials</p>\n</td>\n<td>\n<p><strong>Primaquine &gt;&nbsp;</strong><strong>Chloroquine</strong></p>\n<p>Dapsone/chlorproguanil</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Sulphonamides/sulphones</p>\n</td>\n<td>\n<p><strong>Sulfamethoxazole</strong></p>\n<p>Sulfasalazine, Sulfisoxazole</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Antibacterial/antibiotics</p>\n</td>\n<td>\n<p><strong>Cotrimoxazole,&nbsp;</strong>Ciprofloxacin, Chloramphenicol, Nalidixic acid, Norfloxacin,&nbsp;<strong>Nitrofurantoin</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Others</p>\n</td>\n<td>\n<p>Naphthalene, Rasburicase&nbsp;</p>\n<p><strong>Methylene blue</strong></p>\n<p>&nbsp;</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7566",
      "difficulty": "medium"
    },
    {
      "text": "Choose the correctly matched pairs regarding the drugs used in schizophrenia:<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td>1.</td>\n<td>D2 antagonism</td>\n<td>Reduces positive symptoms</td>\n</tr>\n<tr>\n<td>2.</td>\n<td>5HT2A antagonism</td>\n<td>Reduces negative symptoms</td>\n</tr>\n<tr>\n<td>3.</td>\n<td>5HT1A agonism</td>\n<td>Weight loss</td>\n</tr>\n<tr>\n<td>4.</td>\n<td>Muscarinic antagonism</td>\n<td>Reduces extrapyramidal symptoms</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "1,3"
        },
        {
          "id": 2,
          "text": "1,4"
        },
        {
          "id": 3,
          "text": "1,2,4"
        },
        {
          "id": 4,
          "text": "1,2,3,4"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The correct option regarding the drugs used to treat schizophrenia symptoms is <strong>option C</strong>.</p>\n<p>Drugs used to treat schizophrenia can be classified:</p>\n<ul>\n<li>Typical or 1st generation antipsychotics.</li>\n<li>Atypical or 2nd generation antipsychotics.</li>\n</ul>\n<p>All typical antipsychotics markedly <strong>improve positive symptoms</strong> of schizophrenia, which is attributed to their <strong>antagonism</strong> at&nbsp;the<strong> D<sub>2</sub> receptor</strong>. Some of the drugs included in this class are <strong>chlorpromazine</strong> and <strong>haloperidol.</strong></p>\n<p>Atypical antipsychotics are antagonists or inverse agonists at the 5HT<sub>2A</sub> receptor. <strong>5HT<sub>2A</sub> antagonism</strong> is responsible for <strong>reducing negative symptoms</strong> in schizophrenia. Some of the drugs that belong to this class are clozapine, aripiprazole, and brexpiprazole.</p>\n<p>Atypical antipsychotics have lower extrapyramidal symptoms as compared to typical antipsychotics as the former has a lesser affinity to the D2 receptor. <strong>Muscarinic antagonists</strong>&nbsp;can be given to decrease the extrapyramidal symptoms. For example, <strong>promethazine</strong> or <strong>hydroxyzine</strong> is given for acute muscular dystonia, which is a form of extrapyramidal symptoms.</p>\n<p><strong>5HT<sub>1A</sub> receptor antagonism</strong>,&nbsp;not agonism, has been found to reduce food intake and hence reduce body weight.</p>\n<div class=\"page\" title=\"Page 256\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Aripiprazole and brexpiprazole are atypical antipsychotics that have partial agonist effects at the 5HT<sub>1A</sub> receptor. They have been approved for the treatment of schizophrenia and as an adjunctive treatment for depression.</p>\n</div>\n</div>\n</div>\n</div><hr><h3>Related Pearl: Actions of antipsychotic drugs</h3><table>\n<tbody>\n<tr>\n<td><strong>Dopaminergic pathway</strong></td>\n<td><strong>Significance</strong></td>\n<td><strong>Action of drug blocking D2 receptors</strong></td>\n</tr>\n<tr>\n<td><strong>Nigrostriatal</strong></td>\n<td>Movement</td>\n<td>Extrapyramidal symptoms</td>\n</tr>\n<tr>\n<td><strong>Mesolimbic</strong></td>\n<td>Speech, grasp of reality, mentation, and mood</td>\n<td>Reduces positive symptoms of schizophrenia</td>\n</tr>\n<tr>\n<td><strong>Mesocortical</strong></td>\n<td>Motivation, pleasure, socialization</td>\n<td>May increase negative symptoms of schizophrenia</td>\n</tr>\n<tr>\n<td><strong>Tuberoinfundibular pathway</strong></td>\n<td>Inhibits prolactin release</td>\n<td>Hyperprolactinemia</td>\n</tr>\n<tr>\n<td><strong>Chemoreceptor trigger zone</strong></td>\n<td>Vomiting reflex</td>\n<td>Anti emetic</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7565",
      "difficulty": "medium"
    },
    {
      "text": "A patient presented with a lesion, as shown in the image below. She is an immunocompromised patient currently on HAART. What are the systemic antifungal drugs that can be added along with the HAART in this patient?<div class='question-desc-html'><p>Highly active antiretroviral therapy (HAART)</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Inj. Amphotericin B 4-8 weeks, followed by oral itraconazole"
        },
        {
          "id": 2,
          "text": "Inj. Amphotericin  B 8 weeks, followed by oral posaconazole"
        },
        {
          "id": 3,
          "text": "Inj. Fluconazole, followed by oral fluconazole"
        },
        {
          "id": 4,
          "text": "Inj. Amphotericin  B, followed by flucytosine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical scenario is&nbsp;suggestive of <strong>mucormycosis</strong>. The&nbsp;patient can be given <strong>injection amphotericin B for 8 weeks, followed by oral posaconazole.</strong></p>\n<p>Mucormycosis is an <strong>opportunistic mycosis.</strong> It is typically seen in immunocompromised patients and invades blood vessels.</p>\n<p>The <strong>rhino-orbital-cerebral</strong> is the most common form of mucormycosis. Patients present with <strong>rhinitis</strong>, eye or <strong>facial</strong> <strong>pain,</strong> and <strong>facial</strong> <strong>numbness</strong>, followed by the onset of <strong>conjunctival</strong> <strong>suffusion</strong> and swelling along with <strong>blurry vision.</strong></p>\n<p>Diagnosis is made by <strong>biopsy</strong> with histopathologic examination. The biopsy shows characteristic wide, ribbon-like aseptate hyphal elements that branch at <strong>right angles.</strong></p>\n<p><span data-preserver-spaces=\"true\"><span class=\"s1\">The image&nbsp;below shows biopsy findings seen in mucormycosis:</span></span></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d2ce95171f29405e8b920760512c5d76x800x600.JPEG\" alt=\"Explanation Image\"><div class=\"ng-star-inserted\">\n<div class=\"table-responsive font-weight-light answer-scroll ng-star-inserted\">\n<p>Treatment of the infection includes 4 steps:</p>\n<ol>\n<li>Initiation of therapy <strong>(amphotericin</strong> <strong>B</strong>) as early as possible. Posaconazole can also be used in the management of this condition.</li>\n<li><strong>Surgical</strong> debridement</li>\n<li><strong>Reversal</strong> of underlying conditions and <strong>risk factors</strong></li>\n<li><strong>Treatment</strong> of underlying <strong>malignancy</strong> if present</li>\n</ol>\n<p><strong>Amphotericin B</strong>&nbsp;is a <strong>broad-spectrum antifungal</strong>.&nbsp;It&nbsp;binds to <strong>ergosterol</strong> in the fungal membrane and forms <strong>pores or channels</strong> in the<strong> fungal cell membrane</strong>. This allows the leakage of cytosolic molecules and ions, leading to a loss of membrane integrity.</p>\n<p>Other options:</p>\n<p>Option A: <strong>Itraconazole </strong>can be used for the treatment of <strong>chronic</strong> aspergillosis if there is <strong>resistance </strong>or<strong> failure of voriconazole</strong>.&nbsp;<span data-preserver-spaces=\"true\"><span class=\"s1\"><strong>Ketoconazole </strong>is used for both <strong>dermatophytosis</strong> and deep mycosis, but it has been replaced by <strong>itraconazole</strong>.</span></span></p>\n<p><span data-preserver-spaces=\"true\"><span class=\"s1\">Option C: <strong>Fluconazole </strong>is used for the treatment of <strong>candidiasis</strong>&nbsp;and cryptococcosis.</span></span></p>\n<p>Option D: <strong>Amphotericin B</strong>&nbsp;in combination with 5-flucytosine is used as&nbsp;<strong>induction treatment</strong> for <strong>cryptococcal meningitis.</strong>&nbsp;</p>\n</div>\n</div><hr><h3>Related Pearl: Mechanism of action of Antifungal drugs</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e48d5ad74a9b48c6baa33c90914e13cbx1280x2560.JPEG\" alt=\"Pearl Image\"><hr><h3>Related Pearl: Classification of fungus based on morphology</h3><p>Fungi are classified into 4 types based on their morphology:</p>\n<ul>\n<li>Yeast</li>\n<li>Yeast-like</li>\n<li>Molds</li>\n<li>Dimorphic fungi</li>\n</ul>\n<p><strong>Yeast:</strong></p>\n<ul>\n<li>Unicellular fungi</li>\n<li>Reproduces by budding</li>\n<li>Oval to round forms</li>\n<li>Example: Cryptococcus,&nbsp;Saccharomyces.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0f583d17fa494e93b42864de8e82507cx597x599.JPEG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<p><strong>Yeast like:</strong></p>\n<ul>\n<li>Unicellular fungi</li>\n<li>Reproduces by budding or binary fission</li>\n<li>Spherical or oval forms</li>\n<li>Pseudohyphae may be seen.</li>\n<li>Example: Candida,&nbsp;Malassezia furfur.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/bf7e12378e26462194d6b6f9155af000x800x501.JPEG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<p><strong>Molds/filamentous fungi:</strong></p>\n<ul>\n<li>Have hyphae which may be septate or aseptate</li>\n<li>Aseptate or coenocytic hyphae &ndash; Rhizopus, mucor,&nbsp;Lichtheimia.</li>\n<li>Septate hyphae &ndash; Penicillium, Dermatophytes, Aspergillus, fusarium.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/129499f438c04855bf91806ab6191d23x800x547.JPEG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<p><strong>Dimorphic fungi</strong></p>\n<ul>\n<li>Filamentous forms in the culture at 22<sup>0</sup>C &ndash; 25<sup>0</sup>C and in the environment.</li>\n<li>Yeast form in the culture at 37<sup>0</sup>C and in tissues.</li>\n<li>Examples &ndash; Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides immitis, Paracoccidioides brasiliensis, Talaromyces&nbsp;marneffei, Sporothrix schenckii.</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/b742dd38b7fe4bfb8634f08f18183953.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7574",
      "difficulty": "medium"
    },
    {
      "text": "A patient who is on treatment for hyperlipidemia develops gallstones. What is the mechanism of action of the causative drug that was given to this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Inhibits HMG CoA reductase"
        },
        {
          "id": 2,
          "text": "Activates PPAR alpha"
        },
        {
          "id": 3,
          "text": "Binds to deoxycholic acid"
        },
        {
          "id": 4,
          "text": "Decreases VLDL"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The<strong> antilipidemic drugs</strong> likely to cause<strong> gallstones </strong>are the peroxisome proliferator-activated receptors (<strong>PPARs</strong>) that act by activating <strong>PPAR alpha.</strong></p>\n<p><strong>PPARs</strong> are a superfamily of nuclear receptors involved&nbsp;in the regulation of energy homeostasis and metabolic function.&nbsp;It has three subtypes:</p>\n<ul>\n<li>PPAR&alpha; - reduces triglyceride level&nbsp;</li>\n<li>PPAR&gamma; - causes insulin sensitization&nbsp;</li>\n<li>PPAR&delta; - enhances fatty acids metabolism</li>\n</ul>\n<p>Lipoprotein lipase (LPL) is a key enzyme in the degradation of VLDL. Fibrates bind to PPAR alpha and cause <strong>stimulation</strong> of <strong>lipoprotein lipase</strong> enzyme. Increased LPL synthesis enhances the clearance of triglyceride-rich lipoproteins. Additionally, fibrates also <strong>stimulate fatty acid oxidation</strong> and <strong>reduce</strong> the expression of <strong>apo C-III</strong> (inhibitor of lipolysis). All fibrates increase the lithogenicity of bile, thereby increasing the risk of gall stones</p>\n<p>Other options:&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><span><strong>Class</strong></span></td>\n<td><strong>HMG- CoA reductase inhibitors (statins)</strong></td>\n<td><strong>Niacin</strong></td>\n<td><strong>Bile acid-binding resins</strong></td>\n</tr>\n<tr>\n<td><span><strong>Examples</strong></span></td>\n<td>\n<p class=\"p1\">Lovastatin, atorvastatin</p>\n</td>\n<td>Niacin</td>\n<td>\n<p>Colestipol, <br />colesevelam</p>\n</td>\n</tr>\n<tr>\n<td><span><strong>Mechanism of action</strong></span></td>\n<td>\n<p class=\"p1\">Inhibits HMG-CoA reductase</p>\n</td>\n<td>Decreases the production of VLDLs and the catabolism of HDLs</td>\n<td>Binds to bile acids in the intestinal lumen and increases excretion.&nbsp;</td>\n</tr>\n<tr>\n<td><span><strong>Major effects on lipoprotein levels</strong></span></td>\n<td>\n<p>Reduces LDL levels</p>\n</td>\n<td>\n<ul>\n<li>Reduces triglycerides,&nbsp; LDL, and lipoprotein a levels</li>\n<li>Significant <strong>increase HDL</strong> levels</li>\n</ul>\n</td>\n<td>Reduces LDL levels&nbsp;</td>\n</tr>\n<tr>\n<td><span><strong>Important side effects</strong></span></td>\n<td>\n<ul>\n<li><strong>Myopathy</strong></li>\n<li class=\"p1\">Elevations of serum amino-transferase activity</li>\n<li class=\"p1\">Elevation of creatine kinase activity</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Cutaneous vasodilation</li>\n<li>Elevations in amino-transferases levels&nbsp;</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Constipation</li>\n<li>Bloating&nbsp;</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7502",
      "difficulty": "medium"
    },
    {
      "text": "The dose-response curve for three drugs in the same tissue is shown in the image below. Which of the following statements is true?",
      "choices": [
        {
          "id": 1,
          "text": "Efficacy of drug A is more than that of drug B."
        },
        {
          "id": 2,
          "text": "Potency of drug B is more than that of drug A."
        },
        {
          "id": 3,
          "text": "Drug A & drug B are agonists."
        },
        {
          "id": 4,
          "text": "Drug C is a non-competitive antagonist."
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>In the given image, <strong>drug A &amp; drug B are agonists.</strong>&nbsp;</p>\n<div class=\"page\" title=\"Page 53\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 50\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Drugs that bind to physiological receptors and mimic the regulatory effects of endogenous signaling compounds' are <strong>agonists</strong>. Drugs that are only partially as effective as agonists are <strong>partial agonists</strong>.</p>\n<div class=\"page\" title=\"Page 53\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>The<strong> efficacy</strong> of a drug indicates the capacity of a drug to activate a receptor and <strong>generate a cellular response</strong>. A drug with high efficacy is a full agonist, eliciting a full response at some concentration. A drug with a low intrinsic efficacy will be a partial agonist. <strong>D</strong><strong>rug A &amp; drug B&nbsp;</strong>are <strong>agonists&nbsp;</strong>(Option C) that have the <strong>same efficacy&nbsp;</strong>(Option A), although, at different concentrations.</p>\n<p><strong>Drug C</strong> <strong>does not produce a full response</strong> at any concentration, making it a <strong>partial agonist</strong>. In the <strong>presence of a full agonist</strong>, a partial agonist behaves like a <strong>competitive antagonist</strong>&nbsp;(Option D).</p>\n<p>When two drugs produce equivalent responses, the drug whose dose-response curve lies to the left is said to be the more potent since it requires a lower dose to produce the same effect.&nbsp;<strong>Drug A</strong> &amp; <strong>drug</strong>&nbsp;<strong>B</strong> produce the same action and level of response in the tissue. The curve of drug A on the left indicates that it produces the<strong> same response</strong> at a <strong>lower concentration</strong>, making it <strong>more potent</strong> than drug B (Option B).</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/58ca7aff3ff64887b8cf57ae267880a1.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7440",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs is a β2 agonist?<div class='question-desc-html'><p>1. Dopexamine</p>\n<p>2. Dipivefrine</p>\n<p>3. Fenoldopam</p>\n<p>4. Mirabegron</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 3"
        },
        {
          "id": 2,
          "text": "4, 3, 2, 1"
        },
        {
          "id": 3,
          "text": "1, 2"
        },
        {
          "id": 4,
          "text": "3, 4"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Dipivefrine </strong>and<strong> dopexamine </strong>are&nbsp;&beta;<sub>2</sub>-adrenergic receptor agonists.</p>\n<p><strong>Dipivefrine</strong> causes a decrease in aqueous production and increases outflow. It was used in the treatment of<strong> open-angle glaucoma</strong> and<strong> ocular hypertension</strong>&nbsp;but has since been replaced.</p>\n<p><strong>Dopexamine</strong> is a synthetic analogue related to dopamine with activity at <strong>D1 </strong>and <strong>D2</strong> receptors as well as at <strong>&beta;2 receptors</strong>. It is used in patients with severe congestive heart failure, sepsis, and shock.</p>\n<p>Other options:</p>\n<p>B. <strong>Fenoldopam</strong> is a peripheral <strong>D1 agonist</strong> with moderate affinity for <strong>&alpha;2-adrenergic receptors</strong>. It is a rapidly acting <strong>vasodilator</strong> that is used in <strong>severe hypertension.</strong></p>\n<p>D. <strong>Mirabegron</strong> is a <strong>&beta;3-adrenergic receptor agonist</strong> which is used for <strong>bladder incontinence</strong>. Activation of this receptor in the bladder leads to detrusor muscle relaxation and increased bladder capacity. This action prevents voiding and provides relief for those with an overactive bladder and urinary incontinence.&nbsp;&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7441",
      "difficulty": "medium"
    },
    {
      "text": "What is the mechanism of action of sildenafil?",
      "choices": [
        {
          "id": 1,
          "text": "Inhibition of 5α-reductase"
        },
        {
          "id": 2,
          "text": "Inhibition of phosphodiesterase-5"
        },
        {
          "id": 3,
          "text": "Release of nitrous oxide radicals"
        },
        {
          "id": 4,
          "text": "Blockage of voltage-gated calcium channels"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Sildenafil </strong>acts by inhibiting <strong>phosphodiesterase-5&nbsp;</strong>(PDE-5)&nbsp;and is used in the treatment of <strong>erectile dysfunction.</strong></p>\n<p>PDE-5 inhibitors cause the accumulation of <strong>cGMP</strong> in the corpus cavernosum, which leads to the <strong>relaxation of smooth muscles of penile arteries</strong> that fill the corpus cavernosum, thereby improving erectile function in patients with erectile dysfunction.</p>\n<p>In addition to erectile dysfunction, sildenafil can be used in the treatment of <strong>pulmonary arterial hypertension</strong>.</p>\n<p>Adverse effects include <strong>headache, flushing,</strong> nasal congestion,&nbsp;<strong>blue-green tinting of vision</strong>,<strong>&nbsp;</strong>and erections lasting more than 4 hours.</p>\n<p>Sildenafil is <strong>contraindicated</strong> in patients using <strong>nitrate vasodilators,</strong>&nbsp;which could result in dangerously low blood pressure.</p><hr><h3>Related Pearl: PDE inhibitors</h3><table>\n<tbody>\n<tr>\n<td><span><strong>PDE inhibitors</strong></span></td>\n<td><span><strong>Drugs</strong></span></td>\n<td><span><strong>Clinical application</strong></span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Non-selective PDE inhibitors</strong></span></p>\n<p><span><strong>&nbsp;</strong></span></p>\n</td>\n<td>\n<p><span>Methylated xanthines, Caffeine, Theophylline</span></p>\n</td>\n<td>\n<p><span>Asthma, COPD</span></p>\n</td>\n</tr>\n<tr>\n<td><span><strong>&nbsp;</strong></span></td>\n<td>\n<p><span>Pentoxifylline</span></p>\n</td>\n<td>\n<p><span>Peripheral artery disease &nbsp;</span></p>\n</td>\n</tr>\n<tr>\n<td><span><strong>PDE 2 inhibitor</strong></span></td>\n<td>\n<p><span>Anagrelide</span></p>\n</td>\n<td><span>Essential thrombocytosis</span></td>\n</tr>\n<tr>\n<td><span><strong>PDE 3 inhibitor</strong></span></td>\n<td>\n<p><span>Cilostazol</span></p>\n</td>\n<td><span>Peripheral artery disease</span></td>\n</tr>\n<tr>\n<td><span><strong>&nbsp;</strong></span></td>\n<td>\n<p><span>Milrinone, Amrinone</span></p>\n</td>\n<td><span>Cardiac failure&nbsp;&nbsp;</span></td>\n</tr>\n<tr>\n<td><span><strong>PDE 4 inhibitor</strong></span></td>\n<td>\n<p><span>Roflumilast</span></p>\n</td>\n<td><span>COPD</span></td>\n</tr>\n<tr>\n<td><span><strong>&nbsp;</strong></span></td>\n<td>\n<p><span>Drotaverine</span></p>\n</td>\n<td><span>Antispasmodic drug</span></td>\n</tr>\n<tr>\n<td><span><strong>PDE 5 inhibitor</strong></span></td>\n<td>\n<p><span>Sildenafil, Vardenafil, Tadalafil (Also inhibit PDE6)</span></p>\n</td>\n<td><span>Erectile dysfunction Pulmonary hypertension</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span>&nbsp;</span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7439",
      "difficulty": "easy"
    },
    {
      "text": "Choose the correct options regarding the route of administration and bioavailability.<div class='question-desc-html'><p>A - Intravenous = 1<br />B - 0.75 &lt; Oral &lt;1<br />C - 0.75 &lt; IM&nbsp;<span>&le;</span>1<br />D - 0.75 &lt; SC&nbsp;<span>&le;</span>1</p>\n<p>IM- Intramuscular</p>\n<p>SC- Subcutaneous</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "A,B,D"
        },
        {
          "id": 2,
          "text": "A,C,D"
        },
        {
          "id": 3,
          "text": "A and C"
        },
        {
          "id": 4,
          "text": "A and D"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><span>The correct option among the following is<strong> A, C, and D.</strong></span></p>\n<div class=\"page\" title=\"Page 61\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Bioavailability is defined as the <strong>fraction </strong>of a <strong>drug</strong> reaching<strong> systemic circulation </strong>in an&nbsp;unchanged form after administration by any route.<span>&nbsp;The&nbsp;</span>area under the blood concentration-time curve (AUC)<span> is proportional to the dose and the extent of bioavailability for a drug.</span></p>\n</div>\n</div>\n</div>\n<p><strong>Bioavailability (F) = Quantity of drug reaching systemic circulation/Quantity of drug administered</strong></p>\n<p>Bioavailability depends on two factors, absorption and&nbsp;1st pass metabolism.&nbsp;The bioavailability of the drug&nbsp;<strong>injected intravenously</strong> is <strong>100%.</strong>&nbsp;But it is lower&nbsp;after <strong>oral ingestion</strong> because of&nbsp;incomplete absorption and first-pass&nbsp;metabolism in the intestinal wall or liver and lies between <strong>5% to &lt;100%</strong>. The bioavailability of&nbsp;<strong>subcutaneous </strong>and <strong>intramuscular </strong>routes lies between <strong>75% to&nbsp;<span>&le;100%.</span></strong></p>\n<p>The image given below shows the difference between the bioavailability of drugs injected intravenously (IV) and administered per orally (PO). Note the area under the respective curves shaded in red and blue colors which represent the absorption of the drug.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/7548819eafdf43d6b3155642ccd9e678x1184x1162.PNG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7567",
      "difficulty": "medium"
    },
    {
      "text": "A hypertensive patient on medication presents with the lab values as shown below. Which of the following drugs should be stopped?<div class='question-desc-html'><p>K<sup>+</sup> :6.5 meq/L</p>\n<p>Na<sup>+</sup> :137 meq/L</p>\n<p>Urea: 42 mg/dL</p>\n<p>Creatinine: 3.8 mg/dL</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Amlodipine"
        },
        {
          "id": 2,
          "text": "Metoprolol"
        },
        {
          "id": 3,
          "text": "Losartan"
        },
        {
          "id": 4,
          "text": "Furosemide"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>In this hypertensive patient with <strong>hyperkalemia</strong>, <strong>losartan</strong> must be stopped.</p>\n<p><strong>Losartan</strong>&nbsp;is competitive&nbsp;<strong>angiotensin I (AT1) receptor antagonist</strong>,&nbsp;which&nbsp;binds to the AT<sub>1</sub>&nbsp;receptor with high affinity. Uses of losartan are:</p>\n<ul>\n<li>Antihypertensive</li>\n<li>Renoprotective drug in diabetes mellitus</li>\n<li>Stroke prophylaxis</li>\n<li>Portal hypertension in cirrhosis without compromising renal function</li>\n<li>Anti-aggregant as it is a competitive antagonist of the thromboxane A2 receptor.</li>\n</ul>\n<p><strong>Hyperkalemia</strong>&nbsp;is an important side effect of ARBs.&nbsp;<span class=\"ILfuVd\" lang=\"en\"><span class=\"hgKElc\">Losartan appears to be a safe and efficacious agent to&nbsp;<strong>lower serum uric acid</strong>&nbsp;levels in patients with hyperuricemia.</span></span></p>\n<p>Option A: <strong>Gingival hyperplasia</strong>&nbsp;and&nbsp;<strong>ankle swelling</strong>&nbsp;are side effects of&nbsp;<strong>calcium channel blockers</strong>&nbsp;like&nbsp;<strong>amlodipine.</strong>&nbsp;Ankle edema occurs due to&nbsp;<strong>increased</strong>&nbsp;<strong>hydrostatic pressure</strong>&nbsp;in the capillaries present in the&nbsp;<strong>dependent parts</strong>&nbsp;of the body. This is due to&nbsp;<strong>reflex constriction</strong>&nbsp;of&nbsp;<strong>postcapillary vessels</strong>. Other common side effects of amlodipine include headache, dizziness, and abdominal pain.</p>\n<p>Option B: <strong>Metoprolol</strong>&nbsp;is a cardioselective beta blocker.<strong> Cardioselective</strong> beta blockers are <strong>less likely to cause hyperkalemia</strong> as an adverse effect. The risk of metoprolol-induced hyperkalemia is increased if the patient is also diabetic.</p>\n<p>Option D: <strong>Furosemide</strong>&nbsp;is a&nbsp;<strong>loop diuretic. </strong>It acts by&nbsp;<strong>inhibiting</strong>&nbsp;the<strong>&nbsp;Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup>&nbsp;symporter </strong>in the&nbsp;thick ascending limb&nbsp;of the&nbsp;loop&nbsp;of Henle&nbsp;resulting in increased<strong> excretion of sodium, potassium,</strong> and<strong> chloride</strong>.&nbsp;<strong>Hypokalemia, hyperuricemia, hypocalcemia</strong>, and hypomagnesemia are the important side effects.</p><hr><h3>Related Pearl: Effect of diuretics on excretion of electrolytes</h3><table>\n<tbody>\n<tr>\n<td><strong>Diuretics</strong></td>\n<td><strong>Sodium</strong></td>\n<td><strong>Potassium</strong></td>\n<td><strong>Calcium</strong></td>\n</tr>\n<tr>\n<td><strong>Carbonic anhydrase inhibitors</strong></td>\n<td>&uarr;</td>\n<td>&uarr;&uarr;</td>\n<td>No change</td>\n</tr>\n<tr>\n<td><strong>Osmotic diuretics</strong></td>\n<td>&uarr;&uarr;</td>\n<td>&uarr;</td>\n<td>&uarr;</td>\n</tr>\n<tr>\n<td><strong>Loop diuretics</strong></td>\n<td>&uarr;&uarr;</td>\n<td>&uarr;&uarr;</td>\n<td>&uarr;&uarr;</td>\n</tr>\n<tr>\n<td><strong>Thiazides</strong></td>\n<td>&uarr;</td>\n<td>&uarr;&uarr;</td>\n<td>&darr;</td>\n</tr>\n<tr>\n<td><strong>Epithelial sodium channel blockers</strong></td>\n<td>&uarr;</td>\n<td>&darr;</td>\n<td>&darr;</td>\n</tr>\n<tr>\n<td><strong>Aldosterone antagonists</strong></td>\n<td>&uarr;</td>\n<td>&darr;</td>\n<td>Insufficient data</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Acute effects of thiazides on Ca<sup>2+</sup> excretion are variable but when administered chronically, it decreases Ca<sup>2+</sup> excretion.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7418",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the most effective oral drug in smoking cessation?",
      "choices": [
        {
          "id": 1,
          "text": "Varenicline"
        },
        {
          "id": 2,
          "text": "Cevimeline"
        },
        {
          "id": 3,
          "text": "Muscarine"
        },
        {
          "id": 4,
          "text": "Atropine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Varenicline</strong> is the most effective oral drug for smoking cessation.</p>\n<p><strong>Nicotine</strong> is the principal constituent of tobacco responsible for its addictive behaviour.&nbsp;Varenicline works by blocking the effects of nicotine on the brain. It <strong>blocks</strong> <strong>&alpha;4</strong>, and<strong> &beta;2 nicotinic acetylcholine receptor</strong> subtypes and&nbsp;<strong>inhibits dopaminergic activation</strong> produced by smoking through their <strong>partial agonism. </strong>It&nbsp;decreases the craving and withdrawal syndrome that occurs with cessation attempts. It prevents nicotine stimulation of the mesolimbic dopamine system associated with nicotine addiction, thus helping to occlude the rewarding effect of smoking.</p>\n<p>Varenicline is prescribed only to patients <strong>18 years</strong> or older. It is taken <strong>orally</strong> and the dose taken is 0.5 mg once daily on days 1 to 3, increased to 0.5 mg twice daily on days 4 through 7, and 1 mg twice daily after day 8 for 11 weeks. Therapy should start one week before the target quit date. It can be continued for another 12 weeks (1 mg BD) to maintain abstinence.</p>\n<p>The adverse effects include nausea, disturbed sleep, sleepwalking, agitation, drowsiness, and constipation, and&nbsp;may also increase the risk of pancreatitis. Varenicline has also been implicated in specific skin syndromes such as <strong>Stevens-Johnson&nbsp;syndrome</strong>, erythema multiforme, and photosensitivity. Varenicline can cause renal failure and kidney stones, thus renal function must be monitored.</p>\n<p>The FDA has issued a warning about <strong>mood</strong> and <strong>behavioural changes</strong> associated with its use, and there is some evidence of <strong>increased cardiovascular risk.</strong></p>\n<p><strong>Cevimeline</strong><span data-preserver-spaces=\"true\">&nbsp;is a&nbsp;</span><strong><span data-preserver-spaces=\"true\">muscarinic agonist</span></strong><span data-preserver-spaces=\"true\">&nbsp;with an affinity for both&nbsp;</span><strong><span data-preserver-spaces=\"true\">M1</span></strong><span data-preserver-spaces=\"true\">&nbsp;and</span><strong><span data-preserver-spaces=\"true\">&nbsp;M3&nbsp;</span></strong><span data-preserver-spaces=\"true\">receptors on the lacrimal and salivary glands.&nbsp;</span><span data-preserver-spaces=\"true\">While&nbsp;</span><strong><span data-preserver-spaces=\"true\">M1 activation&nbsp;</span></strong>results in&nbsp;<strong><span data-preserver-spaces=\"true\">increased secretion</span></strong><span data-preserver-spaces=\"true\">,&nbsp;</span><strong><span data-preserver-spaces=\"true\">M3 activation&nbsp;</span></strong>results in<strong><span data-preserver-spaces=\"true\">&nbsp;smooth muscle contraction</span></strong><span data-preserver-spaces=\"true\">, and expulsion of the secretions.&nbsp;</span><span data-preserver-spaces=\"true\">Cevimeline enhances lacrimal secretions in&nbsp;</span><strong><span data-preserver-spaces=\"true\">Sjogren&rsquo;s syndrome.</span></strong></p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7422",
      "difficulty": "easy"
    },
    {
      "text": "Match the following antiarrhythmic drugs with their mechanism of action:<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td>Mechanism of action</td>\n<td>Drug</td>\n</tr>\n<tr>\n<td>1. Na+ channel blocker</td>\n<td>a. Quinidine</td>\n</tr>\n<tr>\n<td>2. K+ channel blocker</td>\n<td>b. Digoxin</td>\n</tr>\n<tr>\n<td>3.&nbsp;Na+ K+ ATPase inhibitor</td>\n<td>c. Esmolol</td>\n</tr>\n<tr>\n<td>4. Beta-blocker</td>\n<td>d. Ibutilide</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div>",
      "choices": [
        {
          "id": 1,
          "text": "1-d, 2-b, 3-a, 4-c"
        },
        {
          "id": 2,
          "text": "1-a, 2-c, 3-d, 4-b"
        },
        {
          "id": 3,
          "text": "1-a, 2-d, 3-b, 4-c"
        },
        {
          "id": 4,
          "text": "1-d, 2-c, 3-a, 4-b"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The correct option is Option C:&nbsp;<strong>1-a, 2-d, 3-b, 4-c</strong></p>\n<p><strong>Quinidine </strong>is a<strong>&nbsp;class IA</strong> anti-arrhythmic agent. Class 1a agents are <strong>sodium channel blockers</strong> with significant potassium channel blocking properties. This slows conduction and <strong>prolongs the QRS duration </strong>and <strong>action potential duration</strong>.&nbsp;</p>\n<p><strong>Digoxin</strong> is a&nbsp;<strong>Na+ K+ ATPase inhibitor</strong> that works by increasing AV node refractoriness.</p>\n<p><strong>Esmolol</strong>&nbsp;is a&nbsp;<strong>&beta;-receptor-blocker </strong>and&nbsp;a<strong>&nbsp;class II antiarrhythmic.</strong></p>\n<p><strong>Ibutilide</strong> is a <strong>class III&nbsp;</strong>anti-arrhythmic agent. It works by <strong>blocking K+</strong> channels.</p><hr><h3>Related Pearl: Anti-arrhythmic drugs</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/7d6c4d5ed4a54f70b2030d71f3d06969x1280x1697.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><span><strong>Class of antiarrhythmic drugs&nbsp;</strong></span></p>\n</td>\n<td>\n<p><span>&nbsp;</span></p>\n<p><span><strong>Mechanism of action</strong></span></p>\n</td>\n<td>\n<p><span><strong>Effect on action potential duration</strong></span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class I</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IA</strong></span></p>\n<p><span>Procainamide</span></p>\n<p><span>Quinidine</span></p>\n<p><span>Disopyramide</span></p>\n</td>\n<td>\n<p><span>&nbsp;</span></p>\n<p><span>Na+ channel blockers with significant K<sup>+</sup> channel blocking property</span></p>\n<p><span>&nbsp;</span></p>\n</td>\n<td>\n<p><span>Prolonged</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IB</strong></span></p>\n<p><span>Lidocaine</span></p>\n<p><span>Mexiletine</span></p>\n</td>\n<td><span>Na+ channel blockers with K<sup>+</sup> channel opening property&nbsp;</span></td>\n<td>\n<p><span>Shortened or no effect</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IC</strong></span></p>\n<p><span>Flecainide</span></p>\n<p><span>Propafenone</span></p>\n<p><span>Moricizine</span></p>\n</td>\n<td><span>Na+ channel blockers with negligible K<sup>+</sup> channel blocking property&nbsp;</span></td>\n<td>\n<p><span>Variable or no effect</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class II</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Propranolol</span></p>\n<p><span>Esmolol</span></p>\n</td>\n<td><span>&beta;- blockers</span></td>\n<td><span>-&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class III</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Amiodarone, dronedarone</span></p>\n<p><span>Dofetilide</span></p>\n<p><span>Sotalol</span></p>\n<p><span>Ibutilide</span></p>\n<p><span>Vernakalant</span></p>\n</td>\n<td><span>K<sup>+</sup> channel blockers&nbsp;</span></td>\n<td><span>Prolonged&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IV</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Verapamil</span></p>\n<p><span>Diltiazem</span></p>\n</td>\n<td><span>Ca<sup>2+</sup> channel blockers</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Miscellaneous</strong></span></p>\n</td>\n<td><span>&nbsp;</span></td>\n<td><span>&nbsp;</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Adenosine</span></p>\n</td>\n<td><span>Activates adenosine receptors</span></td>\n<td><span>Shortened</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Digoxin</span></p>\n</td>\n<td><span>Na<sup>+</sup>-K<sup>+</sup> ATPase inhibitor</span></td>\n<td><span>Increases AV node refractoriness</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Magnesium</span></p>\n</td>\n<td><span>Unknown</span></td>\n<td><span>-</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7416",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following drugs increases trabecular outflow?",
      "choices": [
        {
          "id": 1,
          "text": "Timolol"
        },
        {
          "id": 2,
          "text": "Netarsudil"
        },
        {
          "id": 3,
          "text": "Brimonidine"
        },
        {
          "id": 4,
          "text": "Acetazolamide"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The drug that increases trabecular outflow is <strong>netarsudil</strong>.</p>\n<p>Netarsudil is a <strong>rho-kinase inhibitor</strong> used in the treatment and management of <strong>glaucoma</strong> and ocular hypertension. It lowers the intra-ocular pressure directly through the relaxation of the <strong>trabecular meshwork</strong>, leading to an <strong>increase</strong> in <strong>aqueous outflow</strong>. It also reduces aqueous humor production.&nbsp;</p>\n<p>Netarsudil ophthalmic solution is instilled in <strong>one drop</strong> into the affected eye once daily in the <strong>evening</strong>. Adverse effects are conjunctival hyperemia, and <strong>corneal verticillata</strong>.</p>\n<p>Other options:</p>\n<p>Option A- Timolol is a <strong>non-selective&nbsp;&beta;-blocker</strong> that decreases the IOP by <strong>reducing</strong> the <strong>aqueous humor production</strong> through the blockade of the&nbsp;<strong>&beta;-receptors</strong> on the <strong>ciliary epithelium. </strong>Ocular adverse effects are allergy, decreased corneal sensation, and <strong>punctate keratitis.</strong></p>\n<p>Option C-&nbsp;<strong>Brimonidine</strong>&nbsp;is a <strong>selective alpha-2</strong> <strong>agonist&nbsp;</strong>which decreases aqueous synthesis and increases <strong>uveoscleral outflow</strong>. It can cross the blood-brain barrier and, hence, causes <strong>drowsiness and CNS depression</strong>. It is&nbsp;<strong>contraindicated</strong> in <strong>infants</strong> and <strong>children</strong>.</p>\n<p>Option D- <strong>Acetazolamide</strong> is a topical <strong>carbonic anhydrase inhibitor</strong> that decreases IOP by reducing <strong>aqueous formation</strong>. The main adverse effect is the <strong>bitter taste</strong> following administration. It is <strong>contraindicated</strong> in people with allergies to sulfonamide antibiotics.&nbsp;</p><hr><h3>Related Pearl: Antiglaucoma drugs: Mechanism of lowering intraocular pressure (IOP) at a glance</h3><p><strong>Drugs that increase trabecular outflow</strong></p>\n<ul>\n<li>Miotics (e.g., pilocarpine)</li>\n<li>Epinephrine, dipivefrine</li>\n<li>Bimatoprost</li>\n<li>Rho-kinase inhibitor (Netarsudil)</li>\n</ul>\n<p><strong>Drugs that increase uveoscleral outflow</strong></p>\n<ul>\n<li>Prostaglandins (latanoprost)</li>\n<li>Epinephrine, dipivefrine</li>\n<li>Brimonidine</li>\n<li>Apraclonidine</li>\n</ul>\n<p><strong>Drugs that decrease aqueous production</strong></p>\n<ul>\n<li>Carbonic anhydrase inhibitors (e.g., acetazolamide, dorzolamide)</li>\n<li>Alpha receptor stimulators in ciliary process (e.g., epinephrine, dipivefrine, clonidine, brimonidine, apraclonidine)</li>\n<li>Beta-blockers</li>\n</ul>\n<p><strong>Hyperosmotic agents</strong> - (e.g., glycerol, mannitol, urea)</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/52d74961d2524b3bb5c22c2677259778x1280x1532.JPEG\" alt=\"Pearl Image\"><hr><h3>Related Pearl: Important adverse effects of anti-glaucoma drugs</h3><table>\n<tbody>\n<tr>\n<td><span><strong>Anti-glaucoma drug</strong></span></td>\n<td><span><strong>The adverse effects</strong></span></td>\n</tr>\n<tr>\n<td><span>Beta-blockers</span></td>\n<td>\n<p><span>Corneal hypoesthesia</span></p>\n<p><span>Systemic side effects</span></p>\n</td>\n</tr>\n<tr>\n<td><span>Sympathomimetics</span></td>\n<td>\n<p><span>Lid retraction</span></p>\n<p><span>CNS depression and apnea in infants and children (&lt;2 years)</span></p>\n</td>\n</tr>\n<tr>\n<td><span>Prostaglandin analogs</span></td>\n<td>\n<p><span>Eyelash hypertrichosis</span></p>\n<p><span>Macular edema</span></p>\n<p><span>Iris pigmentation (Heterochromia iridis)</span></p>\n<p><span>Peri-orbital fat depletion</span></p>\n</td>\n</tr>\n<tr>\n<td><span>Miotics</span></td>\n<td>\n<p><span>Retinal detachment</span></p>\n<p><span>Cataract</span></p>\n</td>\n</tr>\n<tr>\n<td><span>Carbonic anhydrase inhibitors</span></td>\n<td>\n<p><span>Systemic side effects</span></p>\n<p><span>Corneal edema</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7428",
      "difficulty": "medium"
    },
    {
      "text": "Finasteride is used to treat male-pattern baldness acts by inhibiting which of the following enzymes?",
      "choices": [
        {
          "id": 1,
          "text": "Aromatase"
        },
        {
          "id": 2,
          "text": "17-hydrolase"
        },
        {
          "id": 3,
          "text": "5-alpha reductase"
        },
        {
          "id": 4,
          "text": "Phosphodiesterase"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Finasteride is used to treat male pattern baldness acts by inhibiting&nbsp;<strong>5-alpha reductase.</strong></p>\n<p>Finasteride&nbsp;is a competitive inhibitor of the&nbsp;5-alpha-reductase enzyme that<strong> inhibits the conversion</strong> of <strong>testosterone</strong> into its active form <strong>dihydrotestosterone</strong> (DHT).&nbsp;</p>\n<p>Finasteride inhibits <strong>type 2 5-alpha reductase</strong> within the hair follicle and reduces the production of DHT. Hence, it is used in the treatment of male pattern hair loss. But,&nbsp;<strong>new hair growth will be lost</strong> when finasteride is discontinued, similar to minoxidil.</p>\n<p>On long-term use (nearly 6 months), it produces an effect by <strong>reducing prostatic epithelial cell proliferation,&nbsp;</strong>thereby reducing the size of the prostate and improving urine flow.</p>\n<p>Adverse effects of finasteride:</p>\n<ul>\n<li>Decreased libido</li>\n<li>Erectile dysfunction</li>\n<li>Ejaculation disorder and decreased ejaculate volume</li>\n</ul>\n<p>Finasteride&nbsp;is <strong>highly teratogenic</strong> and<strong> pregnant women</strong> should not be exposed to the drug because of the <strong>potential for inducing genital abnormalities in male fetuses.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7427",
      "difficulty": "easy"
    },
    {
      "text": "Rituximab is a:",
      "choices": [
        {
          "id": 1,
          "text": "Polyclonal antibody which acts against CD20"
        },
        {
          "id": 2,
          "text": "Polyclonal antibody which acts against CD50"
        },
        {
          "id": 3,
          "text": "Monoclonal antibody which acts against CD20"
        },
        {
          "id": 4,
          "text": "Monoclonal antibody which acts against CD50"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div class=\"page\" title=\"Page 942\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Rituximab</strong> is a&nbsp;<strong>monoclonal antibody</strong> that acts against<strong> CD20 B&shy;-cell antigen</strong> expressed on the surface of B&shy;-lymphocytes, plasma cells, and B&shy;-cell lymphomas.</p>\n<div class=\"page\" title=\"Page 943\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 943\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>It promotes <strong>apoptosis</strong> through transmembrane signal&shy;ling as well as by <strong>antibody &shy;dependent</strong> and <strong>complement</strong>&shy; dependent cytotoxicity. It is used in the treatment of <strong>B&shy;-cell lymphoma</strong>, <strong>non-&shy;Hodgkin lymphoma,</strong> and <strong>chronic lymphocytic leukemia</strong>. It can be used both as a single agent as well as in combination with cyto&shy;toxic chemotherapy.</p>\n<div class=\"page\" title=\"Page 943\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 943\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Adverse effects are infusion reactions like chills, fever, urticarial rashes, pruritus, dyspnea, and hypotension. Pretreatment with antihistaminics and corticosteroids prevents the reactions.</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7426",
      "difficulty": "easy"
    },
    {
      "text": "A new drug application is filed after which phase of clinical trials?",
      "choices": [
        {
          "id": 1,
          "text": "4"
        },
        {
          "id": 2,
          "text": "3"
        },
        {
          "id": 3,
          "text": "2"
        },
        {
          "id": 4,
          "text": "1"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>New drug application is filed after<strong> phase 3 </strong>of clinical trials.</p>\n<p>Other options:</p>\n<p>Option A:&nbsp;<strong>Phase 4</strong> clinical trials are also called <strong>post-marketing surveillance.</strong></p>\n<p>Option C:&nbsp;<strong>Phase 2</strong> trials are the first round of trials in <strong>patients</strong>.</p>\n<p>Option D:&nbsp;<strong>Phase 1</strong> trials are done in <strong>healthy</strong> volunteers.</p><hr><h3>Related Pearl: Phases of Clinical Trials</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Phase I</strong></p>\n<p>(First in human)</p>\n</td>\n<td>\n<p><strong>Phase II</strong></p>\n<p>(First in patient)</p>\n</td>\n<td>\n<p><strong>Phase III</strong></p>\n<p>(Multisite trial)</p>\n</td>\n<td>\n<p><strong>Phase IV</strong></p>\n<p>(Postmarketing)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>10&ndash;100&nbsp;</p>\n</td>\n<td>\n<p>50 - 500&nbsp;</p>\n</td>\n<td>\n<p>500 - 3000</p>\n</td>\n<td>\n<p>Large or according to study</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Usually healthy volunteers</p>\n</td>\n<td>\n<p>Patients with the target disease</p>\n</td>\n<td>\n<p>Patients&nbsp; with the target disease</p>\n</td>\n<td>\n<p>Real-world patients</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Open-label study</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Usually the observational or open-label</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Human pharmacology and safety</strong>: The study aims at safety and tolerability; PK parameters</p>\n</td>\n<td>\n<p><strong>Therapeutic exploration and dose-ranging</strong>: Efficacy and dose-ranging</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Therapeutic confirmation/comparison</strong>: Indications&nbsp;are finalized and guidelines for therapeutic use are formulated. Monitoring of adverse reactions</p>\n</td>\n<td>\n<p><strong>Postmarketing surveillance/studies</strong>: Drug interactions; long-term or rare side effects</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Extends from Months to 1year</p>\n</td>\n<td>\n<p>1&ndash;2 years</p>\n</td>\n<td>\n<p>3&ndash;5 years</p>\n</td>\n<td>\n<p>Unending, after drug approval</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7679",
      "difficulty": "easy"
    }
  ]
}